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The discovery of the (pro)renin receptor [(P)RR] 15 years ago stimulated ideas on prorenin 
being more than renin’s inactive precursor. Indeed, binding of prorenin to the (P)RR induces 
a conformational change in the prorenin molecule, allowing it to display angiotensin-gener-
ating activity, and additionally results in intracellular signaling in an angiotensin-indepen-
dent manner. However, the prorenin levels required to observe these angiotensin-dependent 
and -independent effects of the (P)RR are many orders above its in vivo concentrations, 
both under normal and pathological conditions. Given this requirement, the idea that the (P)
RR has a function within the renin-angiotensin system (RAS) is now being abandoned. In-
stead, research is now focused on the (P)RR as an accessory protein of vacuolar H+-ATPase 
(V-ATPase), potentially determining its integrity. Acting as an adaptor between Frizzled 
co-receptor LRP6 and V-ATPase, the (P)RR appears to be indispensable for Wnt/β-catenin 
signaling, thus explaining why (P)RR deletion (unlike renin deletion) is lethal even when 
restricted to specific cells, such as cardiomyocytes, podocytes and smooth muscle cells. 
Furthermore, recent studies suggest that the (P)RR may play important roles in lipoprotein 
metabolism and overall energy metabolism. In this review, we summarize the controversial 
RAS-related effects of the (P)RR, and critically review the novel non-RAS-related func-
tions of the (P)RR, ending with a discussion on the potential of targeting the (P)RR to treat 
cardiovascular diseases.
Introduction
The renin-angiotensin system (RAS) is a key system regulating blood pressure and con-
trolling body fluid homeostasis. Renin is formed by cleavage of the N-terminal proseg-
ment from its non-active precursor prorenin exclusively in the juxtaglomerular cells of the 
kidney and secreted into the circulation in a controlled manner. Active renin catalyzes the 
conversion of angiotensinogen to angiotensin (Ang) I, which is then further converted by 
angiotensin-converting enzyme (ACE) to Ang II, the main effector molecule of the RAS. 
Unlike renin, prorenin is constantly secreted into the circulation by the kidney and other 
organs, such as the eye, reproductive organs and adrenal gland 1. Plasma prorenin levels are 
in excess of plasma renin levels under physiological conditions, and can be up to 100-fold 
higher under pathological conditions such as diabetes mellitus 2-4. Since proteolytic activa-
tion of prorenin has never been demonstrated outside the juxtaglomerular cells, it seemed 
unlikely that prorenin would somehow contribute to angiotensin generation at tissue sites. 
Consequently, prorenin’s function remained solely as the inactive precursor of renin until 







 1RR, prorenin is activated in a non-proteolytic manner. In addition, binding of renin and pro-
renin triggers intracellular signaling pathways independent from the generation of Ang II. 
This indicates that the (pro)renin-(P)RR interaction could be a potential target for treating 
cardiovascular and renal complications, and it soon drew great attention. Now, more than a 
decade later, it is still not clear how and to what degree the (P)RR contributes to end-organ 
damage and whether this involves local RAS activation. Yet, novel and Ang II-independent 
functions of the (P)RR have been identified, as an accessory protein of vacuolar H+-ATPase 
(V-ATPase), with important roles in Wnt signaling, low-density lipoprotein (LDL) clear-
ance, and glucose metabolism. In this review, we summarize the latest findings on the novel 
functions of the (P)RR and discuss the pharmacological potential of targeting the (P)RR for 
the treatment of cardiovascular diseases.
(P)RR and the RAS
The (P)RR is a 350-amino acid protein with a single transmembrane domain, encoded by 
the ATP6AP2 gene located on the X chromosome, which is highly conserved in vertebrates 
5. The C-terminal fragment (CTF) of the (P)RR is identical to the 8.9 kDa accessory protein 
of V-ATPase 6. Identification and characterization of a novel 9.2-kDa membrane sector-as-
sociated protein of vacuolar proton-ATPase from chromaffin granules, and the N-terminal 
domain (NTD) of the (P)RR can bind both renin and prorenin 7, denoted together as (pro)
renin. The (P)RR induces a conformational change in prorenin upon binding, resulting in 
full exposure of the catalytic cleft with the prosegment still being present 7-10. In addition, 
the (P)RR also directly stimulates intracellular signaling networks, including extracellular 
signal-regulated kinases 1/2 (Erk1/2) activation in vascular smooth muscle cells, meningeal 
cells, monocytes, collecting duct cells, endothelial cells and adipocytes, and phosphatidy-
linositol 3-kinase/Akt (PI3K/Akt) activation in HEK293T cells 11-19 (Figure 1). Activation 
of these signaling pathways can subsequently result in upregulation of profibrotic genes in-
cluding transforming growth factor-1, plasminogen-activator inhibitor 1 (PAI-1), fibronectin 
and collagen-1 12, 20, 21. As a consequence, the (P)RR might directly (i.e., independent from 
Ang II formation) promote tissue damage. If true, it would be a novel target to prevent 
cardiovascular and renal complications. In agreement with this concept, aging transgenic 
rats overexpressing the human (P)RR develop proteinuria and glomerulosclerosis 22 in the 
absence of hypertension, and ACE inhibition, although capable of lowering Ang II, did not 
prevent this renal damage.
A peptidic antagonist (handle region peptide, HRP) has been designed based on the concept 
that the prosegment of prorenin contains a “handle region” that binds to the (P)RR 23. HRP 
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Figure 1. Potential functions of the (P)RR. Upon binding (pro)renin, the (P)RR can activate intracellular signaling 
pathways, via both angiotensin-dependent and -independent ways, resulting in upregulation of profibrotic genes. In 
addition, the (P)RR is required for Wnt/β-catenin signaling. Besides, s(P)RR can be generated from full length (P)
RR by furin and ADAM19, and potentiate Wnt/β-catenin signaling. HRP, handle region peptide; ACE, angioten-
sin-converting enzyme; AOG, angiotensinogen; ATR, angiotensin II receptor; MAPK, mitogen-activated protein 
kinase; PLZF, promyelocytic leukemia zinc finger; s(P)RR, soluble (P)RR; TGF-β1, transforming growth fac-
tor-β1; PAI-1, plasminogen-activator inhibitor 1; COX2, cyclo-oxygenase 2; En2, homeobox protein engrailed-2, 








 1should thus theoretically occupy the binding pocket of the (P)RR, preventing prorenin bind-
ing and activation. Initially, studies reported that HRP indeed prevented nephropathy and 
retinopathy in streptozotocin-induced diabetic human (P)RR transgenic rats 24-26 and reduced 
ocular inflammation, cardiac hypertrophy and cardiac fibrosis in other pathological animal 
models 27-30, as reviewed elsewhere 31. However, later studies demonstrated no or even detri-
mental effects of HRP in hypertensive and diabetic models 30, 32-36. In addition, in vitro stud-
ies showed that HRP does not prevent (pro)renin-induced signaling, not even when applied 
at micromolar concentrations, and that HRP might actually behave as a partial agonist of (P)
RR 14, 30, 37, 38. Even more confusing, new transgenic mice models with enhanced (P)RR ex-
pression show no alterations in blood pressure, and no damage in the heart or kidney 39, 40. 
Contrasting data on the (P)RR-prorenin interaction in the brain have also been reported. 
Given the low, if not absent, renin levels in the brain, prorenin should be the exclusive ag-
onist of the (P)RR. Indeed, the brain (P)RR has been suggested to play an important role 
in prorenin-stimulated signaling pathways associated with the pathogenesis of neurogenic 
hypertension 41. Inhibiting (P)RR expression in the brain using shRNA decreased blood 
pressure and vasomotor sympathetic tone, possibly through a reduction in Ang II type 1 re-
ceptor expression 42. Moreover, neuron-specific (P)RR KO mice, showing a normal cardio-
vascular phenotype, were resistant to salt-dependent hypertension 43. Conceptually in line 
with these studies, intracerebroventricular infusion of the newly developed HRP-like (P)RR 
peptidic inhibitor PRO20 attenuated DOCA-salt induced hypertension 44. Interestingly, Ang 
II upregulates the expression of brain (P)RR by increasing cAMP response element-binding 
protein binding to the promoter of the (P)RR 45. The (P)RR is expressed in hypothalamic 
magnocellular neurosecretory cells and in the parasympathetic paraventricular nucleus, and 
prorenin stimulates the neuronal activities in these areas via both Ang II-dependent and -in-
dependent effects 46. Nevertheless, recently, we were unable to detect prorenin in the brain, 
nor did brain (pro)renin levels increase following the induction of neurogenic hypertension 
with DOCA-salt 47. Taken together these studies suggest that the (P)RR-prorenin interaction 
in the brain is highly unlikely, and that the central effects of putative (P)RR antagonists like 
HRP and PRO20 occur independently of the RAS 44. Importantly, this does not exclude the 
possibility that the brain (P)RR plays a role in blood pressure regulation via a non RAS-me-
diated pathway. In fact, given the above findings, it is highly likely that there is a link 
between the (P)RR and neurogenic hypertension. To solve these discrepancies, a detailed 
pharmacological characterization of PRO20 is still anxiously awaited.  
Cleavage of the NTD of the (P)RR by proteases such as furin and ADAM (a disintegrin 
and metalloproteinase 19) is followed by its secretion into the circulation 48, 49. The secreted 
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form of the (P)RR is denoted as s(P)RR [soluble (P)RR]. Initially, s(P)RR was thought to 
be able to bind and activate prorenin in the circulation, resulting in chronic RAS overactiva-
tion. However, this hypothesis was incorrect 50. In fact, to what degree the (pro)renin-(P)RR 
interaction truly occurs in vivo remains questionable until today. As reviewed elsewhere, 
to observe angiotensin-dependent and -independent effects in in vitro experiments, the re-
quired prorenin levels are 1000-fold and 10,000-fold, respectively, above its normal physio-
logical (i.e., picomolar) concentrations 31. Such elevations are unlikely to ever occur in vivo, 
even under pathophysiological conditions, and have also never been achieved in transgenic 
animal models. Although the collecting duct is believed to be a prorenin-synthesizing site 
which abundantly expresses the (P)RR, also in collecting duct cells 10 nmol/L prorenin was 
required to activate Erk1/2 51. This implies that even at sites where prorenin-(P)RR interac-
tion is theoretically feasible, it may not happen easily in vivo. In agreement with this con-
cept, a recent study using kidney-specific (P)RR knockout mice observed that renal Ang II 
production, sodium handling and angiotensin-dependent blood pressure regulation were not 
affected by (P)RR abolishment 52. Finally, unlike other RAS components, deletion of (P)RR 
in mice is lethal, even when (P)RR deletion is restricted to cardiomyocytes 53, podocytes 54, 
55 or nephron progenitor cells 56. Taken together, the (pro)renin-(P)RR interaction is unlikely 
to occur in normal physiology, and the (P)RR is more likely to play an important role be-
yond the RAS.
Novel functions of the (P)RR
Table 1 summarizes the findings from recent (P)RR transgenic, knock-out (KO) and 
knocking-down (KD) animal models. As discussed, the CTF of the (P)RR is identical to 
ATPA6P2, i.e., accessory protein 2 of V-ATPase. This implies that the function of the (P)
RR may be linked to V-ATPase. V-ATPase is a multisubunit proton pump that consists of 
a Vo domain which translocates protons and a V1 domain which hydrolyzes ATP 57. The 
Vo domain contains 6 different subunits of which the a and d subunits have tissue-specif-
ic isoforms in mammalians. The V1 domain contains 8 different subunits of which the B, 
C, E and G subunits have tissue-specific isoforms. In addition to these complex-forming 
subunits, V-ATPase also has two accessory proteins which are not always co-purified with 
V-ATPase: ATP6AP1 (also known as Ac45) and ATP6AP2. V-ATPases are expressed in 
virtually all cell types on the membrane of intracellular compartments, playing an import-
ant role in vesicle trafficking, protein degradation and intracellular signaling 58. V-ATPases 
are also abundantly expressed in the plasma membrane of certain cells, such as osteoclasts, 
intercalated cells, macrophages and tumor cells, thus contributing to bone resorption, sys-







 1V-ATPase function remains largely unknown. One possibility is that the (P)RR may help to 
maintain V-ATPase integrity 65.
Cardiomyocyte-specific (P)RR deletion in mice resulted in severe heart failure and the mice 
died within 3 weeks after birth 53. Similarly, podocyte-specific ablation of the (P)RR in mice 
caused severe glomerulosclerosis and consequently fetal renal failure within 2-4 weeks 54, 
55. Both (P)RR-deleted cardiomyocytes and podocytes showed accumulation of multivesi-
cle vacuoles in the perinuclear regions, indicating impaired autophagic degradation, which 
was attributed to deacidification of intracellular vesicles as a consequence of selective 
down-regulation of subunits of the Vo domain by (P)RR deletion. Complete loss of func-
tional lysosomes was also observed in smooth muscle cell-specific (P)RR knockout animals 
66. These data suggest that the (P)RR is indeed essential for V-ATPase integrity and stability. 
Moreover, specific (P)RR knockout in photoreceptor cells and the ureteric bud also resulted 
in phenotypes related to V-ATPase defects 67, 68. However, it is worth to note that in these in 
vivo studies, mRNA levels of Vo subunits were not assessed. In addition, the protein levels 
of the Vo subunits were marginally reduced, if at all, at an early stage of (P)RR deletion (4 
days of transfection/cre expression), and became evident only at a later stage, although (P)
RR deletion was apparent immediately 53-55. This suggests that the downregulation of Vo 
subunits is a secondary effect of (P)RR deletion rather than a direct consequence of im-
paired V-ATPase assembly or integrity. Indeed, silencing the (P)RR in collecting duct cells 
did not affect plasma membrane V-ATPase activity and only altered the protein abundance 
of certain Vo subunit isoforms 38. Moreover, lysosome-dependent protein degradation re-
mained intact upon (P)RR silencing, suggesting that at least lysosomal V-ATPase activities 
were not impaired 69.
The (P)RR has been identified as a crucial player in the Wnt/-catenin signaling pathway 69. 
The canonical -catenin signaling pathway contributes to embryonic development, stem cell 
biology, cell polarity, cell proliferation and neuron patterning, and is crucial for a normal de-
velopment of the cardiovascular and renal systems 70, 71. Mechanistic studies suggest that the 
(P)RR acts as an adaptor between Frizzled (Fz) co-receptor low-density lipoprotein recep-
tor-related protein 6 (LRP6) and V-ATPase, since V-ATPase activity was required for LRP6 
activation and its downstream signaling events 69. Further studies in Drosophila revealed 
that (P)RR deletion disturbed Fz localization, suggesting that the (P)RR is important for Fz 
trafficking 72, 73. Increased Wnt/β-catenin signaling is observed in kidneys of diabetic pa-
tients and rodents 74-76, and this may underlie, at least in part, the phenotype of (P)RR-over-
expressing rats. However, in vitro experiments showed that overexpressing the full-length 
(P)RR did not activate Wnt/β-catenin signaling, while overexpressing a truncated (P)RR (its 
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Table 1. Summary of (pro)renin receptor [(P)RR] transgenic and knock out (KO) animal models.
Adipocyte P2 (AP2); CMV early enhancer/chicken β-actin (CAG); cone-rod homeobox (Crx); cyclo-oxygenase 
(COX); deoxycorticosterone acetate (DOCA); homeeobox protein Hox-b7 (Hoxb7); heart rate (HR); myosin heavy 








 1CTF) enhanced Wnt signaling 
69. In line with these findings, a recent study reported (P)RR 
upregulation in kidney biopsy samples from patients with chronic kidney disease (CKD), as 
well as in the renal tubular epithelium of mice with CKD induced by either ischemia-reper-
fusion injury (IRI), adriamycin or Ang II 76. According to this same study, overexpressing 
the (P)RR in renal cells potentiated Wnt/β-catenin signaling in a V-ATPase-dependent (and 
renin-independent) manner, resulting in augmented expression of, among others, PAI-1 and 
fibronectin, i.e., exactly the profibrotic proteins that have been linked to renin-induced (P)
RR stimulation. Conversely, knocking down the (P)RR ameliorated kidney injury and fibro-
sis in the IRI model. Based on these data, a unifying concept might be that the previously 
observed upregulation of profibrotic pathways by (pro)renin simply is the consequence of 
artificially stimulating the (P)RR- Wnt/β-catenin-V-ATPase pathway when applying (pro)
renin at pharmacological concentrations. Moreover, the close interaction between the (P)
RR and Wnt/β-catenin signaling provides an explanation why (P)RR deletion is lethal, 
even when restricted to specific cell types. Interestingly, s(P)RR lacks the CTF enhanced 
urine-concentrating capability by activating Wnt/β-catenin signaling 77. However, the un-
derlying molecular mechanisms of this phenomenon are far from clear. Finally, targeted de-
letion of the (P)RR in lymphocytes resulted in thymus atrophy and a profound reduction of 
peripheral native T cells, suggesting impaired thymus development 78. However, T-cell-spe-
cific deletion of β-catenin resulted in a similar, but less profound phenotype 79. This implies 
that the (P)RR has functions beyond regulating the Wnt/β-catenin signaling pathway. 
We recently used an unbiased proteomics approach to identify the (P)RR-interactome in 
human embryonic kidney cells, and found sortilin-1 as a novel (P)RR-interacting protein 80. 
Sortilin-1, encoded by the SORT1 gene, plays an important role in neuron survival and in-
tracellular protein sorting, and has been identified as a determinant of LDL metabolism 81-84. 
Silencing the (P)RR reduced SORT1 and low-density lipoprotein receptor (LDLR) protein 
levels, albeit without affecting their transcription, and consequently also diminished cellular 
LDL uptake in hepatocytes. (P)RR silencing-induced LDLR degradation could be reversed 
by lysosomal inhibitors, such as bafilomycin A1. These findings suggest that the (P)RR has 
a role in lipid metabolism and atherosclerosis (Figure 2). Wu et al. recently also concluded 
that the (P)RR contributes to energy metabolism and adipogenesis 85. Specifically knocking 
out the (P)RR in adipocytes almost completely abolished white adipose tissue, increased 
systolic blood pressure, and caused severe lipid accumulation in the liver. Moreover, adi-
pocyte-specific (P)RR knockout mice were resistant to diet-induced obesity and displayed 
better glycemic control than control mice. Mechanistic studies revealed that (P)RR silenc-
ing markedly reduced the adipocyte transcript levels of peroxisome proliferator-activated 
receptor gamma (PPARγ), a nuclear receptor playing important roles in adipose tissues by 
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regulating fat storage, lipid metabolism and glucose metabolism 86. How this reduction in 
PPARγ mRNA levels occurred is still unknown. Upregulation of PPARγ is important for 
differentiation of pre-adipocytes to adipocytes, also known as adipogenesis. Shamansurova 
et al. reported similar results using adipose tissue-specific (P)RR knockout mice generated 
using AP2-cre rather than the adiponectin-cre applied in the previous report 87. These knock-
out mice were also leaner than control mice, and had less total fat mass. Male adipose (P)
RR knockout mice displayed increased O2 consumption and CO2 production, suggesting an 
increase in basal metabolic rate. Intriguingly, a high-fat/high-carbohydrate diet upregulated 
(P)RR expression 2-fold in adipose tissue in mice, likely caused by reduced expression of 
promyelocytic leukemia zinc finger protein, a transcription factor which suppresses (P)RR 
transcription 88. Moreover, in insulin-resistant obese women, adipose (P)RR expression was 
found to be increased by 33% as compared to insulin-sensitive obese women 88.
Finally, the (P)RR has been observed to interact with the pyruvate dehydrogenase E1  sub-
unit (PDHB) 89. Indeed, knocking down the (P)RR reduced PDHB protein levels and there-
fore enzymatic activity of the PDH complex. The PDH complex is an enzyme complex 
converting pyruvate to acetyl-CoA, a crucial step in glucose catabolism. Consequently, re-
ducing the PDH complex will affect the tricarboxylic acid cycle, resulting in insufficient en-
Figure 2. Novel functions of the (P)RR as a regulator of LDL metabolism. Knocking down the (P)RR reduces LDL 
receptor (LDLR) and SORT1 protein levels, but does not affect their transcript levels, while lysosomotropic agents 
like bafilomycin A1 prevents this. This suggests that the (P)RR is required for LDLR and SORT1 transportation 
from the Golgi apparatus to the plasma membrane, while in the absence of the (P)RR, the LDLR is transported to 
lysosomes for degradation, and SORT1 is degraded via unknown mechanism(s). Inhibiting (P)RR should reduce 







 1ergy supply. As a result, energy utilization from other acetyl-CoA sources, like fatty acids, 
is required to supplement the insufficient acetyl-CoA supply from pyruvate. This could po-
tentially lead to increased fatty acid catabolism and reduced fat deposition. In this regard it 
is of interest to note that the (P)RR has recently been identified as an interacting protein of 
the glucagon-like peptide 1 (GLP1) receptor, so that silencing the (P)RR in pancreatic beta 
cells resulted in reduced GLP1-stimulated insulin secretion 90. Since this involved impaired 
Ca2+ influx, it appears that the (P)RR is indispensable for GLP1 receptor signaling. Given 
the GLP1 receptor-dependent regulation of insulin secretion and blood glucose levels, and 
its potential contribution to blood pressure regulation 91-93, it is highly likely that the (P)RR 
not only plays a crucial role in lipid homeostasis, but also in energy metabolism. 
(P)RR as a pharmacological target for treating cardiovascular diseases
Genome-wide association studies have revealed that single nucleotide polymorphisms in 
the (P)RR gene are associated with increased cardiovascular risk. The 5+169C>T polymor-
phism is associated with blood pressure in Japanese 94 and Caucasian men 95. In Japanese 
women, the +1513A>G polymorphism is associated with the risk of lacunar infarction and 
left ventricular hypertrophy 96. Two additional polymorphisms, one in the promoter region 
and the other in an intron region of the (P)RR, is associated with hypertension in two car-
diovascular diseases cohorts, EUROPA and PROGRESS 97. However, it is worthy to note 
that none of the above-mentioned polymorphisms have been validated to affect the expres-
sion or function of the (P)RR. The most interesting clinical indication was provided by a 
unique exonic splice enhance mutation (c.321C>T) which causes deletion of exon 4 of the 
(P)RR, and a profound reduction (~50%) in full length functional (P)RR protein levels 98. 
Carriers of this mutation have X-linked mental retardation and epilepsy, without cardiovas-
cular or renal abnormalities. This mutation was also found in patients with X-linked Parkin-
sonism with spasticity 99, and again no cardiovascular or renal phenotype was observed in 
these patients. Taken together, the role of the (P)RR in hypertensive disease is still ambigu-
ous, and more studies to clarify the molecular functions of the (P)RR are urgently needed. 
As reviewed above, the (P)RR seems to have a role in regulating lipid metabolism, glucose 
metabolism and overall energy metabolism. Since hypercholesterolemia, diabetes and obe-
sity are well-known risk factors for cardiovascular disease, targeting these parameters via 
the (P)RR might indirectly affect cardiovascular disease progression. Indeed, deleting the 
adipose (P)RR prevented diet-induced obesity and improved glycemic control in mice 85, 87, 
although it simultaneously caused severe lipid deposition in the liver due to impaired adipo-
genesis by reduced adipocyte PPARγ levels 85. Interestingly, a high-fat diet upregulated he-
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patic PPARγ and resulted in de novo lipogenesis, also leading to liver steatosis and dyslip-
idemia 100-102. Therefore, inhibiting the (P)RR in the liver may reduce high-fat diet induced 
lipogenesis and dyslipidemia by reducing PPARγ-mediated upregulation of lipogenic genes. 
However, the precise interaction between the (P)RR and PPARγ needs to be unraveled, to 
further understand their respective roles in the regulation of lipid metabolism. An important 
question that remains is whether the impaired adipogenesis caused by (P)RR deletion is not 
simply due to developmental issues, as observed in many previous conditional knockout 
models, or to suppressed adipocyte proliferation. To address this question, in the absence of 
specific (P)RR antagonists, inducible deletion of the (P)RR in adult animals is recommend-
ed, or antisense oligonucleotides targeting the (P)RR. 
Finally, a major concern when considering the (P)RR as a therapeutic target for the treat-
ment of cardiovascular diseases is the lethality of the (P)RR knockout. Will inhibiting the (P)
RR cause (lethal) renal and cardiovascular damage as seen in the cell-specific KO models? 
The important role of the (P)RR during development has made investigating its molecular 
functions, involving the (pro)renin-binding NTD and/or the V-ATPase associated CTF, a 
major challenge. It is for instance possible that the CTF is indispensable for development, 
while the NTD is not. To address this question, it is recommended to generate transgenic 
mice with conditional knock-in of the CTF, expressed only after Cre-mediated recombina-
tion and deletion of the wild type (P)RR allele. 
Conclusions
Fifteen years of research on the (P)RR have shown that its functions are largely, if not com-
pletely, unrelated to the RAS, implying that its name is inappropriate. The (pro)renin levels 
required to stimulate the (P)RR are many orders of magnitude above any (pro)renin level 
ever measured in vivo, even in transgenic animals, and the confusing data obtained with 
non-specified (P)RR antagonists do not support the occurrence of (pro)renin-(P)RR interac-
tion, not even in (pro)renin synthesizing, (P)RR-expressing tissues. Therefore, the concept 
of inhibiting (P)RR-mediated RAS activation is currently being abandoned. Instead, (P)
RR-oriented research is now focusing on its relationship with V-ATPase. Indeed, the (P)
RR appears to act as an adaptor between V-ATPase and multiple receptors/proteins, such 
as Fz, thereby regulating signaling events, receptor trafficking, and protein degradation by 
V-ATPase-dependent acidification. This results, among others, in enhanced Wnt/β-catenin 
signaling and the upregulation of profibrotic genes. It may also contribute to neurogenic 
hypertension. Thus, inhibiting the (P)RR may potentially exert beneficial cardiovascular 







 1presence of the Wnt/β-catenin signaling pathway, targeting the (P)RR with pharmacological 
tools (e.g., receptor antagonists) is likely to exert affects on vital processes in multiple, if 
not all, cells of the body. This will undoubtedly limit the therapeutic application of such a 
drug in cardiovascular diseases. This leaves the possibility of targeting the (P)RR in specific 
cells, e.g., with antisense oligonucleotides. Whether such an approach holds promise, e.g. to 
treat obesity or CKD, needs to be answered in the coming years.
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 1Aim of the thesis
Cardiovascular disease (CVD) is the leading cause of death world-wide. Increased blood 
pressure (BP), or hypertension, is a major risk factor for CVD.  Hypertension, if not well 
treated, will cause heart and kidney damage in the longer term. Controlling BP is therefore 
a major goal in patients with CVD. The renin-angiotensin system (RAS) is one of the most 
important systems regulating blood pressure. Renin, secreted by juxtaglomerular cells in the 
kidney, cleaves angiotensinogen (AGT) to generate angiotensin I, which is further cleaved 
by angiotensin-converting enzyme (ACE) to form angiotensin II (Ang II), the effector 
peptide of the RAS. Prorenin, the inactive precursor of renin, can be activated both proteo-
lytically (via prosegment cleavage) and non-proteolytically (by allowing the prosegment 
to move out of the enzymatic cleft, e.g. in an acid environment). About two decades ago, a 
receptor that binds prorenin (and to a lesser degree renin) was identified. It has been named 
(pro)renin receptor [(P)RR]. Binding of renin and prorenin to the (P)RR induces the activa-
tion of intracellular signaling cascades, resulting in extracellular signal-regulated kinase1/2 
(Erk1/2) and p38 mitogen-activated protein kinase (MAPK) upregulation. Prorenin binding 
to the (P)RR has also been suggested to result in its non-proteolytic activation. Yet, apart 
from its role in the RAS, the (P)RR has also been identified as an accessory protein of the 
vacuolar H+-ATPase (V-ATPase). V-ATPase is a multiple subunit complex, expressed in vir-
tually all cell types, which plays an important role in the acidification of intracellular com-
partments, such as lysosomes, and signaling endosomes. A recent study surprisingly found 
that silencing the (P)RR reduces low-density-lipoprotein receptor (LDLR) protein levels via 
a lysosome-dependent pathway, suggesting a role of the (P)RR in lipoprotein metabolism. 
In Chapter 2, we investigated the role of (P)RR in lipid metabolism in vivo.  We found that 
inhibiting the hepatic (P)RR prevents high-fat diet-induced obesity and non-alcoholic fatty 
liver disease and lowers plasma cholesterol and triglyceride in LDLR-/- mice. Mechanisti-
cally, we found that inhibition of (P)RR resulted in reduced lipid synthesis and increased 
fatty acid oxidation by reducing acetyl-CoA carboxylase and pyruvate dehydrogenase abun-
dance.
RAS inhibitors, such as direct renin inhibitors (DRI), ACE inhibitors and angiotensin re-
ceptor blockers (ARBs), are the most commonly used medicines in the clinic for controlling 
BP. However, RAS inhibition results in a significant rise in renin due to a negative feedback 
loop, thus compromising the management of BP. Hence, there is a compelling need for 
novel therapies that circumvent this problem to better control BP. In Chapter 3, we tested 
the effect of inhibiting hepatic AGT, the initiator of RAS, on BP and hypertension-induced 
heart - and kidney injury in spontaneously hypertensive rats. The AGT-targeting siRNA is 
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stable in vivo and potently suppresses AGT expression in the liver over a long period. We 
found that abolishing AGT expression effectively lowered BP. Furthermore, we found that 
applying this siRNA in combination with the ARB valsartan resulted in a far greater reduc-
tion in BP and prevention of cardiac hypertrophy. 
Human plasma prorenin levels are usually 10-fold higher than renin levels. Plasma prorenin 
and renin are filtered through the glomerulus and either reabsorbed in the proximal tubule 
or excreted in urine. Urinary renin levels normally amount to 6-7% of plasma renin levels, 
while prorenin is undetectable in urine. Moreover, in Cyp1a1-Ren2 rats whose plasma pro-
renin levels are increased 200-fold as compared with non-transgenic rats, urinary prorenin is 
still undetectable. Considering that prorenin and renin have similar molecular weights, the 
average glomerular sieving coefficients for filtering prorenin and renin through the glomer-
ulus are also similar, excluding the possibility that different filtration rates account for the 
discrepancies in their urinary levels. This suggests that an as yet unidentified recycling re-
ceptor for prorenin may exist in the proximal tubule. Interestingly, urinary (pro)renin levels 
are drastically elevated in patients with Lowe syndrome and Dent’s disease. Importantly, 
these patients carry mutations in the genes encoding for OCRL1 and CLC-5, which are 
known to impair megalin function. Megalin is a multi-ligand receptor that can bind and in-
ternalize nutrients or hormones in the proximal tubule. In Chapter 4 and 5, we summarize 
the current knowledge about megalin and hypothesize that megalin could be the missing 
receptor that explains the discrepancies in urinary prorenin and renin levels. In Chapter 6, 
we subsequently studied whether megalin binds and internalizes (pro)renin, making use of 
Brown Norway Rat yolk sac epithelial cells (BN16 cells) which highly express megalin. We 
found that BN16 cells show higher binding and internalization for prorenin than for renin, 
while uptake disappeared after silencing megalin. Moreover, we found that silencing the (P)
RR reduced prorenin/renin internalization but not binding. Our work therefore identified 
megalin as a novel receptor for prorenin and renin, and shows that megalin-mediated inter-
nalization of (pro)renin requires the (P)RR.
Preeclampsia is a disease that involves the development of hypertension and proteinuria af-
ter 20 weeks of gestation in previously normotensive women. It is one of the leading causes 
of maternal mortality during pregnancy. The placenta is believed to play a key role in the 
development of preeclampsia, as preeclampsia may even occur in the absence of fetal tis-
sue, in the form of gestational trophoblastic disease (hydatidiform mole). Many studies have 
suggested that a local placental RAS exists, in addition to the circulating RAS, based on the 
demonstration of RAS component gene expression in the placenta. Interestingly, circulating 







 1eclamptic uteroplacental unit are conflicting, with evidence for decreases, increases and no 
alteration. To better understand the role, if any, of the local placental RAS in preeclampsia, 
we compared the gene expression and protein levels of RAS components in healthy preg-
nant subjects and preeclamptic patients (Chapter 7). We found that (pro)renin levels are 
comparable in preeclamptic and healthy placentas, with no alterations in their mRNA ex-
pression. (P)RR expression was increased, and the same tended to be true for megalin. AGT 
protein could be easily detected in healthy placentas, despite its barely detectable mRNA 
levels. Placental AGT levels were reduced in preeclamptic placental tissue. To further un-
derstand the origin of placental (pro)renin and AGT, we also explored the release of AGT 
and (pro)renin from perfused placentas. AGT release gradually declined during perfusion 
time, while (pro)renin release remained stable. These findings suggest that placental AGT 
originates from maternal blood, while (pro)renin is locally synthesized. Interestingly, the 
proton pump inhibitor esomeprazole blocked megalin/(pro)renin receptor-mediated renin 
uptake. To what degree this implies that such drugs may interfere with placental RAS activ-
ity remains to be demonstrated. 
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Rationale: An elevated level of plasma low-density lipoprotein (LDL) is an established risk 
factor for cardiovascular disease. Recently, we reported that the (pro)renin receptor ([P]RR) 
regulates LDL metabolism in vitro via the LDL receptor (LDLR) and SORT1, independent-
ly of the renin-angiotensin system. 
Objectives: To investigate the physiological role of (P)RR in lipid metabolism in vivo.
Methods and Results: We used N-Acetylgalactosamine (GalNAc) modified antisense oligo-
nucleotides (ASO) to specifically inhibit hepatic (P)RR expression in C57BL/6J mice, and 
studied the consequences this has on lipid metabolism. In line with our earlier report, he-
patic (P)RR silencing increased plasma LDL cholesterol. Unexpectedly, this also resulted in 
markedly reduced plasma triglycerides in a SORT1-independent manner in C57BL/6J mice 
fed a normal or high fat diet. In LDLR-deficient mice, hepatic (P)RR inhibition reduced 
both plasma cholesterol and triglycerides, in a diet-independent manner. Mechanistically, 
we found that (P)RR inhibition decreased protein abundance of acetyl-CoA carboxylase 
(ACC) and pyruvate dehydrogenase (PDH). This alteration reprograms hepatic metabolism, 
leading to reduced lipid synthesis and increased fatty acid oxidation. As a result, hepatic (P)
RR inhibition attenuated diet-induced obesity and hepatosteatosis. 
Conclusions: Collectively, our study suggests that (P)RR plays a key role in energy homeo-
stasis and regulation of plasma lipids by integrating hepatic glucose and lipid metabolism. 
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Abbreviations
ACC  acetyl-CoA carboxylase
ApoB  apolipoprotein B
ASO  antisense oligonucleotides
LDL  low-density lipoprotein
LDLR  low-density lipoprotein receptor
LPL  lipoprotein lipase
mTOR  mechanistic target of rapamycin
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PCSK9  proprotein convertase subtilisin/kexin type 9
PDH  pyruvate dehydrogenase 
(P)RR  (pro)renin receptor
RAS  renin-angiotensin system
SORT1  sortilin 1
V-ATPase vacuolar H+-ATPase 
VLDL  very low-density lipoprotein
Introduction 
Elevated plasma low-density lipoprotein (LDL) levels are a major risk factor for develop-
ing atherosclerosis and ensuing ischemic cardiovascular disease (CVD), a leading cause of 
world-wide death. LDL, which is derived by peripheral lipolysis of very low-density lipo-
protein (VLDL), is primarily cleared from the circulation in the liver via the LDL receptor 
(LDLR) pathway.1, 2 Hence, plasma LDL levels are determined by the dynamic balance be-
tween hepatic VLDL secretion and LDL clearance. 
VLDL particles are formed by lipidation of ApoB100, the core protein of VLDL, in the 
ER and Golgi apparatus.3 The assembly of VLDL particles depends on ApoB100 produc-
tion and cellular availability of triglycerides. Accordingly, genetic mutations in ApoB100 
are associated with altered VLDL secretion and plasma LDL levels.4-6 Overexpression of 
ApoB100 results in increased VLDL secretion and plasma LDL levels in rabbits.7 Similarly, 
the activity of enzymes involved in de novo lipid biosynthesis also affect VLDL assembly 
and secretion.8, 9 For example, impaired loading of triglycerides into nascent VLDL parti-
cles, caused by mutations in the microsomal triglyceride carrier protein (MTP), result in 
defective VLDL secretion.10 
Disturbed LDL clearance can increase plasma LDL levels and risk for cardiovascular 
diseases. In line with this, loss-of-function LDLR mutations are associated with elevated 
plasma LDL levels and cardiovascular risk.11-13 Recently, GWAS studies have identified 
single-nucleotide polymorphisms (SNPs) mapping to 1p13.3 that strongly associated with 
plasma LDL levels and coronary heart disease.14-19 Subsequent mechanistic studies revealed 
that sortilin-1 (SORT1), located within the 1p13.3 region, is a novel regulator of LDL me-
tabolism.20-22 Overexpression of SORT1 increases LDL clearance and decreases plasma 
LDL levels,16, 21, 22 while SORT1 deficiency reduces cellular LDL uptake in vitro and LDL 
clearance in vivo.22, 23 Additionally, SORT1 also plays a role in VLDL secretion. Overex-
pressing SORT1 promotes ApoB degradation via an endolysosome-dependent route, and 
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hence reduces VLDL secretion and plasma triglyceride levels.22 Controversially, mice de-
ficient for SORT1 also display reduced VLDL secretion and triglyceride levels.20, 22 These 
opposing results highlight the complex, and not yet fully elucidated, role of SORT1 in lipo-
protein metabolism.
The (pro)renin receptor ([P]RR) interacts with renin/prorenin (denoted as [pro]renin) at 
supra-physiological concentrations that are even several orders of magnitude higher than 
(patho)physiological concentrations, questioning the physiological relevance of the (P)
RR-(pro)renin interaction.24, 25 Recently, the (P)RR was reported to play a role in Wnt/
β-catenin signaling pathway, vacuolar H+-ATPase (V-ATPase) integrity and T-cell develop-
ment, independently of (pro)renin.26-30 Moreover, we have recently identified the (P)RR as a 
SORT1-interacting protein,31 and demonstrated that silencing (P)RR expression in hepato-
cytes in vitro reduces protein abundance of SORT1 and LDLR post-transcriptionally, and 
consequently cellular LDL uptake. To understand the role of the (P)RR in lipoprotein me-
tabolism in vivo, we studied here the consequence of hepatic (P)RR silencing on lipoprotein 
metabolism. We report that hepatic loss of (P)RR in mice results in a SORT1-dependent 
increase in plasma LDL levels, but unexpectedly also in a reduction in plasma triglycerides 
that was SORT1-independent that resulted from altered metabolic reprogramming of he-
patocytes.  Our study thus highlights hepatic (P)RR as a crucial regulator of energy and lip-
id metabolism. 
Methods: 
A detailed description of methods used in this study is available in the Online Supplemental 
Materials.
Results 
Inhibiting hepatic (P)RR reduced both hepatic LDL clearance and VLDL secretion
We have previously reported that (P)RR inhibition attenuates cellular LDL uptake by reduc-
ing LDLR and SORT1 protein abundance in hepatocytes.31 To understand the role of hepatic 
(P)RR in lipoprotein metabolism in vivo, we used N-Acetylgalactosamine (GalNAc) mod-
ified antisense oligos (ASOs) to inhibit hepatic (P)RR expression. At a dose of 3.0 mg/kg/
week, GalNAc (P)RR ASO [G-(P)RR] potently reduced (P)RR expression in liver, but had 
no effects on its expression in other major organs, including heart, kidney, intestine, spleen, 
and different adipose tissues (Online Figure I A , C-F). In line with our previous report, in-
hibiting the (P)RR specifically reduced hepatic LDLR and SORT1 protein levels without af-
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fecting their transcript levels (Online Figure I B). As a result of reduced hepatic LDLR and 
SORT1 protein abundance, (P)RR inhibition elevated plasma cholesterol levels in normal 
diet (ND) fed mice, primarily by increasing cholesterol content in IDL/LDL fractions (Fig-
ure 1 A&B). Since plasma LDL-c concentrations refl ect the balance between hepatic LDL 
clearance and VLDL secretion, we then investigated the effects of (P)RR inhibition on LDL 
clearance and hepatic VLDL output. In line with decreased LDLR and SORT1, inhibiting 
hepatic (P)RR led to attenuated clearance of injected Dil-labeled human LDL (Figure 1C). 
Unexpectedly, (P)RR inhibition also signifi cantly decreased plasma triglyceride concentra-
tions (Figure 1D), a fi nding could be attributed to reduced hepatic VLDL secretion (Figure 
1E). 
Figure 1. Inhibiting hepatic (P)RR induces hypercholesterolemia by reducing hepatic LDL clearance in 
normal diet (ND)-fed C57BL/6J mice. Eight-weeks-old male C57BL/6J mice were inject with either saline 
(blue), G-control (magenta) or G-(P)RR (green) intraperitoneally. Mice were sacrifi ced after 7 days and blood 
samples were collected for (A) determining circulating levels of cholesterol (N=12-18 per group). Each bar 
and error represent the mean ± SEM; ***: p<0.001, or (B) pooled plasma samples were loaded on FPLC for 
lipoprotein fractionation analysis, and cholesterol content in each fraction was determined. (C) 7 days after 
injection, mice (n=6 per group) were injected with 50 μg Dil-labeled human LDL. Blood samples were drawn 
retro-orbitally at the indicated time points and the Dil-LDL was determined. Each point represents the mean ± 
SEM and the area-under curve (AUC) was constructed for each group and used to compare the difference in LDL 
clearance. ***: p<0.001. (D) Blood was collected as in (A) and used to determine plasma triglyceride levels. 
(N=12-18 per group); Each bar and error represent the mean ± SEM ***: p<0.001. (E) 7 days after injection, 
mice (n=6 per group) were fasted for 6 hours, and injected with Pluronic F127 to inhibit lipoprotein lipase. 
Blood samples were drawn retro-orbitally at the indicated time points and the concentration of triglycerides was 
determined. The mean VLDL secretion for saline-, G-control-, or G-(P)RR-injected mice is 474 ± 16 mg/dL*h, 
460 ± 14 mg/dL*h, and 342 ± 10 mg/dL*h, respectively. The AUC was calculated for individual mice and used 
to compare the differences in the rate of VLDL secretion. ***: p<0.001; G-control vs. G-(P)RR.
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We then asked if silencing (P)RR in hepatocytes could aggravate hypercholesterolemia in 
C57BL/6J mice fed a high-fat diet (HFD). Like in ND-fed mice, 1 week after (P)RR inhibi-
tion, plasma cholesterol levels were 3~4 fold higher than those measured in GalNAc control 
ASO (G-control) injected mice (Figure 2A). This elevation was primarily attributed to a 
marked increase in cholesterol content in the IDL/LDL fraction (Figure 2B). Notably, (P)
RR inhibition also increased cholesterol contents in the VLDL fraction and reduced choles-
terol contents in the HDL fraction. Unexpectedly, within two weeks, plasma cholesterol lev-
els of G-(P)RR injected mice normalized and were similar to those in the saline or G-con-
trol injected mice (Figure 2 A&C, Online Figure I G). This contrasts with the sustained 
increase in plasma cholesterol levels in C57BL/6J mice fed with ND (Online Figure I H). 
Nevertheless, (P)RR inhibition in HFD-fed mice reduced hepatic LDL clearance and VLDL 
secretion (Figure 2 D&E). Plasma triglycerides and VLDL triglycerides were both lower in 
G-(P)RR injected mice as compared to saline or G-control injected mice (Figure 2 F&G), 
thus mimicking the pattern seen under ND feeding. Importantly, plasma lipoprotein lipase 
(LPL) activity was not affected by hepatic (P)RR inhibition (Figure 2H). This excludes 
the possibility that increased triglyceride hydrolysis underpins reduced levels of plasma tri-
glycerides in (P)RR-silenced mice. 
Since SORT1 deficiency in vivo reduces VLDL secretions and plasma triglycerides and (P)
RR-silencing decreases SORT1,20, 22, 31 we wondered if the effect of (P)RR inhibition on he-
patic lipid output is SORT1-dependent. To address this possibility, we studied plasma lipid 
levels in (P)RR-silenced mice in which we overexpressed human SORT1 (hSORT1). Exog-
enous hSORT1 protein was detected in liver, and hSORT1 partially rescued the (P)RR-in-
hibition-induced LDLR protein reduction (Online Figure II). Given that SORT1 itself is 
a clearance receptor for LDL,20-22 it is not surprising that hSORT1 overexpression reversed 
the (P)RR-inhibition-induced increase in plasma cholesterol levels, primarily by decreasing 
the cholesterol content in the VLDL and IDL/LDL fractions (Figure 3 A&B). However, 
hSORT1 overexpression did not prevent the reduction in plasma triglycerides caused by (P)
RR inhibition (Figure 3C), implying that (P)RR inhibition reduced plasma triglycerides in 
a SORT1-independent manner. 
Hepatic (P)RR inhibition reduced plasma cholesterol levels in LDLR deficient mice
As (P)RR affects both hepatic LDL clearance and VLDL secretion, it is possible that (P)RR 
has a differential role in governing plasma cholesterol levels under distinct diet conditions. 
Under ND, LDL clearance may govern plasma cholesterol levels, while under HFD VLDL 
secretion may become more prominent in determining plasma cholesterol levels. To address 
this issue, we tested the effects of hepatic (P)RR inhibition on plasma cholesterol levels in 
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Figure 2. Inhibiting hepatic (P)RR does not result in hypercholesterolemia in HFD-fed C57BL/6J mice. 
Eight-weeks-old male C57BL/6J mice were injected with either saline (blue), G-control (magenta) or G-(P)RR 
(green), and fed a HFD for 4 weeks. (A) Plasma cholesterol concentrations were determined weekly and each 
point represents the mean ± SEM. N=10 per group; ***: p<0.001; G-control vs. G-(P)RR. (B,C) Pooled plasma 
samples were collected after the (B) 1st week of diet, or (C) following 4 weeks of diet  and the lipoprotein 
distribution was determined.  The cholesterol content in each fraction was determined and is plotted. (D) Two 
weeks after start of HFD diet, mice (n=6 per group) were injected with 50 μg Dil-labeled human LDL, and LDL 
clearance was assessed. Each point represent the mean ± SEM and the AUC was constructed for each treatment 
and used to compare the differences in LDL clearance. *: p<0.05. (E) Two weeks after (P)RR inhibition, mice 
were fasted for 6 hours and VLDL secretion was assessed (n=6 per group) by injecting mice with Pluronic 
F127 to inhibit lipoprotein lipase. Blood samples were drawn retro-orbitally at the indicated time points and the 
concentration of triglycerides was determined and the AUC was calculated and used to compare the differences 
in the rate of VLDL secretion. **: p<0.01; G-control vs. G-(P)RR. (F,G) Plasma triglyceride levels were 
analyzed in samples collected following 4 weeks of HFD. Each bar represents the mean ± SEM, N=10 per 
group. ***: p<0.001, or (G) pooled plasma samples were analyzed by FPLC. (H) Plasma lipoprotein lipase (LPL) 




Figure 3. SORT1 overexpression prevents PRR-dependent hypercholesterolemia, but does not affect 
reduction in plasma triglycerides. Eight-week-old male C57BL/6J mice were injected with G-control or G-(P)
RR intraperitoneally, and subsequently injected with either adenovirus carrying GFP (Ad-GFP) or adenovirus 
carrying human SORT1 (Ad-SORT1) via the tail-vein. Mice were fed with ND or HFD for 1 week and (A) plasma 
cholesterol levels were determined. Each bar represents the mean ± SEM (N=6 per group). **: p<0.01; ***: 
p<0.001. Alternatively, (B) Lipoprotein composition in pooled plasma samples was analyzed by fractionation. (C)
Plasma was collected as in (A) and analyzed for triglyceride content. Each bar and error represent the mean ± SEM 
(N=6 per group). **: p<0.01.  
mice with impaired LDL clearance by injecting adeno-associated virus (AAVs) expressing 
the gain-of-function PCSK9 D377Y mutant 32, 33 and in LDLR-/- mice. As expected, inject-
ing C57BL/6J mice with the PCSK9 D377Y-encoding AAVs led to a marked increase in 
the circulating levels of LDL cholesterol (from 77 ± 2 mg/dL to 167 ± 2 mg/dL, n=39). We 
subsequently injected these mice with either saline, G-control, or G-(P)RR for 4 weeks, and 
fed either ND or HFD. We found that after this treatment period, (P)RR inhibition reduced 
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plasma cholesterol levels in both ND and HFD fed mice, despite the lack of functional 
LDLR-mediated clearance (Figure 4 A-D). Similarly, inhibiting hepatic (P)RR in LDLR-/-
mice induced a sustained decrease in plasma cholesterol levels independent of diet (Online 
Figure III A&B). These results confi rm that LDL clearance is more dominant than VLDL 
secretion in determining circulating LDL levels in mice fed ND. Similar to the observation 
in wildtype C57BL/6J mice, plasma triglycerides and VLDL-associated triglycerides were 
Figure 4. Hepatic (P)RR inhibition in the absence of LDLR reduces plasma lipid levels and hepatic lipid 
deposition. Eight-week-old male C57BL/6J mice were injected intraperitoneally with 10×1010 genomic copies 
of mouse PCSK9D377Y AAV, and fed with ND for 4 weeks. Subsequently, mice were injected with either saline 
(blue), G-control (magenta) or G-(P)RR (green) and fed with ND or HFD for an additional 4 weeks. (A-D) Plasma 
cholesterol levels and lipoprotein profi les at the end of study were determined for ND fed (A,B) and HFD fed (C,D)
mice. (E-H) Plasma triglycerides and lipoprotein distribution were determined for ND fed (E,G) and HFD fed (F,H)
mice. (N=6 per group). **: p<0.01; ***: p<0.001; G-control vs. G-(P)RR. (I) Representative images of Oil Red 
O stained liver samples from above-indicated mice fed with ND or HFD for 4 weeks. scale bar = 100 μm. (J,K)
Lipids were extracted from liver samples and analyzed for triglycerides and cholesterol levels. *: p<0.05; G-control 
v.s G-(P)RR.    
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reduced by (P)RR inhibition under ND or HFD feeding (Figure 4 E-H), in PCSK9-induced 
LDLR deficient mice. Moreover, in LDLR-/- mice, hypertriglyceridemia was prevented by 
hepatic (P)RR inhibition (Online Figure III C&D). We reasoned that if (P)RR inhibition 
primarily affects lipid export pathways, we should observe lipid accumulation in liver, espe-
cially under HFD feeding. However, we found that hepatic lipid levels were also reduced by 
(P)RR inhibition (Figure 4 I-K, Online Figure IV), implying that the reduced plasma lipid 
levels are not the result of impaired lipid secretion. 
Hepatic (P)RR inhibition attenuated diet-induced obesity and improved metabolic disor-
ders
(P)RR inhibition resulted in decreased hepatic VLDL secretion without concomitant hepatic 
lipid accumulation. This could point towards (P)RR regulating hepatic lipid biosynthesis, an 
important facet of fatty liver disease and obesity.34 We therefore questioned whether hepatic 
(P)RR inhibition can ameliorate diet-induced fatty liver disease and obesity. To address this, 
we inhibited hepatic (P)RR expression in C57BL/6J mice fed a HFD for 14 weeks. In line 
with our hypothesis, loss of hepatic (P)RR attenuated diet-induced obesity in C57BL/6J 
mice (Figure 5A). Body composition analyses using EchoMRI revealed that inhibiting he-
patic (P)RR lowered fat weight of the mice, but did not affect the weight of lean mass (Fig-
ure 5B, Online Figure V A). Furthermore, the size of the livers and white adipose tissues 
(WATs) of G-(P)RR injected mice were smaller than control mice (Figure 5 C&D). Under 
HFD, lipid accumulates in liver and increases liver weight. Mean liver weight of saline or 
G-control injected mice was ~2 gram, which was nearly twice the mean liver weight (1.07 ± 
0.02 gram, n=12, p<0.001) of ND fed C57BL/6J mice at same age (22 weeks old). Hepatic 
(P)RR inhibition attenuated HFD-induced liver weight gain and prevented abnormal lipid 
deposition in the liver (Figure 5 E&F). Liver/body weight ratios of G-(P)RR injected mice 
were also significantly lower than that of G-control injected mice, and resembled the ratio 
of ND fed C57BL/6J mice at the same age (Online Figure V B). Moreover, mice in which 
hepatic (P)RR was inhibited had smaller adipocytes in inguinal WATs (Online Figure V C), 
but normal brown adipose tissues weight (Figure 5D). In agreement with reduced adipose 
tissues, plasma leptin concentrations were also reduced by hepatic (P)RR inhibition (Online 
Figure V D). However, plasma adiponectin concentrations were unaltered by (P)RR inhi-
bition despite the marked reduction in adipose tissue weight (Online Figure V E), likely 
due to increased expression of adiponectin in white adipose tissues (Online Figure I C&E). 
This suggests that hepatic (P)RR inhibition can indirectly affect adipokines secretion by ad-
ipose tissues, thereby contributing to improved metabolic control. 
Accompanied by less body weight gain, fasting blood glucose concentrations were reduced 
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by (P)RR inhibition (Online Figure V F), which also improved glucose tolerance and 
lowered plasma insulin levels (Online Figure V G&H). Plasma AST, ALT and AST/ALT 
ratio indicates (P)RR inhibition did not cause liver damage (Online Figure V I). In addi-
tion, H&E staining also revealed improved liver morphology by (P)RR inhibition (Figure 
5E). Cumulative food intake of the mice during the 14 weeks experimental period was also 
recorded. G-(P)RR injected mice consumed slightly less food than saline or G-control in-
jected mice, but when corrected for their body weight, their food consumption was actually 
higher (Online Figure V J), suggesting that the reduced body weight gain is not due to re-
duced food intake. In addition, we did not observe any difference in blood pressure or heart 
rate between saline, G-control or G-(P)RR injected mice (Online Figure V K&L), suggest-
ing that the activity of the autonomic nervous system was not affected. We then monitored 
oxygen consumption and physical activity of the mice using metabolic cages. Inhibiting he-
patic (P)RR increased oxygen consumption and 24h respiratory quotient (RQ) of the mice, 
implying increased catabolism of energy sources (Figure 5G). Yet, physical activities of the 
Figure 5. Hepatic (P)RR inhibition attenuates diet-induced obesity and metabolic deregulation. Eight-
week-old mice were injected with saline (blue), G-control (magenta) or G-(P)RR (green) and fed a HFD for 
14 weeks. (N=10 per group). (A) Body weight was monitored during the study period and each point and error 
represent the mean ± SEM. ***: p<0.001. Representative picture showing that G-(P)RR injected mice are leaner 
than control mice. (B) Fat and lean mass were measured by EchoMRI. Each bar and error represent the mean ± 
SEM. ***: p<0.001.  (C) Liver weight, and representative pictures showing G-(P)RR treated mice have less fatty 
liver.  **: p<0.01. (D) Weight and representative picture of different adipose tissue depots. Brown fat tissue of 
saline and G-control injected mice were surrounded with white fat which was removed to give a correct estimation 
of the weight of the brown fat.  ***: p<0.001.  (E) Representative images of Oil Red O and H&E staining of the 
livers (scale bar = 200 μm). (F) Hepatic lipids were extracted and measured. *: p<0.05; G-control vs. G-(P)RR. (G)
Oxygen consumption and 24h average respiratory quotient (RQ) of G-control injected and G-(P)RR injected mice 
was monitored with a metabolic monitoring system 4 days prior to sacrifi ce. N=8 per group. 
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mice were not different (Online Figure V M). Collectively, these results support the benefi-
cial metabolic effects of (P)RR inhibition. 
Inhibiting the (P)RR up-regulated genes involved in fatty acid oxidation
Currently recognized functions of the (P)RR are not linked with lipid biosynthesis and ener-
gy homeostasis. To understand how (P)RR may regulate these processes, we transcription-
ally profiled mice following (P)RR inhibition. Male mice (8-weeks old) were injected either 
with saline or G-(P)RR for 5 days, and liver samples were collected and extracted for total 
RNA and RNAseq analysis. We identified that (P)RR inhibition led to up- and down-regu-
lation of 199 genes and 202 genes, respectively (Online Table III). GO enrichment analysis 
revealed that metabolic pathways, including fatty acid (FA) degradation and elongation, 
were strongly affected by (P)RR inhibition (Online Figure VI A&B). Among the affected 
genes, several genes involved in FA β-oxidation, such as Hadha, Acaa2, Acadvl, and Acadl, 
were up-regulated by (P)RR inhibition, as confirmed by qPCR (Online Figure VII). As 
such, increased FA β-oxidation may contribute to increased oxygen consumption and re-
duced hepatic lipid content. 
Inhibiting (P)RR reduced protein abundance of ACC and PDH 
To complement the RNAseq analysis and to better understand the function(s) of the (P)RR, 
we next performed comparative quantitative proteomics to identify hepatic proteins which 
are affected by (P)RR inhibition. Through this unbiased approach, we identified 191 and 
116 proteins that were down- and up-regulated, respectively, following (P)RR inhibition 
during feeding of either ND and HFD (Online Table IV). As reported previously, LDLR 
protein abundance was decreased by (P)RR inhibition (Online Table IV), validating the 
effectiveness of this approach to identify proteins with altered abundance. GO enrichment 
analyses revealed that proteins involved in lipid biosynthesis, lipid metabolism, and cho-
lesterol metabolism were markedly affected by (P)RR inhibition (Online Figure VI C&D). 
Among the identified proteins, pyruvate dehydrogenase (PDH), acetyl-CoA carboxylase α 
(ACCα), and acetyl-CoA carboxylase β (ACCβ) were markedly decreased. PDH is the en-
zyme responsible for converting pyruvate to acetyl-CoA, and is a central metabolic node.35 
ACC catalyzes the formation of malonyl-CoA, an essential substrate for FA synthesis and 
a potent inhibitor of FA oxidation.36 ACC is crucial in determining lipid storage and overall 
energy metabolism.37 Thus, reduced PDH and ACC may contribute to increased FA oxida-
tion and decreased lipid synthesis. To confirm this, we examined ACCα/β and PDH protein 
abundance in the liver of saline, G-control or G-(P)RR injected C57BL/6J mice fed with 
HFD for 14 weeks. Corroborating the proteomic-based approach, hepatic ACCα/β, PDHA, 
and PDHB were reduced by ~40-60% after hepatic (P)RR inhibition (Figure 6A), whereas 
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the transcript abundance of ACCα/β, PDHA, and PDHB remained unaltered (Online Fig-
ure VII). Inhibiting the (P)RR in human hepatoma HepG2 cells with siRNAs also reduced 
protein abundances of ACCα/β, PDHA, and PDHB (Online Figure VIII A), suggesting 
that this outcome is conserved in both mouse and humans. The (P)RR knockdown induced 
reduction in ACCα/β protein abundance was partially reversed by the lysosome inhibitor 
bafi lomycin A1 (BafA1), but was not affected by the autophagy inhibitor 3-methyladenine 
(3-MA) or the proteasome inhibitor MG-132 (Online Figure VIII B), suggesting acceler-
ated lysosome-dependent degradation of ACCα/β by (P)RR inhibition. In contrast, BafA1, 
3-MA and MG-132 were unable to rescue (P)RR knockdown induced reduction in PDHA 
and PDHB, implying that a different mechanism underlies the control of these proteins by (P)
RR. 
Figure 6. Inhibiting the (P)RR reduces PDH and ACC protein abundance and activity. (A) Representative blot 
of liver samples from mice injected with saline, G-control, or G-(P)RR, and fed a HFD for 14 weeks. The protein 
abundance of PDHA, PDHB, and ACCα/β was quantifi ed and normalized to the level of β-actin in the same lysate. 
(N=6 per group); *: p<0.05; ***: p<0.001. (B) C57BL/6J mice were treated with ASOs and fed with HFD for 14 
weeks. Hepatic pyruvate concentrations (B), plasma pyruvate concentrations (C), plasma lactate concentrations (D), 
hepatic PDH activity (E), and acetyl-CoA concentrations (F) were determined. (G)  Mouse primary hepatocytes 
were treated with G-control or G-(P)RR for 36 hours, and cellular Acetyl-CoA concentrations were determined. 
Three independent experiments in triplicates were performed. ***: p<0.001. Oxygen consumption rate (OCR) (H)
and fuel dependency (I) were measured in mouse primary hepatocytes treated with G-control or G-(P)RR for 36 
hours. Arrow 1-3 indicates addition of oligomycin, FCCP and the mixture of rotenone and antimycin, respectively. 
N=6 per group. *: p<0.05; ***: p<0.001. 
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(P)RR inhibition reduced cellular acetyl-CoA abundance and FA synthesis in hepatocytes
Collectively, our results suggest that by reducing protein abundance of PDH, (P)RR inhibi-
tion reduces pyruvate to acetyl-CoA conversion, and therefore reduces cellular acetyl-CoA 
production from glucose. Lower cellular acetyl-CoA levels will limit cellular FA and cho-
lesterol synthesis. This biosynthetic block will be compounded by reduced ACC abundance, 
which will further limit FA synthesis and reduce plasma triglyceride levels. To test this 
hypothesis, we first measured relevant hepatic metabolites in mice injected with saline, 
G-control, or G-(P)RR and fed with HFD for 14 weeks. As expected, G-(P)RR injected 
mice displayed hepatic pyruvate accumulation (Figure 6B), increased plasma pyruvate and 
lactate concentrations (Figure 6 C&D), and decreased hepatic PDH activity (Figure 6E). 
Nevertheless, despite these changes, hepatic acetyl-CoA concentrations were unaltered by 
(P)RR inhibition (Figure 6F). Yet importantly, cellular acetyl-CoA levels in isolated mouse 
primary hepatocytes in which (P)RR was inhibited using G-(P)RR ASO, were reduced 
(Figure 6G). Similarly, acetyl-CoA levels were decreased by (P)RR inhibition in HepG2 
cells, combined with a decrease in cellular PDH activity, increased cellular pyruvate con-
centrations and medium lactate concentrations, and reduced cellular lipid levels (Online 
Figure VIII C-G). These data support our hypothesis, and simultaneously suggest that in 
vivo, alternative sources, especially fatty acids supply, are available to overcome reduced 
pyruvate to acetyl-CoA conversion. This may also explain why acetyl-CoA levels were not 
reduced in the liver, as they were in HepG2 cells and primary hepatocytes. It is plausible 
that increased FA oxidation provides additional acetyl-CoA to compensate the increased 
energetic demand, which could also explain the increased oxygen consumption observed in 
G-(P)RR injected mice. Therefore, we examined if (P)RR inhibition affects the oxygen con-
sumption rate (OCR) in mouse primary hepatocytes and HepG2 cells. As expected, inhib-
iting the (P)RR significantly increased basal OCR by ~50% in mouse primary hepatocytes 
(Figure 6H) and ~30% in HepG2 cells (Online Figure VIII H) and, implying increased 
energy expenditure and utilization of high-oxygen-consuming fuels such as FA. To fully 
understand the mechanism, we further examined cellular fuel dependency on long chain 
FA (LCFA) in mouse primary hepatocytes and HepG2 cells. In the presence of 50 µmmol/
L oleic acid, LCFA accounted for ~20-30% oxidized fuels (glucose, glutamine and LCFA 
together) in control cells, while it accounted for more than 40% oxidized fuels in primary 
mouse hepatocytes and HepG2 cells with (P)RR inhibited (Figure 6I, Online Figure VIII 
I). These data suggest that reduced acetyl-CoA supply from pyruvate is compensated by in-
creased FA oxidation, as a mechanism to sustain cellular energy needs. 
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We recently reported that the (P)RR is a novel modulator of LDL metabolism in vitro.31 
In the current study, we demonstrate that also in vivo, inhibiting the (P)RR in hepatocytes 
leads to defective LDL clearance as a result of reduced SORT1 and LDLR protein abun-
dance. SORT1 is a recently identified hepatic clearance receptor for LDL, which also reg-
ulates VLDL secretion and plasma triglycerides.16, 20-22, 38 SORT1 deficiency reduces VLDL 
secretion and plasma triglycerides,20 and in line with this, we found that (P)RR inhibition 
reduced VLDL secretion and plasma triglycerides, likely as a consequence of reduced 
SORT1. However, hepatic overexpression of hSORT1 in mice with (P)RR silencing was 
unable to prevent the reduction in plasma triglycerides, despite completely preventing the 
increase in plasma LDL-c. This implies that the (P)RR regulates plasma triglycerides via a 
SORT1-independent manner. Furthermore, plasma LPL activity was not affected by (P)RR 
inhibition, excluding the possibility that increased triglyceride hydrolysis accounts for the 
reduced plasma triglycerides. In fact, hepatic lipid concentrations, including triglycerides 
and cholesterol, were both markedly reduced by (P)RR inhibition, indicating that lipid 
synthesis is diminished. Indeed, we found that the protein abundance of ACC, the crucial 
enzyme catalyzing the first step in fatty acid synthesis, was markedly reduced by (P)RR 
inhibition. As a consequence, limited amounts of lipid being available for ApoB lipidation 
likely caused the reduction in plasma triglycerides. This may also explain why (P)RR inhi-
bition even reduced plasma cholesterol levels in LDLR deficient mice, in whom SORT1-de-
pedendent LDL clearance is impaired. 
Our results raise the question of how the (P)RR regulates cellular lipid levels. Intriguing-
ly,  vacuolar H+-ATPase (V-ATPase) has recently been identified as a component of the 
mechanistic target of rapamycin complex 1 (mTORC1) pathway.39  Indeed, acidification of 
lysosomes by V-ATPase is crucial for mTOR activation and function.40 Increased mTORC1 
activity is observed in genetic, and HFD-induced obesity, and has been implicated in the 
regulation of lipogenesis and VLDL secretion.41-43 Knocking down the (P)RR reduces the 
protein levels of several subunits of the V-ATPase complex.28-30, 44 Consequently, (P)RR 
inhibition may prevent mTORC1 activation. Nevertheless, this seems unlikely as a recent 
report found that mTORC1 signaling was unaffected by (P)RR.45 
An alternative explanation for the effect of (P)RR on hepatic lipid metabolism may be 
related to the renin-angiotensin system, which has been linked with obesity and lipid me-
tabolism.46 However, this too seems unlikely, as the affinity of (P)RR to (pro)renin is very 
low, and in fact their interaction requires supraphysiological concentrations of (pro)renin. 
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Rather, by using a combined unbiased transcriptome and proteomic approach, we now 
identified PDH and ACC as downstream effectors of (P)RR inhibition. (P)RR inhibition 
has previously been reported to reduce PDHB protein levels via a tyrosine-phosphorylation 
dependent manner in mouse retina and human retinal pigment epithelium cells.47 We found 
that both PDHA and PDHB were reduced by (P)RR inhibition. PDH is a ubiquitously ex-
pressed enzyme complex that catalyzes the conversion of pyruvate to acetyl-CoA,48, 49 acting 
as a central node that links lipid metabolism, glucose metabolism and the tricarboxylic acid 
(TCA) cycle. We thus speculated that by reducing PDH protein abundance and activity, (P)
RR inhibition would reduce acetyl-CoA production from glucose, and consequently dimin-
ish FA synthesis and increase FA oxidation (Figure 7).50 Indeed, this is what we observe in 
the livers of (P)RR-silenced mice. Additionally, (P)RR inhibition also reduced ACC protein 
abundance. ACC plays an essential role in regulating FA synthesis and degradation.37 Ge-
netic deletion, or inhibition, of ACC reduces body-weight gain and fat mass, suppresses tri-
glycerides synthesis, and increases FA oxidation and energy expenditure,51, 52 which resem-
bles the phenotype of hepatic (P)RR inhibition. Moreover, PPARγ expression was reduced 
by (P)RR inhibition by ~50% (Online Figure VII), and this may also have contributed to 
the reduced hepatic lipogenesis, as hepatic PPARγ plays important roles in HFD-induced 
upregulation of lipogenic genes and de novo lipogenesis.53-55 Recent studies have reported 
that genetically deleting adipose (P)RR in mice resulted in resistance to diet-induced obesi-
ty56 and accelerated oxygen consumption,57 yet causing severe hepatosteatosis.56 Unaltered 
(P)RR expression in both white adipose tissues and brown adipose tissues excluded the 
possibility that adipose (P)RR deficiency also contributed to the observed phenotype in our 
study. However, it raises the question whether inhibiting the (P)RR in both adipose tissue 
and liver would provide additional beneficial effects in treating metabolic disorders. 
Post-transcriptional regulation of ACC and PDH is not well understood, and thus nov-
el studies are required to fully understand their protein degradational regulation, and the 
role of the (P)RR in this process. TRB3 has been reported to control ACC degradation 
under fasting conditions by coupling ACC to the E3 ligase COP1.58  Interestingly, (P)RR 
inhibitions upregulated the expression of several E3 ligases, including HECTD1 (Online 
Table III), and both ACCα and ACCβ have been reported to interact with HECTD1.59 It is 
therefore conceivable that (P)RR inhibition accelerates ACC degradation via lysosomes by 
upregulating HECTD1. Simultaneously, the (P)RR-inhibition-induced reduction in PDH 
abundance is more difficult to understand. Inhibiting either autophagy, the lysosome or the 
proteasome did not rescue this reduction, nor did was inhibiting mitophagy, a special form 
of autophagy involved in degradation of mitochondrial proteins (data not shown). This may 
suggest that (P)RR inhibition regulates PDH abundance via an as yet unsolved mechanism, 
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as seems to be the case with SORT1 as well.31
In conclusion, we report that hepatic (P)RR is a crucial regulator of lipid metabolism. Inhib-
iting hepatic (P)RR reduced ACC and PDH protein levels, and consequently increases FA 
oxidation and reduces lipid synthesis, thus attenuating diet-induced obesity and liver ste-
atosis, as well as improving glycemic controls in C57BL/6J mice. Taken together, our study 
highlights the potential of inhibiting hepatic (P)RR as a therapeutic treatment for metabolic 
disorders such as fatty liver diseases, and familial hypercholesterolemia.   
Figure 7. Model for reprogramed hepatic metabolism by (P)RR inhibition. Inhibiting hepatic (P)RR reduces 
PDH activity, impairing pyruvate metabolism and reducing acetyl-CoA supply from pyruvate, which limits FA 
biosynthesis. (P)RR inhibition further limits FA biosynthesis by reducing protein abundance of ACC, the crucial 
enzyme in FA biosynthesis. It further signals to increase FA oxidation via reduced malonyl-CoA, an inhibitor of FA 
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C57BL/6 mice and LDLR-/- mice were obtained from Model Animal Research Center of 
Nanjing University (Nanjing, China), and were housed at a 10-hour light/14-hour dark 
cycle. 8-week old male C57BL6 mice were injected weekly with saline, GalNAc control 
ASOs (G-conrol), or GalNAc (P)RR ASOs [G-(P)RR] subcutaneously. For experiments ≤ 4 
weeks, ASOs were dosed at 3 mg/kg/week. For experiments ≥ 4 weeks, ASOs were dosed 
at 3 mg/kg/week in the first 4 weeks, and were then reduced to 1.5 mg/kg/week until end 
of the experiment. Mice were either fed with ND (Harlan Teklad) or HFD (42% kcal fat, 
0.2% cholesterol, Harlan Teklad). LDLR-/- mice were treated in the same way as C57BL/6 
mice. Body weight was monitored weekly. Food consumption of each cage hosting 6 mice 
was recorded weekly. Blood samples were collected via submandibular bleeding after 
6h fasting. Plasma lipid TC and TG levels were monitored bi-weekly, unless indicated 
elsewhere. Experimental procedures were approved by local animal ethnic committee (no. 
2014-0140). 
Antisense Oligonucleotides (ASOs)
ASOs with 5’-methyl modified cytosine and a phosphorothioate backbone containing 
2-O, 4-C-[(S)-ethylidene]-D-ribose (cEt) modified sugars were synthesized as described 
previously.1 Chimeric ASOs containing 16mer cEt chemistries were used with the gapmer 
design of 3-10-3 wherein the terminal 5’ and 3’ nucleotides contained the cET modified 
sugars that flanked 10 nucleotides with unmodified sugars. The liver targeting conjugate 
GalNAc was connected through a trishexylamino-(THA)-C6 linker at the 5’ end of the 
ASO.2 Extensive in vitro activity screens were performed followed by in vivo tolerability 
and activity studies to identify the lead (P)RR ASO with the following nucleotide sequence 
AGATATTGGTCCATTT. A control ASO that did not hybridize to any known rodent 
mRNA was used and had the following nucleotide sequence, GGCCAATACGCCGTCA. 
Intraperitoneal glucose tolerance test (IPGTT) 
IPGTT was performed as described elsewhere,3 one week prior to the end of the study. 
Briefly, following 16h fasting, 2 g/kg glucose was injected intraperitoneally to mice. Blood 
samples were collected from tail vain at 0, 15, 30, 60 and 120 min after glucose injection, 
and blood glucose was measured using a glucometer (Roche). Glucose levels at each time 
point were compared, and overall differences in glycemic control were compared using 
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area under curve (AUC). 
In vivo LDL clearance assay
In vivo LDL clearance was measured as described before.4 In short, mice were injected 
with 50 μg human Dil-labeled LDL (AngYuBio, Shanghai) via a tail-vein. Then, blood 
samples were collected retro-orbitally at 2, 10, 20, 40, 80, 160, and 300 min after injection. 
A standard curve was constructed by serial dilution of the human Dil-labeled LDL into mice 
plasma. Dil-LDL concentrations at 2 min after injection were the highest and were thus set 
as the baseline value for further analysis. Differences in VLDL secretion were compared 
using area under curve (AUC). 
Hepatic VLDL secretion
To determine VLDL-TG secretion rate, mice were fasted for 4 hours and injected 
intraperitoneally with 1 mg/g Pluronic F127 (Sigma Aldrich), a detergent that inhibits 
lipolysis. Subsequently, blood samples were collected by retroorbital bleeding at 0, 1, 2 and 
4 hours after Pluronic F127 injection. Differences in VLDL secretion were compared using 
area under curve (AUC). 
Fast Protein Liquid Chromatography (FPLC) analysis of plasma lipoproteins
FPLC analysis of plasma lipoproteins was performed as described before.5 In short, plasma 
samples were pooled, and cleared by centrifugation and filtering through a 0.22 μm filter. 
200 μL cleared plasma samples were loaded for FPLC analysis using an AKTA purifier 
(GE) and Superose-6 Increase 10/300 GL (GE). Flow rate was set to 0.5 mL/min, and 
fractions between 10-16 mL were collected at intervals of 0.25 mL/fraction. Cholesterol and 
triglycerides content in each fraction was measured.   
Oxygen consumption and physical activity measurement
Metabolic and physical activity of the mice were measured using an indirect open-circuit 
calorimeter (Oxylet, Panlab).6 Mice were housed individually in metabolic chambers 
and oxygen consumption, CO2 production, and physical activity were recorded at 30 min 
intervals for consecutive 48 hours. For accuracy, the recorded data from the first 12-14 
hours after the mice have been housed in the chamber were not analyzed. 
Body composition analysis
Fat and lean mass composition of the mice were evaluated by EchoMRI (Echo Medical 
Systems, Houston, TX, USA) before sacrifice. Weights of different fat tissues were 
measured using a scale balance with 0.0001-gram accuracy (Sartorius). 
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H&E staining and Oil Red O staining
Hematoxylin and eosin (H&E) staining was performed on 5 μm tissue sections which were 
Bouin’s-fixed and paraffin-embedded. Oil Red O staining was used to detected hepatic 
neutral lipids. Fresh liver and adipose tissues embedded in OCT were cryosectioned for 7 
μm. After fixation with 4% paraformaldehyde, sections were stained with 0.3% oil red o 
following standard procedures 7 and then counterstained with hematoxylin. Images were 
scanned using Cytation 5 Cell Imaging Multi-mode reader (Biotek). 
Measurement of ALT and AST
Blood samples were pre-cleared by centrifugation at 3,000×g for 5 minutes. Plasma alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) activities were measured by 
commercial kits (Biosino) following the manufacture’s protocol.
Adenovirus and Adeno-associated virus
Adeno-associated virus (AAV) expressing the D377Y PCSK9 mutant and their use was 
previously described.8 Eight-week-old mice were intraperitoneally with AAV-PCSK9 at a 
concentration of 10×1010 genomic copies, and fed a chow-diet for 4 weeks to induce LDLR 
degradation. Afterwards, mice were treated with saline, G-control, or G-(P)RR for 4 weeks, 
and fed with chow or HFD. Human SORT1 under control of a CMV promotor was cloned 
and inserted in to pAd-EF1a-GFP vector (Vigenebio, China). Packaging of adenovirus 
was performed by linearization of the plasmid and transfection of 293A cells. Adenoviral 
particles were purified by ultracentrifugation, and virus titer was determined by serial 
dilution and plaque formation. 8-weeks old male mice were injected with 1.5×109 pfu Ad-
hSORT1 or Ad-GFP (purchased from Vigenebio) via tail-vein. Mice were fed with chow or 
HFD for 7 days, and sacrificed after 6h fasting. 
Transcriptome analysis
To assess whether silencing hepatic (P)RR affects gene expression in the liver, we 
injected mice (3 mice/group) intraperitoneally with saline or G-(P)RR as described above. 
After 5 days, the mice were sacrificed after 6h fasting, and liver samples were collected 
immediately and stored in Trizol at -80 °C until use. Total RNA was extracted and a RNA 
sequencing library was constructed for each sample using the Illumina mRNA-Seq Prep 
Kit. Paired-End libraries were prepared following Illumina’s protocols and sequenced on the 
Illumina HiSeq X10 platform. RNA Sequencing reads were analyzed following the reported 
protocol with HISAT, StringTie and Ballgown.9 More specifically, high quality sequencing 
reads were firstly mapped to the mouse reference genome (version Ensembl GRCm38) 
using HISAT with default parameters.10 Transcriptomic expression at gene and transcript 
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level, characterized by FPKM (Fragments Per Kilobase of transcript per Million mapped 
reads), was then quantified by StringTie.9 The Ballgown package was used to identify 
differential expressed genes (DEGs) with P <0.05 between G-(P)RR and saline control.11 
Functional analysis of all DEGs was preformed using DAVID functional annotation 
clustering tool.12 Gene numbers were calculated for each Gene ontology (GO) category, and 
a hypergeometric test was used to identify significantly enriched GO categories in DEGs. 
Comparative proteomics using iTRAQ
To understand how does (P)RR inhibition affects lipid metabolism and energy metabolism, 
we performed comparative proteomics analysis. Mice (n=3/group) were treated with 
G-control or G-(P)RR for 4 weeks, and fed with chow or HFD. Mice were sacrificed 
after 6h fasting. Livers were collected and homogenized in lysis buffer by TissueLyzer. 
Proteins were precipitated by acetone and resuspended with dissolving buffer containing 6 
M guanidine hydrochloride and 300 mM TEAB (triethylammonium bicarbonate). Protein 
concentrations were determined by BCA, and equal amounts of proteins from individual 
samples per group were mixed and processed for iTRAQ labeling. Labeled samples were 
fractionated by high pH separation using Acquity UPLC H-Class Bio system (Waters 
Corporation, Milford, MA) connected to a reverse phase column (XBridge C18 column, 
2.1 mm×150 mm, 3.5 μm, 300 Å, Waters Corporation, Milford, MA). High pH separation 
was performed using a linear gradient, starting from 5% B to 35% B in 40 min (B: 5 mM 
ammonium formate in 90% acetonitrile, pH 10.0, adjusted with ammonium hydroxide). The 
column flow rate was maintained at 200 μL/min and column temperature was maintained 
at room temperature. Ten fractions were collected. Each fraction was dried in a vacuum 
concentrator for the next step. The peptide samples were resuspended with 30 μL solvent 
A respectively (A: water with 0.1% formic acid; B: acetonitrile with 0.1% formic acid), 
separated by nano-RPLC (EASY-nLC 1000, Thermo Fisher Scientific) and analyzed by 
on-line electrospray tandem mass spectrometry (Q Exactive mass spectrometer, Thermo 
Fisher Scientific). 5 μL peptide sample was loaded onto the trap column (Thermo Scientific 
Acclaim PepMap C18, 75 μm × 2 cm), and subsequently separated on the analytical column 
(Acclaim PepMap C18, 75 μm × 15 cm) with a linear gradient, from 5% B to 35% B in 70 
min, at a flow rate of 300 nL/min. The electrospray voltage of 1.6 kV versus the inlet of the 
mass spectrometer was used. The Q Exactive mass spectrometer was operated in the data-
dependent mode to switch automatically between MS and MS/MS acquisition. Survey full-
scan MS spectra (m/z 300-1600) were acquired in Orbitrap with a mass resolution of 70,000 
at m/z 200. The AGC target was set to 1 000 000, and the maximum injection time was 20 
ms. The ten most intense peaks were isolated in the quadrupole with isolation window of 2.0 
m/z units. Ions with charge states 2+, 3+, and 4+ were sequentially fragmented by higher 
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energy collisional dissociation (HCD) with a normalized collision energy of 27%, fixed 
first mass was set at 100, and further analyzed in the Orbitrap mass analyzer with 17,500 
resolution. The AGC target was set to 500,000, and the maximum injection time was 200 
ms. In all cases, one microscan was recorded using dynamic exclusion of 35 seconds. 
The expression ratio [G-(P)RR/G-control] was calculated for each protein, under different 
diet conditions. Cut-off value was set to 1.2-fold [G-(P)RR/G-control >1.2 or <0.083]. 
Proteins with altered abundance were compared between HFD and chow, and only proteins 
that were regulated in the same trend by (P)RR inhibition were identified as differential 
expressed proteins (DEPs). Functional analysis of all DEGs was preformed using DAVID 
functional annotation clustering tool. Gene numbers were calculated for each Gene ontology 
(GO) category, and hypergeometric test was used to identify significantly enriched GO 
categories in DEGs. 
Measurement of pyruvate, acetyl-CoA, lactate and PDH activity
Plasma pyruvate and lactate levels were detected using Pyruvate Assay kit (Sigma Aldrich) 
and Lactate Assay kit (Sigma Aldrich), following the manufacture’s protocols. To measure 
hepatic pyruvate, acetyl-CoA, and PDH activity, liver samples (~25 mg) were homogenized 
in the assay buffers provided with the kits, and measurements were performed according 
to the manufacture’s protocol. To measure cellular pyruvate levels, HepG2 cells were 
transfected with either control siRNA (siNC) or (P)RR siRNA [si(P)RR] for 48 hours. Cells 
were then detached using TrypLE and collected by centrifugation at 4 °C at 100×g, followed 
by washing with ice-cold PBS for three times. Measurement of pyruvate levels from an 
equal number of cells was performed according to manufacturer’s protocol, and normalized 
to cell number. Acetyl-CoA levels were measured using the PicoProbe Activity Microplate 
Assay kit (Abcam) in a similar approach, except that protein concentration was used to 
normalize acetyl-CoA levels. To measure lactate concentration, 24h after transfection, cells 
were switched to conditional medium (CM) that does not contain phenol red for 24 hours. 
Lactate levels in CM were then measured using the Lactate Assay kit (Sigma Aldrich). PDH 
activity was detected by a commercial kit (Sigma Aldrich), following the manufacture’s 
protocol. 
Measurement of lipoprotein lipase (LPL) activity
Mice were treated with saline, G-control, or G-(P)RR and fed an HFD for 4 weeks. To 
measure LPL activity, mice were injected with 0.2 U/g heparin via tail-vein, and blood 
were drawn 15 min after heparin injection. Plasma LPL activity were then measured with a 
commercial kit from Abcam (catalog nr. ab204721). 
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Measurement of plasma insulin
Mice were treated with saline, G-control, or G-(P)RR and fed an HFD for 14 weeks. At 12th 
week, after 6-hour-fasting, plasma samples were collected and measured for insulin levels 
with an ultrasensitive mouse insulin ELISA kit from ALPCO (catalog nr. 80-INSMSU-E01), 
following the standard manufacturer’s protocol. 
Isolation and culture of primary hepatocytes
Primary hepatocytes were isolated from C57BL/6J mice using previously described two-
step collagenase perfusion method with modifications.13 Briefly, mice were first perfused 
with O2 gassed perfusion buffer (5 mmol/L HEPES, 4 mmol/L KCl, 120 mmol/L NaCl, 
1 mmol/L KH2PO4, 2.4 mmol/L MgSO4, 40 mmol/L NaHCO3, 20 mmol/L glucose) 
supplemented with 0.1 mmol/L EDTA, for 5-7 minutes at a constant flow rate at 7 mL/
min. Perfusion path was set to flow into liver via inferior vena cava and flow out through 
portal vein. After the first perfusion step, mice were then perfused with O2 gassed perfusion 
buffer supplemented with 2.7 mmol/L CaCl2 and 1.6 mg/mL Type IV collagenase (Sigma 
Aldrich, catalog nr. C5138), for 3-4 minutes at a constant flow rate at 6 mL/min. Primary 
hepatocytes were released by removing liver capsule, and filtered through 100 µm filtered. 
Then, primary hepatocytes were washed with ice-cold DMEM and centrifuged at 50×g for 
2 min, which was repeated for three times. Primary hepatocytes were seeded at a density of 
600,000 cells/well or 8,000 cells/well into collagen coated 6-well plate or Seahorse 24-well 
plate, respectively, and cultured with DMEM GlutaMax™ high glucose supplemented with 
5% FBS. To inhibit (P)RR expression in mouse primary hepatocytes, 0.05 mg/mL G-(P)RR 
ASO was added to culture medium 3 hours after seeding cells. 
Seahorse XFe24 analyzer
HepG2 cells were seeded to Seahorse 24-well plate, and cultured with DMEM GlutaMax™ 
high glucose with 10% FBS. HepG2 cells were transfected with siNC or si(P)RR for 
48 hours. Mouse primary hepatocytes were isolated, seeded to Seahorse 24 well plate, 
and cultured with DMEM GlutaMax™ high glucose supplemented with 5% FBS. To 
inhibit (P)RR expression, mouse primary hepatocytes were treated with 0.05 µg/mL final 
concentration of G-(P)RR ASOs for 36 hours. Mitochondrial function and cellular fuel 
dependency were then measured using Seahorse XF Cell Mito Stress Test Kit and Seahorse 
XF Mito Fuel Flex Test Kit, following manufacturer’s protocol, with the exception that for 
FA dependency assay oleic acid was added to a final concentration of 50 µmol/L to the cell 




For protein expression and phosphorylation studies, 50 mg mouse liver samples were 
homogenized in RIPA buffer (50 mM Tris-HCl, 150mM NaCl, 1% Triton X-100, 1% sodium 
deoxycholate, 0.1% SDS, pH 7.4) with phosphatase inhibitor cocktail (Sigma Aldrich) 
and protease inhibitors cocktail (Roche) using TissueLyzer (Qiagen). Homogenates were 
centrifuged at 10,000×g at 4 °C for 10 minutes to clear any cell debris or insoluble proteins. 
Protein concentrations were then determined using BCA assay (Pierce). Equal amounts 
of proteins (30-40 mg) were loaded and separated on 4-20% Bis-Tris gels (GenScript), 
and transferred to PVDF membranes using iBlot® 2 Dry Blotting System (Thermo Fisher 
Scientific). For high-molecular weight proteins such as acetyl-CoA carboxylase (ACC), 
samples were loaded and separated on 6% SDS-PAGE gels with ice-cold buffers for 3-5 
hours, and transferred to PVDF membranes using traditional wet transferring system at 4 °C 
for 16 hours. The blots were then probed with the antibodies listed in Online Table I and 
detected by ClarityTM Western Substrate (Bio-rad). The intensities of bands were analyzed 
using ImageJ. 
Online Table I. Antibodies used in the study. 
RNA isolation and qPCR analysis
Liver samples were homogenized with Trizol (Thermo Fisher Scientific) and total RNA was 
extracted using Direct-zolTM RNA MiniPrep kit (ZYMO Research). One microgram of 
total RNA was reverse transcribed with Prime ScriptTM RT Master Mix (TaKaRa). SYBR 
Green real-time quantitative PCR assays were performed on a qTOWER apparatus (Analytic 
Jena) using SYBR®Premix Ex TaqTM II kit (TaKaRa). Primers used in the study were 
listed in Online Table II. 
Hepatic lipids extraction and measurement
To measure hepatic lipid contents, lipids in the liver were extracted using Folch’s method.14 
In short, 50 mg liver samples were homogenized using Tissue lyzer (60Hz, 30s) in 
chloroform and methanol mixture (2:1) followed by adding methanol, chloroform and 
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Online Table II.List of qPCR primer sequences. 
MQ. Extracted lipids were dried with N2 gas and dissolved with 200µL PBS containing 
1% Triton X-100. Cholesterol, triglycerides and non-esterified fatty acid (NEFA) were 
measured using colorimetric kits (Wako). 
Statistics
All values were presented as mean ± SEM. For experiments with n number ≥ 8/group, 
D'Agostino-Pearson omnibus test was performed to test normality. For experiments 
with less n number, Kolmogorov-Smirnov test was performed for normality test. After 
passing normality test, one-way ANOVA followed by the Bonferroni test was performed 
for comparison of more than two groups. And student t-test was used to compare the 
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Online Figure II.  SORT1 overexpression does not prevent PRR deficiency induced reduction in LDLR 
protein levels in the liver. Eight-week-old male mice were treated with G-control or G-(P)RR, in combination of 
control adenovirus (Ad-GFP) or SORT1 expressing adenovirus (Ad-SORT1). N=6 per mice. Representative blot. 
Ex: exogenously expressed hSORT1. En: endogenously expressed mSORT1. 
Online Figure III.  Inhibiting hepatic (P)RR in LDLR-/- mice reduces plasma cholesterol and triglyceride 
levels under both chow and HFD conditions. Eight-weeks-old male mice were treated with G-control (magenta) 
or G-(P)RR (green), and fed with ND or HFD for 16 weeks. Plasma cholesterol levels (A&B) and plasma 
triglyceride levels (C&D) were monitored weekly in the fi rst 4 weeks, and bi-weekly afterwards. N=8 per group. *: 
p<0.05; **: p<0.01; ***: p<0.001. 
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Online Figure IV.  Inhibiting hepatic (P)RR in LDLR-/- mice reduces plasma cholesterol and triglyceride 
levels under both chow and HFD conditions. Eight-weeks-old male mice were treated with G-control (magenta) 
or G-(P)RR (green), and fed with ND or HFD for 16 weeks. Plasma cholesterol levels (A&B) and plasma 
triglyceride levels (C&D) were monitored weekly in the fi rst 4 weeks, and bi-weekly afterwards. N=8 per group. 
*: p<0.05; **: p<0.01; ***: p<0.001. 
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Small interfering ribonucleic acids (siRNA) targeting hepatic angiotensinogen (Agt) may 
provide long-lasting antihypertensive effects, but the optimal approach remains unclear. 
Here we assessed the efficacy of a novel AGT siRNA in spontaneously hypertensive rats 
(SHRs). SHRs were treated with vehicle, siRNA (10 mg/kg fortnightly; subcutaneous), 
valsartan (31 mg/kg/day; oral), captopril (100 mg/kg/day; oral), valsartan+siRNA, or 
captopril+valsartan for four weeks (all groups n=8). Mean arterial pressure (recorded via 
radiotelemetry) was lowered the most by valsartan+siRNA (-68±4 mmHg), followed by 
captopril+valsartan (-54±4 mmHg), captopril (-23±2 mmHg), siRNA (-14±2 mmHg) and 
valsartan (-10±2mmHg). siRNA and captopril monotherapies improved cardiac hypertrophy 
equally, but less than the dual therapies, which also lowered NT-proBNP. Glomerular filtra-
tion rate, urinary neutrophil gelatinase-associated lipocalin and albuminuria were unaffected 
by treatment. siRNA lowered circulating AGT by 97.9±1.0%, and by 99.8±0.1% in combi-
nation with valsartan. Although siRNA greatly reduced renal angiotensin I, only valsartan+-
siRNA suppressed circulating and renal angiotensin II. This coincided with decreased renal 
sodium hydrogen exchanger type 3 and phosphorylated sodium chloride co-transporter 
abundances. Renin and plasma K+ increased with every treatment, but especially during 
valsartan+siRNA; no effects on aldosterone were observed. Collectively, these data indicate 
that angiotensin II elimination requires >99% suppression of circulating AGT. Maximal 
blockade of the renin-angiotensin system (RAS), achieved by valsartan+siRNA, yielded the 
greatest reduction in blood pressure and cardiac hypertrophy, while AGT lowering alone 
was as effective as conventional RAS inhibitors. Given its stable and sustained efficacy, 
lasting weeks, RNA interference may offer a unique approach to improving therapy adher-
ence and treating hypertension.
Keywords
Treatment resistant hypertension, novel therapeutics, small interfering RNA, renin-angio-
tensin-aldosterone system, acute kidney injury, hypertensive heart disease 
Introduction 
Treatment of hypertension generally requires multiple antihypertensive drugs, but is ham-
pered by reduced adherence with every drug added to the treatment regimen.1, 2 The man-
agement of hypertension is further complicated by the upregulation of counterbalancing 
mechanisms, e.g., the rise in renin during blockade of the renin-angiotensin system (RAS). 
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As a consequence, angiotensin (Ang) II levels are often restored to their original, pre-treat-
ment levels during the chronic treatment phase.3-5 All angiotensin stems from angiotensino-
gen (AGT), and blockade of the RAS at this level may ultimately annihilate RAS activity. 
Indeed, subcutaneously-delivered Agt-directed antisense oligonucleotides (ASO) and 
intravenous injection of lipid nanoparticles containing small interfering ribonucleic acids 
(siRNA) targeting Agt effectively lower blood pressure in hypertensive rats.6, 7 Still, these 
approaches typically require weekly doses and may have a less-ideal safety profile.8 On-
going efforts to optimize siRNA designs have now yielded hepatocyte-directed, N-acetyl-
galactosamine (GalNAc)-conjugated molecules with long-term, single-dose efficacy. In 
fact, stable suppression of proprotein convertase subtilisin/kexin type 9 (PCSK9) has been 
achieved in a phase 2 clinical trial, employing biannual dosing of one such siRNA.9 In the 
current study we set out to investigate the efficacy of a GalNAc-conjugated siRNA targeting 
Agt in spontaneously hypertensive rats (SHR), making a detailed comparison with the ACE 
inhibitor (ACEi) captopril and the angiotensin receptor blocker (ARB) valsartan, as well as 
with dual RAS blockade (AGT siRNA+valsartan and captopril+valsartan). We focused not 
only on blood pressure, but also unraveled the underlying RAS biochemistry and monitored 
the renal effects of these treatments, given the well-known side effects of RAS blockade, i.e., 
hypotension, renal dysfunction and hyperkalemia.10 Using this approach, we demonstrate a 
sustained antihypertensive and cardioprotective effect of AGT siRNA.  
     
Concise Methods 
All supporting data are available within the article and its online-only Data Supplement. 
Animal studies
All studies were performed under the regulation and permission of the Animal Care Com-
mittee of the Erasmus MC (protocol number 16-511-01). Male, 12-week old spontaneously 
hypertensive rats (SHRs), receiving a standard sodium diet, were treated for four weeks 
with vehicle, valsartan (31 mg/kg/day dissolved in drinking water), captopril (100 mg/kg/
day dissolved in drinking water), captopril+valsartan, AGT siRNA (10 mg/kg fortnightly; 
subcutaneous injection; provided by Alnylam Pharmaceuticals, Cambridge MA, USA), or 
valsartan+siRNA (all groups n=8). Conjugation of siRNA to triantennary GalNAc ensures 
selective delivery to hepatocytes. Although single and biweekly dosing provided similar 
AGT suppression (Supplemental Table S1), fortnightly dosing of 10 mg/kg AGT siRNA 
was selected to ensure maximal target silencing over the four-week period. For valsartan 
and captopril, water intake was checked every other day, and drug concentrations were ad-
justed to achieve the described daily doses. Blood pressure, heart rate and activity were re-
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corded continuously via radiotelemetry. Oligonucleotide synthesis and complete procedures 
are described in the Supplemental Material.
Biochemical measurements, qPCR, siRNA quantification and Western blotting
In plasma, AGT and active plasma renin concentration (APRC) were measured by enzyme 
kinetic assays. In the cases that measurements were at or below the lower limit of detection 
(LLOD), this limit was applied to allow for statistical analysis. Urinary AGT was measured 
by direct AGT radioimmunoassay, and plasma aldosterone by solid-phase radioimmunoas-
say. Angiotensin and bradykinin (BK) metabolites in blood and renal tissue were measured 
by LC-MS/MS analysis as described before. Procedures and LLOD are described in the 
Supplemental Material.
Total RNA was isolated from selected tissues and reverse transcribed into cDNA. Gene ex-
pression was quantified using primers designed with NCBI (Primer-BLAST; Supplemental 
Table S2). A gene specific TaqMan assay was used for Agt mRNA quantification. The DDCt 
method was used for relative quantification of mRNA expression levels.
siRNA quantification was performed as described previously. Antisense levels in siRNA 
standard curve dilutions, kidney and liver samples were quantified by stem loop reverse 
transcription followed by qPCR. Primer and probe sequences are described in the Supple-
mental Material. Ct values derived from samples were interpolated onto the standard curve, 
adjusted for sample dilution, and expressed as micrograms of antisense strand per gram of 
tissue.
Whole kidney protein extract was separated by electrophoresis, transferred to a membrane 
and incubated overnight at 4°C with primary antibodies against renal transporters described 
in the Supplemental Material. Signals were detected by chemiluminescence and quantified 
using ImageQuant. Samples (n=8 per group) were divided over two blots (n=4 per group 
per blot). To allow for combined statistical analysis, samples were first normalized to the 
loading control actin, followed by normalization to the average of the vehicle-treated rats 
from the respective immunoblot.
Kidney function
GFR in awake rats was measured prior to treatment (baseline), and after two and four weeks 
of treatment via transcutaneous measurement of fluorescein isothiocyanate (FITC)-labeled 
sinistrin, administered via the tail vein. A non-invasive clearance (NIC)-kidney fluorescent 
detection device together with partner software generates the elimination kinetics curve of 
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FITC-sinistrin. Excretion half-life (t1/2) is used to derive GFR using a conversion factor and 
formula validated for rats: 
GFR (mL/min per 100g body weight (BW)) = 31.26 (mL/100g BW) / t1/2 FITC-sinistrin 
(minutes).
Histology 
Cardiomyocyte size was measured after Gomori silver staining of sections (5μm) of the left 
ventricle of the heart. Sirius red staining was applied to visualize collagen as a measure of 
cardiac fibrosis. 
Myograph studies
Responses of iliac arteries were measured in a Mulvany myograph as changes in isometric 
force. Exposure to 100 mmol/l potassium chloride determined the maximum contractile 
response. Concentration response curves (CRCs) were constructed to endothelin-1 (ET-
1) in the absence or presence of ETA or ETB receptor antagonists. Iliac arteries were 
preconstricted with U46619 to construct CRCs to the endothelium-dependent vasodilator 
acetylcholine, in the absence or presence of the NO synthase inhibitor L-NAME, the small 
conductance Ca2+-activated K+ channel inhibitor apamin and the intermediate conductance 
Ca2+-activated K+ channel inhibitor TRAM34.
Statistical analysis
Data are expressed as mean values ± SEM. Data were analyzed with a one-way analysis 
of variance (ANOVA; for data obtained at a single point in time) or a repeated-measures 
ANOVA (for data obtained at multiple points in time) using Prism v7 (Graphpad Software 
Inc., La Jolla, USA). Post-hoc correction according to Bonferroni was performed in case of 
multiple comparisons. To conform to normality, non-parametric data were transformed to 
natural logarithms before statistical testing (AGT, renin, angiotensin metabolites, albumin-
uria). Univariate linear associations were assessed by calculation of Pearson’s coefficient of 
correlation. Two-tailed P values <0.05 were considered statistically significant.
Results 
AGT siRNA causes a similar antihypertensive effect as valsartan or captopril
Mean arterial pressure (MAP) at baseline was 137±2 mm Hg and progressively increased 
over time in vehicle-treated rats (9±1 mm Hg; P≤0.001 vs. baseline; Figure 1A-B). After 
four weeks, valsartan+siRNA lowered MAP the most (-68±4 mm Hg; P≤0.05 vs. capto-
pril+valsartan), followed by combined treatment with captopril+valsartan (-54±4 mm Hg; 
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P≤0.0001 vs. captopril; Figure 1B). Monotherapy with either captopril, AGT siRNA or 
valsartan lowered MAP similarly (-23±2, -14±2, and -10±2 mmHg, respectively; P=0.12 
captopril vs. siRNA, P>0.99 siRNA vs. valsartan, all P≤0.0001 vs. vehicle). None of the 
treatments affected heart rate (Figure 1C) or locomotor activity (Figure 1D).
Figure 1. Mean arterial pressure, heart rate and locomotor activity. SHRs were treated for 28 days with 
vehicle, valsartan, AGT siRNA, captopril, valsartan+siRNA or captopril+valsartan (all groups n=8). A) Mean 
arterial pressure (MAP), B) change from baseline MAP (D MAP), C) heart rate (HR) and D) locomotor activity 
were recorded via radiotelemetry. Data, represented as means ± SEM, were analyzed using two-way ANOVA and 
post-hoc Bonferroni (* P≤0.0001 vs. vehicle; $ P≤0.01; # P≤0.0001; % P≤0.05). Abbreviations: BPM, beats per 
minute.
Near-complete AGT depletion is required for lowering plasma Ang II
Plasma AGT levels amounted to 651±50 pmol/mL at baseline. They were lowered by 
97.9±1.0% after four weeks of treatment with AGT siRNA, and this increased to 99.8±0.1% 
in combination with valsartan (P≤0.0001 vs. siRNA; Figure 2A). Captopril with or without 
valsartan reduced plasma AGT levels by 86±4% and 44±13%, respectively (both P≤0.05 vs. 
baseline), while valsartan alone had no effect on AGT. Reductions in AGT concentrations 
were paralleled by increases in APRC in all treatment groups, the highest rise occurring 
after valsartan+siRNA (Figure 2B). In agreement with previous observations,11, 12 APRC 
exhibited a negative correlation with both circulating AGT and MAP (P<0.001; Supple-
mental Figure S1A and S1B). The well-known correlation between APRC and Ang I 
(r=0.80, P<0.0001 in non-siRNA-exposed rats, data not shown) disappeared when including 
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siRNA-treated rats in the analysis (Supplemental Figure S1C). In fact, now AGT correlat-
ed with Ang I (Supplemental Figure S1D). This was anticipated, since at very low AGT 
levels an increase in renin no longer results in a parallel rise Ang I. Accordingly, circulating 
Ang I levels were elevated after four weeks of treatment with valsartan, captopril and cap-
topril+valsartan (all P≤0.01 vs. vehicle; Figure 2C). Valsartan alone also increased Ang 
II (P≤0.0001 vs. vehicle; Figure 2C). Captopril, with or without valsartan, did not lower 
Ang II levels, although, consistent with ACE inhibition, it did diminish the Ang II/Ang I 
ratio (Figure 2C-D). Remarkably, only valsartan+siRNA lowered plasma Ang II (-76±5%; 
Figure 2. RAS parameters in plasma. Plasma levels of A) angiotensinogen (AGT) and B) active plasma renin 
concentration (APRC) of SHRs prior to treatment (baseline) and after four weeks of vehicle, valsartan, captopril, 
AGT siRNA, captopril+valsartan or valsartan+siRNA treatment (all groups n=8). Plasma C) angiotensin (Ang) 
levels and D) Ang II/Ang I ratio after four weeks of treatment. Data are represented as means ± SEM. Natural log-
transformed data were analyzed using repeated measures or one-way ANOVA and post-hoc Bonferroni (ø P≤0.05, 




P≤0.05 vs. vehicle; Figure 2C). No treatment altered plasma aldosterone after four weeks 
(Supplemental Table S3).  
AGT siRNA reduces renal Ang I, but requires valsartan for simultaneous Ang II lowering
After four weeks, hepatic siRNA levels amounted to 36±13 mg/g tissue, versus 3.7±0.5 mg/
g in the kidneys of rats treated with siRNA with or without valsartan. No siRNA could be 
detected in control rats. Given average liver and kidney weights of 12±1 and 2.3±0.1 g, this 
translates to a  ≈50-fold siRNA enrichment in liver versus kidney. In agreement with this, 
siRNA lowered hepatic Agt mRNA levels to 0.7±0.1% of control, while renal Agt mRNA 
levels remained unaffected (88±8% of control; Supplemental Figure S2A). Of note, Agt 
mRNA levels in the liver of control animals were approximately 170-fold higher than in the 
kidneys of these animals, based on Gapdh-normalized Agt ΔCt values (kidney ΔCt 8.2 ±0.5 
vs. liver ΔCt 0.8±0.3).
Although liver-targeted Agt silencing did not affect renal Agt expression, dual blockade 
with valsartan+siRNA did lower urinary AGT by 89±2% (Figure 3A). Valsartan and cap-
topril increased renal Ang I (both P<0.01 vs. vehicle), while captopril+valsartan did not 
affect renal Ang I (Figure 3B). Only siRNA with or without valsartan lowered renal Ang I 
by 97±1% and 86±1% respectively (both P<0.0001 vs. vehicle). Yet, valsartan did not affect 
renal Ang II, siRNA and captopril modestly lowered renal Ang II (P=NS for siRNA), and 
only dual blockade greatly reduced renal Ang II (P<0.0001; Figure 3B). As a consequence, 
the renal Ang II/Ang I ratio was increased 4-fold after siRNA (P<0.0001), reduced by 
>70% after valsartan, captopril and captopril+valsartan (all P<0.0001) and unaltered after 
siRNA+valsartan (Figure 3C). Renal Ang-(1-7) was increased after valsartan and captopril, 
unchanged after captopril+valsartan, and reduced after siRNA with or without valsartan 
(Supplemental Table S3). Captopril with or without valsartan impaired the renal degrada-
tion of BK-(1-9) into BK-(1-7), as reflected by reduced BK-(1-7)/BK-(1-9) ratios, without 
increasing BK-(1-9) levels (Figure 3D and E). Systemic bradykinin levels were all below 
the LLOD.
Dual RAS blockade synergistically improves cardiac hypertrophy
Cardiac weight (indexed to tibia length) exhibited a strong positive correlation to MAP 
(r=0.84; P≤0.0001; Figure 4A). Proportional to the magnitude of blood pressure reduc-
tions achieved, AGT siRNA and captopril monotherapies improved the cardiac weight/tibia 
length ratio equally, but less than dual RAS blockade (Figure 4B). Whereas valsartan+-
siRNA lowered this ratio the most (P≤0.01 vs. captopril+valsartan), valsartan monotherapy 
had no effect. Likewise, all treatments, except for valsartan, decreased cardiomyocyte sur-
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face area (Figure 4C). Between-group differences were no longer detectable. Only capto-
pril+valsartan lowered plasma NT-proBNP levels (P≤0.05 vs. vehicle), and a similar trend 
was observed for valsartan+siRNA (P=0.07 vs. vehicle; Figure 4D). At this stage, cardiac 
fibrosis had yet to develop (left ventricular collagen content 0.3±0.1% in vehicle-treated 
rats). Hence, this could not be improved by any treatment (data not shown).
None of the treatments caused acute kidney injury
GFR at baseline was 1.3±0.1 mL/min per 100 g body weight and remained stable through-
out the four-week treatment period in all groups (P≥0.65 vs. baseline; Figure 5A). Daily 
urine production was 4-fold higher after captopril and doubled after valsartan+siRNA 
Figure 3. Renal RAS and bradykinin levels. A) Urinary angiotensinogen (AGT) and renal B) angiotensin (Ang) 
levels, C) Ang II/Ang I ratio, D) bradykinin (BK) levels and E) BK 1-7/1-9 ratio of SHRs after four weeks of 
vehicle, valsartan, captopril, AGT siRNA, captopril+valsartan or valsartan+siRNA treatment (all groups n=8). 
Data are represented as means ± SEM. Natural log-transformed data were analyzed using ANOVA and post-hoc 
Bonferroni (* P≤0.05, ** P≤0.01, *** P≤0.0001 vs. vehicle or otherwise indicated in graph).
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(P≤0.0001 vs. captopril; both P≤0.0001 vs. baseline; Figure 5B). This was due to equiva-
lent increases in water intake (Supplemental Table S4). None of the treatments decreased 
urine output or increased urinary neutrophil gelatinase-associated lipocalin (NGAL) levels, 
a biomarker for early manifestations of kidney damage which precede renal function de-
cline in acute kidney injury (Figure 5C). Pre-existing chronic kidney disease was negated 
by very low levels of albuminuria at baseline (0.6±0.1 mg/day), which could not be im-
proved further by any treatment (Figure 5D). None of the treatments affected natriuresis 
(Figure 5E). Plasma potassium levels tended to increase in all groups (P≤0.001 for linear 
trend), significance being reached only with valsartan+siRNA (P≤0.01 vs. vehicle; Figure 
Figure 4. Indices of cardiac hypertrophy. A) Relationship between heart weight (HW) indexed for tibia length 
(TL) and mean arterial pressure (MAP), B) HW:TL ratio, C) cardiomyocyte surface area and D) plasma NT-
proBNP levels in SHRs after four weeks of vehicle, valsartan, captopril, AGT siRNA, captopril+valsartan or 
valsartan+siRNA treatment (all groups n=8). r denotes Pearson’s correlation coefficient. Data, represented as 
means ± SEM, were analyzed using a one-way ANOVA and post-hoc Bonferroni (* P≤0.05, ** P≤0.01, **** 
P≤0.0001 vs. vehicle or otherwise indicated in graph).
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5F). Both types of dual blockade attenuated normal growth (as indicated by body weight) 
from the second week of treatment onwards, without altering food intake (Supplemental 
Table S4).
Treatment did not alter renal AT1 or ACE expression, but reduced NHE3, pNCC and 
γ-ENaC 
AT1a receptor expression in cortex or medulla was not affected by any treatment (Supple-
mental Figure S2). AT1b receptor expression in the cortex was reduced after valsartan+siR-
NA (P≤0.01 vs. control), and a similar trend was found for captopril+valsartan (P=0.07 vs. 
control). All treatments decreased AT2 receptor expression in the medulla. Captopril+valsar-
tan increased AT2 and ACE expression in the cortex. None of the treatments affected ACE2 
or (pro)renin receptor expression. As anticipated, all treatments increased renin expression 
in the renal cortex (paralleling the changes in plasma renin), while dual blockade addition-
ally increased medullary renin expression.
Figure 5. Indices of kidney damage. A) Glomerular filtration rate (GFR), determined by transcutaneous 
measurement of FITC-sinistrin clearance curves, B) 24-hour urine production, C) urinary neutrophil gelatinase-
associated lipocalin (NGAL) levels, D) 24-hour albuminuria and E) 24-hour sodium (Na+) excretion of SHRs 
prior to treatment (baseline) and after four weeks of vehicle, valsartan, captopril, AGT siRNA, captopril+valsartan 
or valsartan+siRNA treatment (all groups n=8). F) Plasma potassium (K+) levels after four weeks of treatment. 
Data, represented as means ± SEM, were analyzed using repeated measures or one-way ANOVA and post-hoc 
Bonferroni (О P≤0.0001 vs. baseline; * P≤0.01, ** P≤0.0001 vs. vehicle or otherwise indicated in graph).
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All treatments reduced sodium-hydrogen exchanger type 3 (NHE3) abundance (P<0.01; 
Figure 6), although the reduction was non-significant in the case of valsartan+siRNA 
(P=0.1). Significant reductions in the phosphorylated (at threonine-58) form of the sodi-
um-chloride co-transporter (pNCC) were seen in the groups with the largest blood pressure 
decreases (captopril and the two dual-blockade groups with modest non-significant chang-
es in the other groups). NCC abundance changes followed this pattern. Valsartan+siRNA 
increased the abundance of sodium-potassium-chloride co-transporter (NKCC2; P=0.07 
vs. control; P<0.01 vs. AGT siRNA). Only siRNA with or without valsartan decreased the 
Figure 6. Renal sodium transporter protein abundance. A) Representative immunoblots showing protein 
abundances of renal sodium transporters: sodium-hydrogen exchanger type 3 (NHE3), Na-K-Cl co-transporter 
(NKCC2), Na-Cl co-transporter (NCC), NCC phosphorylated at Thr58 (pNCC), α- and γ-subunit of the epithelial 
sodium channel (α-ENaC; γ-ENaC), serum- and glucocorticoid-regulated kinase 1 (SGK1), neural precursor 
cell expressed, developmentally downregulated protein 4-2 (NEDD4-2), aquaporin-2 (AQP2) and β-actin in 
whole kidney homogenates after four weeks of vehicle, valsartan, captopril, AGT siRNA, captopril+valsartan or 
valsartan+siRNA treatment. B) Data, expressed as fold induction relative to vehicle-treated control (means ± SEM; 
all groups n=8), were analyzed using one-way ANOVA and post-hoc Bonferroni (* P≤0.05, ** P≤0.01 vs. vehicle 
or otherwise indicated in graph).
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g-subunit of the epithelial sodium channel (γ-ENaC; P<0.05 vs. control). None of the treat-
ments affected aquaporin-2, neural precursor cell expressed, developmentally downregulat-
ed protein 4-2, serum- and glucocorticoid-regulated kinase 1, or α-ENaC. In summary, these 
data confirm that blood pressure lowering during RAS blockade is accompanied by NHE3 
and NCC inhibition, while the observed potassium rise may have occurred secondary to de-
creased ENaC activity. 
Endothelial function and ET-1 responsiveness were not affected by any treatment
Acetylcholine relaxed preconstricted iliac arteries of vehicle-treated rats by 89±7% (Sup-
plemental Figure S3A). Blockade of both NO and EDHF was required to prevent this 
effect. None of the treatments altered this outcome. ET-1 potently constricted iliac arter-
ies of control SHR (pEC50 [the negative logarithm of the half-maximal effective concen-
tration] 8.2±0.6). ETA receptor blockade (pEC50 7.6±0.1; P≤0.5), but not ETB receptor 
blockade (pEC50 8.2±0.2), prevented this effect in control SHR. Single RAS blockade did 
not alter this outcome, while after dual RAS blockade ETB receptor blockade resulted in 
a leftward shift, suggesting ETB receptor-mediated vasodilation, with the rightward shift 
after ETA receptor blockade being significant only when compared to the ET-1 curve in the 
presence of BQ788 (Supplemental Figure S3B).
Discussion 
This is the first study comparing liver-directed AGT siRNA treatment with single and dual 
RAS blockade in a well-established hypertension animal model, the SHR. The results show 
that AGT siRNA is as effective in lowering blood pressure as single RAS blockade, while 
impressive synergy occurs in combination with a second RAS blocker, valsartan (Supple-
mental Figure S4). Remarkably, the data also reveal that siRNA-induced suppression of 
hepatic Agt mRNA, which reduced circulating AGT by almost 98%, did not significantly 
lower plasma or renal Ang II levels. This is reminiscent of clinical observations after chron-
ic ACE inhibition, which also did not result in chronic Ang II suppression, despite an acute 
initial decrease in Ang II.4, 13 This Ang II ‘escape’ can be explained by the rise in renin fol-
lowing treatment. Previous studies in humans, applying high renin inhibitor doses, demon-
strated that the capacity of the body to upregulate renin expression is almost unlimited, 
with elevations of several hundred-fold possible.11 In fact, a low AGT/high renin condition 
naturally occurs in mice.14 Their AGT levels are in the same range as those in SHR after 
AGT siRNA, while their renin levels are 2-3 orders of magnitude above those in rats, pigs 
and humans.15 Yet, mouse Ang II levels are identical to those in the latter species.16, 17 Thus, 
the body has a tremendous capacity to restore Ang II levels, simply by upregulating renin. 
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Nevertheless, at a very high degree of RAS blockade (obtained in this study by combining 
AGT siRNA+valsartan), the limit of this mechanism is reached: the high renin levels then 
essentially deplete any remaining AGT, and thus Ang II levels fall. As a consequence, blood 
pressure decreased sharply, resulting in the largest reduction in cardiac hypertrophy of all 
treatment groups. Such strong antihypertensive effects in rodents have been described pre-
viously during dual RAS blockade, particularly under low-salt conditions, and were accom-
panied by a similar degree of weight loss as observed in the present study as well as renal 
insufficiency.18, 19 Indeed,  dual RAS blockade with conventional RAS blockers is known to 
result  in renal dysfunction, both in animals and humans.10 Renal dysfunction was not ap-
parent in the present study, most likely because renal function (reflected by GFR, albumin-
uria and NGAL levels) was normal at the start of the study. Yet, siRNA+valsartan did raise 
potassium, possibly because low angiotensin II levels reduced ENaC activity. Plasma al-
dosterone levels were not suppressed after four weeks of treatment, suggestive for its well-
known restoration in an Ang II-independent manner after prolonged RAS blockade.13, 20 
A question raised by these data is why AGT suppression lowered blood pressure in the ab-
sence of changes in plasma Ang II. Such observations are typically attributed to alterations 
in tissue angiotensin levels, e.g., in the kidney. Agt mRNA is present in renal tissue, as 
confirmed in the present study. Yet, based on the ΔCt values, these levels are approximately 
170-fold lower than the hepatic Agt mRNA levels, and were unaffected by liver-targeted 
AGT siRNA. Nevertheless, AGT siRNA did lower renal Ang I levels by >85% (single 
treatment) or >95% (combined treatment with valsartan), and under the latter conditions, 
urinary AGT virtually disappeared. Therefore, as has been concluded before in renal and 
hepatic Agt KO mice,21, 22 renal angiotensin generation entirely depends on hepatic AGT, 
which suggests that renal AGT has no function, even when some of it is released into urine. 
Secondly, given the fact that renal Ang I levels already dropped during single AGT siRNA 
treatment, while circulating Ang I levels still remained intact, it appears that tissue angio-
tensin generation is even more sensitive to decreases in hepatic AGT synthesis. This has 
been observed before in cardiac tissue of heart failure patients,23 and most likely reflects the 
difficulty of circulating AGT diffusing into the tissue interstitium.24 Despite the substantial 
reduction in renal Ang I production, AGT siRNA alone did not significantly reduce renal 
Ang II levels. Here it is important to realize that tissue Ang II is bound to AT1 receptors, 
i.e., it is located either on the cell surface or internalized.16, 25, 26 An increase in AT1 receptor 
density will therefore result in a rise in tissue Ang II levels.25 Alternatively, ACE upregula-
tion might overcome the reduction in Ang II formation.27 Quantification of AT1a receptor, 
AT1b receptor, and ACE expression in the kidney ruled out these possibilities. Most likely 
therefore, factors affecting Ang II internalization (e.g., AT1 receptor-associated protein
28) are 
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responsible for maintaining near-normal renal Ang II levels, even when renal Ang I gener-
ation is diminished. Preventing internalization should then lower tissue Ang II levels. This 
is indeed what was observed during AT1 receptor blockade with valsartan co-administered 
with AGT siRNA: renal Ang II now decreased in parallel with Ang I, and the renal Ang II/I 
ratio was no longer different from control.
Ang II is a well-known regulator of both NHE329 and NCC, thus determining sodium bal-
ance.30, 31 In the present study, changes in pNCC fully paralleled the changes in blood pres-
sure, i.e., the largest pNCC reductions were seen in the rats with the largest blood pressure 
reduction. Alterations in renal Ang II synthesis and internalization (not necessarily reflected 
by reduced renal Ang II levels) may underlie these pNCC reductions, which then in combi-
nation with the RAS blockade-induced suppression of NHE3, may explain, at least in part, 
the antihypertensive (circulating RAS-independent) effect of RAS blockade. An additional 
explanation is that the higher plasma potassium concentrations inhibited pNCC.32 
We did not quantify tissue Ang II levels in the heart, vascular wall or adrenal gland, but 
given their dependency on hepatic AGT,15, 33, 34 it is reasonable to assume that alterations in 
their Ang II content paralleled those in the kidney. Such alterations, as for example reflect-
ed by the occurrence of ETB receptor-mediated vasodilation, may have contributed to the 
blood pressure-lowering effect. The virtual disappearance of Ang-(1-7) after AGT siRNA 
suggests that a contribution of this metabolite is unlikely. Similarly, the lack of BK-(1-9) ac-
cumulation during ACE inhibition in renal tissue argues against a major role for BK-(1-9), 
although the BK-(1-7)/BK-(1-9) ratio did decrease during this treatment. Together with the 
reduction in Ang II/Ang I ratio, this latter observation at least confirms that ACE inhibition 
was achieved at the tissue level. 
Perspectives
In SHRs, near-elimination of hepatocyte-derived AGT with siRNA+valsartan depleted an-
giotensin, causing a synergistic reduction in blood pressure and cardiac hypertrophy, greater 
than that induced by captopril+valsartan. Yet, renal function was preserved.  AGT siRNA 
as monotherapy provided similar antihypertensive and cardioprotective efficacy as conven-
tional small-molecule RAS inhibitors. Unique to AGT siRNA is the long-term effectiveness 
of a single subcutaneous injection. Indeed, preliminary studies in cynomolgus monkeys 
support AGT suppression for >100 days after a single siRNA injection of 10 mg/kg (n=3; 
unpublished observations). As medication nonadherence is associated with greater cardio-
vascular risk, long-acting agents have the potential to significantly improve outcomes. Such 
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efforts are already underway for the management of hypercholesterolemia. Inclisiran, a 
GalNAc-conjugated siRNA targeting PCSK9 now in phase 3 trials, requires only biannual 
dosing. Future studies should better define the relationship between AGT suppression and 
blood pressure to establish optimal dosing, as well as safety and efficacy in the context of 
common comorbidities, such as heart failure and chronic kidney disease, and in combina-
tion with other RAS blockers or a low-salt diet. Such studies should also address whether 
the massive renin rise in the absence of AGT involves recruitment of renin secreting cells 
outside the juxtaglomerular apparatus and/or juxtaglomerular hypertrophy.35
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Novelty and significance
What is new?
Small interfering RNA targeting liver angiotensinogen (AGT) provides antihypertensive 
and cardioprotective efficacy comparable to that of single RAS blockade.
Angiotensin II elimination requires >99% suppression of circulating AGT, and under such 
circumstances blood pressure decreases substantially.
What is relevant?
Given its stable and sustained efficacy, lasting weeks, RNA interference may offer a unique 
approach to improving therapy adherence and treating hypertension.
Summary
Maximal blockade of the renin-angiotensin system (RAS), achieved by valsartan+siRNA, 
yielded the greatest reduction in blood pressure and cardiac hypertrophy, while AGT lower-
ing alone was as effective as conventional RAS inhibitors. In clinical practice, RNA inter-
ference at the AGT level may not only prevent RAS reactivation, but also improve cardio-
vascular outcome and medication adherence, due to its long-lasting and stable efficacy after 
a single subcutaneous injection.
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All studies were performed under the regulation and permission of the Animal Care 
Committee of the Erasmus MC (protocol number 16-511-01). Male, 12-week old 
spontaneously hypertensive rats (SHRs) were obtained from Charles River, Germany 
(n=20), and, due to temporary unavailability of the SHR strain at Charles River, 
additionally from Janvier Labs, France (n=28). Rats were housed in individual cages 
and maintained on a 12-h light-dark cycle with access to standard rat chow and water 
ad libitum. Radiotelemetry transmitters (HD-S10, Data Sciences International, St. Paul, 
USA) were implanted for continuous measurement of blood pressure, heart rate and 
activity.1 After a one-week recovery period, SHRs were treated for four weeks with 
vehicle, valsartan (31 mg/kg/day dissolved in drinking water; Santa Cruz Biotechnology, 
Heidelberg, Germany),2, 3 captopril  (100 mg/kg/day dissolved in drinking water; Sigma 
Aldrich, Zwijndrecht, The Netherlands),4 captopril+valsartan, AGT siRNA (10 mg/kg; 
subcutaneous fortnightly injection; provided by Alnylam Pharmaceuticals, Cambridge, MA, 
USA), or valsartan+siRNA (all groups n=8). The siRNA consisted of a chemically modified 
antisense strand with sequence UUGAUUUUUGCCCAGGAUAGCUC, hybridized with a 
chemically modified sense strand of sequence GCUAUCCUGGGCAAAAAUCAA, with a 
triantennary GalNAc (a high-affinity ligand for the hepatocyte-specific asialoglycoprotein 
receptor, resulting in selective and efficient delivery to hepatocytes) attached to the 3’ end of 
the sense strand.5 To identify a dosing regimen for AGT siRNA, suppression of circulating 
AGT by AGT siRNA was evaluated in male, 16-week old SHRs (Charles River), treated 
with a single dose of phosphate buffered saline (PBS), 3 mg/kg, or 10 mg/kg siRNA on Day 
0; 3 mg/kg or 10 mg/kg on Day 0 and 14; or 10 mg/kg on Day 0, 7, 14, and 21. Circulating 
AGT levels were determined by enzyme kinetic assay as described below in serum collected 
at baseline (defined as Day 0), at two, and at four weeks post study start. While the various 
dosing regimens performed similarly (Supplemental Table S1), fortnightly dosing of 
10 mg/kg was selected to ensure maximal target silencing over the four-week period for 
assessment of efficacy. For valsartan and captopril, water intake was checked every other 
day, and drug concentrations were adjusted to achieve the described daily doses. During the 
study, blood plasma was collected from the lateral tail vein by venipuncture and 24-h urine 
was collected in metabolic cages prior to treatment (baseline), and after two and four weeks 
of treatment for biochemical measurements. At the end of antihypertensive treatment, 
rats were anaesthetized by inhalation of isoflurane and sacrificed by exsanguination: 1 
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mL blood was collected in 4 mol/L guanine thiocyanate (Sigma Aldrich), and remaining 
blood was supplemented with EDTA and centrifuged at 13000 rpm to obtain plasma. 
Kidneys and heart were excised, weighed, divided into transverse segments and fixated in 
4% paraformaldehyde for histological analysis, or snap frozen in liquid nitrogen for gene 
expression and protein analysis. 
Oligonucleotide synthesis
Oligonucleotides were synthesized on a MerMade-12 DNA/RNA synthesizer. Sterling 
solvents/reagents from Glen Research, 500-Å CPG solid-supports from Prime Synthesis, 
custom 2′-trivalent GalNAc 500-Å CPG solid-support, and 2′-O-methyl (2′-OMe), 
2′-deoxy-2′-fluoro (2′-F) ribonucleoside-phosphoramidites from Hongene were all used 
as received.5 Low-water content acetonitrile was purchased from EMD Chemicals. 
Oligonucleotides were synthesized using modified synthesis cycles, based on those 
provided with the instrument. A solution of 0.6 M 5-(S-ethylthio)-1H-tetrazole in 
acetonitrile was used as the activator. The phosphoramidite solutions were 0.15 M in 
anhydrous acetonitrile with 15% dimethylformamide as a co-solvent for 2′-OMe uridine 
and cytidine. The oxidizing reagent was 0.02 M I2 in THF/pyridine/H2O. N,N-Dimethyl-
N′-(3-thioxo-3H-1,2,4-dithiazol-5-yl)methanimidamide (DDTT), 0.09 M in pyridine, was 
used as the sulfurizing reagent. The detritylation reagent was 3% dichloroacetic acid (DCA) 
in dichloromethane (DCM). After completion of the solid-phase synthesis, the CPG solid 
support was washed with 5% (v/v) piperidine in anhydrous acetonitrile three times with 
5-minute holds after each flow. The support was then washed with anhydrous acetonitrile 
and dried with argon. The oligonucleotide was then incubated with 28-30% (w/v) NH4OH, 
35°C, 20 h.6 The solvent was collected by filtration and the support was rinsed with water 
prior to analysis. Oligonucleotide solutions of ~ 1 OD260 Units/mL were used for analysis of 
the crude material, where 30 – 50 μL of solution were injected. LC/ESI-MS was performed 
on an Agilent 6130 single quadrupole LC/MS system using an XBridge C8 column 
(2.1 × 50 mm, 2.5 μm) at 60°C. Buffer A consisted of 200 mM 1,1,1,3,3,3-hexafluoro-
2-propanol (HFIP) and 16.3 mM triethylamine (TEA) in H2O, and buffer B was 100% 
methanol. A gradient from 0% to 40% of buffer B over 10 min followed by washing and 
recalibration at a flow rate of 0.70 mL/min. The column temperature was 75°C. Crude 
oligonucleotides were purified by anion-exchange HPLC using a linear gradient of 0.17 M 
to 0.45 M NaBr buffer of pH 8.5/10% (v) acetonitrile in 120-150 min at room temperature. 
All single strands were purified to >85% HPLC (260 nm) purity and then desalted by size 
exclusion chromatography using an AP-2 glass column (20 × 300 mm, Waters) custom-
packed with Sephadex G25 (GE Healthcare), eluted with sterile nuclease-free water. 
Hybridization to generate siRNA duplexes was performed by mixing equimolar amounts of 
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complementary strands to a final siRNA concentration of 10 mg/mL in 1×PBS buffer, pH 
7.4, and by heating in a water bath at 95°C for 5 minutes followed by slow cooling to room 
temperature.
Biochemical measurements, RT-PCR, siRNA quantification and Western blotting
In plasma, AGT was measured by enzyme kinetic assay as the maximum quantity of 
angiotensin (Ang) I generated during incubation, at pH 7.4 and 37°C, with rat kidney 
renin in the presence of a mixture of ACE, angiotensinase, and serine protease inhibitors.7, 
8 The lower limit of detection (LLOD) of this assay was 0.2 pmol/mL. In the cases that 
measurements were at or below the LLOD, this limit was applied to allow statistical 
analysis. For comparison, in a selected set of samples, plasma AGT was also measured by 
direct AGT radioimmunoassay (Immuno-Biological Laboratories Co. Ltd., Japan), and 
AGT in urine was measured exclusively with this kit (LLOD 0.32 ng/mL or 0.006 pmol/
mL). Measurements by direct AGT radioimmunoassay fully confirmed the measurements 
by enzyme kinetic assay (n=36, data not shown), although levels in absolute terms were 5-10 
times lower with the direct assay as compared to those measured with the enzyme-kinetic 
assay. This is most likely due to the fact that the standard of the direct AGT assay, when 
determined by enzyme-kinetic assay (applying Ang I as standard), yielded 5-10-fold higher 
levels than predicted. Similar observations have been made with a human direct AGT 
assay.9
Active plasma renin concentration (APRC) was measured by enzyme kinetic assay, by 
quantifying Ang I generation in the presence of excess porcine angiotensinogen (LLOD 10 
fmol/ml.hr).7 Plasma aldosterone was measured by solid-phase radioimmunoassay (LLOD 
14.8 pg/mL; Diagnostic Products Corporation; Siemens Medical Solutions Diagnostics, 
Los Angeles, USA). NT-proBNP was measured with a rat ELISA NT-proBNP kit (LLOD 
15.6 pg/mL; Aviva Systems Biology, San Diego, USA). Angiotensin and bradykinin (BK) 
metabolites in plasma and renal tissue were measured by LC-MS/MS analysis as described 
before.10, 11 Briefly, tissue samples were homogenized under liquid N2 and extracted with a 
guanidinium based extraction buffer. Stabilized whole blood and tissue extracts were spiked 
with stable isotope labelled internal standards for each individual target analyte (Sigma 
Aldrich) before being subjected to C18 based solid phase extraction and subsequent LC-
MS/MS analysis. The lower limit of quantification (LLOQ) in blood/tissue were 4/8 (Ang 
I), 1/3 (Ang II), 7/17 (Ang-(1–7)), 1/9 (Ang-(1–5)), 3/6 (Ang-(2–8)), 1/8 (Ang-(3–8)), 11/11 
(BK-(1-9)) and 2/6 (BK-(1-7)) pg per mL or g tissue, respectively. In 24-h urine, albumin 
was measured with a rat albumin ELISA kit (LLOD 7 µg/mL; Abcam, Cambridge, UK) and 
NGAL with a rat NGAL ELISA kit (LLOD 0.1 pg/mL; Abcam, Cambridge, UK). Plasma 
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potassium and urinary sodium and total protein (both 24-hour urine) were measured at the 
clinical chemistry laboratory of the Erasmus MC. 
Total RNA was isolated from snap-frozen kidney cortex and medulla using TRI Reagent 
(Sigma Aldrich, Zwijndrecht, The Netherlands) and reverse transcribed into cDNA using 
the QuantiTect Reverse Transcription Kit (Qiagen, Venlo, The Netherlands). cDNA was 
amplified in 40 cycles in triplicate (denaturation at 95°C for 3 min; thermal cycling at 95°C 
for 3 sec, annealing/extension at 60°C for 20 sec) followed by a melt curve with a CFX384 
(Bio-rad) using Kapa SYBR® Fast (Kapa Biosystems). The intron-spanning oligonucleotide 
primers were designed with NCBI (Primer-BLAST; Supplemental Table S2). The ΔΔCt 
method was used for relative quantification of mRNA expression levels, using the geometric 
mean of housekeeping genes β2-microglobulin (B2M) and β-actin (Actb) for normalization. 
For quantification of Agt mRNA, snap-frozen liver and kidney samples of a subset of rats 
(vehicle-, AGT siRNA- and valsartan+siRNA-treated; n=3/group) were homogenized 
in a SPEX GenoGrinder (250 strokes per second, 1x speed, 120 seconds). Total RNA 
was isolated with a RNAqueous 96 Total RNA Isolation kit (ThermoFisher) and reverse 
transcribed into cDNA according to manufacturer protocol (Applied Biosystems). Multiplex 
qPCR reactions were performed in duplicate using a gene specific TaqMan assay for Agt 
(ThermoFisher Scientific #Rn00593114_m1) and rat Gapdh (#4352338E) as an endogenous 
control. Real-Time PCR was performed on a Roche LightCycler 480 using LightCycler 
480 Probes Master Mix (Roche). Data were analyzed using the ΔΔCt method, normalizing 
AGT expression to Gapdh, followed by normalization to the average of the control-treated 
animals. Data were expressed as percent of control.
siRNA quantification was performed as previously described.12 Briefly, tissue powder from 
homogenized livers and kidneys (vehicle-, AGT siRNA- and valsartan+siRNA-treated; n=3/
group) was reconstituted in PBS containing 0.25% Triton-X 100 at a concentration of 10 
mg/mL. A standard curve of siRNA comprised of ten four-fold serial dilutions from 8 ng/µL 
duplex (3.7 ng/µL antisense strand) was implemented for quantification of antisense strand. 
Samples and standard curve dilutions were then heated at 95°C for 10 minutes, followed by 
incubation on ice for 10 minutes and centrifugation at 15,000 × g for 10 minutes at 4°C. The 
supernatants were then transferred to new tubes. Kidney samples were diluted 1:1 in PBS 
with 0.25% Triton-X 100 prior to RT, while liver samples were diluted 1:500. Antisense 
levels were quantified by stem loop reverse transcription followed by qPCR based on 
previously-described methods.13, 14 The primer and probe sequences were GTCGTATCC
AGTGCAGGGTCCGAGGTATTCGCACTGGATACGACGAGCTATCCT (RT primer), 
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GCCGCGCTTGATTTTTGCCC (Forward qPCR primer), CTGGATACGACGAGCTATCC 
(Taqman probe), GTGCAGGGTCCGAGGT (Reverse qPCR primer), using 5’ FAM and 
3’ MGBNFQ for the probe. Ct values derived from samples were interpolated onto the 
standard curve for the antisense strand, adjusted for sample dilution, and expressed as 
micrograms of antisense strand per gram of tissue.
To perform immunoblotting, kidneys were cut into 4 equal pieces, and one piece was 
homogenized on ice in a buffer containing 0.3 M sucrose, 50mM Tris-HCl pH 7.5, 1mM 
EDTA, 1mM EGTA, 1mM DTT supplemented with protease inhibitors. Protein (40-60 ug; 
DCTM protein assay kit, Bio-Rad) were separated by electrophoresis on a Criterion TGX 
precast protein gel (Bio-Rad) and transferred to a membrane using the Trans-Blot Turbo 
Transfer System (Bio-Rad). Membranes were incubated with 5% bovine serum albumin 
(BSA) or 5% milk powder in Tris-buffered saline containing 0.1% Tween-20. Next, blots 
were incubated overnight at 4°C with primary antibodies against the following proteins: 
sodium-hydrogen exchanger type 3 (NHE3; StressMarq; 1:1000), sodium-potassium-
chloride co-transporter (NKCC2; StressMarq; 1:1000); sodium-chloride co-transporter 
(NCC; StressMarq; 1:500) and its phosphorylated form at threonine-58 (pNCC; a kind gift 
by Dr. R.A. Fenton15; 1:500), the α- and β-subunits of the epithelial sodium channel (ENaC; 
both StressMarq; 1:1000), serum- and glucocorticoid-regulated kinase 1 (SGK1; Millipore; 
1:1000), neural precursor cell expressed, developmentally downregulated protein 4-2 
(NEDD4-2, 1:1000, Abcam, Cambridge, UK), aquaporin-2 (AQP2; StressMarq; 1:1000). 
β-actin (Millipore; 1:50,000) was used for normalization of protein levels. After washing, 
blots were incubated with horseradish peroxidase-conjugated secondary antibodies (1:3000; 
Bio-Rad, Veenendaal, The Netherlands). Signals were detected by chemiluminescence 
(Clarity Western ECL substrate; Bio-Rad) and quantified using ImageQuant LAS 4000 
(GE Healthcare, Diegem, Belgium). Samples (n=8 per group) were divided over two maxi-
blots (n=4 per group per blot). To allow for combined statistical analysis, samples were first 
normalized to the loading control actin, followed by normalization to the average of the 
vehicle-treated rats from the respective immunoblot.
Kidney function
GFR was determined prior to treatment (baseline), and at two and four weeks of treatment 
via transcutaneous measurement of fluorescein isothiocyanate (FITC)-labeled sinistrin 
clearance curves using a miniaturized non-invasive clearance (NIC)-kidney fluorescent 
detection device (Mannheim Pharma & Diagnostics GmbH, Mannheim, Germany).16 
Briefly, rats were lightly anesthetized (2–2.5% v/v isoflurane). The NIC-Kidney device was 
attached to a depilated region on the back of the rat using a double-sided adhesive patch 
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and adhesive tape. Following a 3 to 5-minute baseline period, a bolus of FITC-sinistrin 
(3 mg/100 g made up in 0.9% sodium chloride solution) was administered via the tail vein. 
The rat was then returned to its cage for 2 hours. At the end of the 2-hour recording period, 
rats were lightly anesthetized and the NIC-kidney device was removed. The collected 
data were subsequently analyzed using NIC-kidney device partner software. The software 
generates the elimination kinetics curve of FITC-sinistrin from which excretion half-life 
(t1/2) was determined using a one-compartment model. The derived t1/2 was converted into 
GFR using a validated conversion factor and formula for rats previously described17, 18:
GFR (mL/min per 100g body weight (BW)) = 31.26 (mL/100g BW) / t1/2 FITC-sinistrin 
(minutes).
Histology 
Fixated heart sections were dehydrated and paraffin-embedded. Gomori silver staining 
was applied to deparaffinized sections (5μm) of the left ventricle of the heart to visualize 
individual cardiomyocytes. Sirius red staining was applied to visualize collagen as a 
measure of cardiac fibrosis. Cardiomyocyte size and the amount of collagen was measured 
using Qwin (Leica, Cambridge, UK). Only transversally cut cells showing a nucleus were 
used to determine the cardiomyocyte area.
Myograph studies
Following isolation, iliac arteries were cut into segments of ≈2 mm length and mounted in 
a Mulvany myograph (Danish Myo Technology, Aarhus, Denmark) with separated 6-mL 
organ baths containing Krebs bicarbonate solution, aerated with 95% O2 and 5% CO2, 
and maintained at 37°C.19 Tissue responses were measured as changes in isometric force, 
using Powerlab with Labchart software (AD Instruments, Oxford, UK). Following a 30-
min stabilization period, the optimal internal diameter was set to a tension equivalent of 0.9 
times the estimated diameter at 100 mm Hg effective transmural pressure, as described by 
Mulvany and Halpern.20 Subsequently, to determine the maximum contractile response, the 
tissue was exposed to 100 mmol/L KCl. The segments were then allowed to equilibrate in 
fresh organ bath fluid for 30 min. Next, segments were preincubated for 30 min with the NO 
synthase inhibitor L-NAME (Nω-nitro-L-arginine methyl ester hydrochloride; 100 μmol/
L), the small conductance Ca2+-activated K+ channel inhibitor apamin (100 μmol/L), the 
intermediate conductance Ca2+-activated K+ channel inhibitor TRAM34 (10 μmol/L), the 
ETA receptor antagonist BQ123 (1μmol/L), and the ETB receptor antagonist BQ788 (1μmol/
L). Thereafter, CRCs were constructed to ET-1. To construct CRCs to the endothelium-
dependent vasodilator acetylcholine (ACh), iliac arteries were preconstricted with U46619 
(0.1–0.3 μmol/L). All drugs were from Sigma-Aldrich. 
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Statistical tests were performed using Graphpad Prism version 7.0 for Windows (Graphpad 
Software Inc., La Jolla, USA). Data are expressed as mean values ± standard deviation (± 
SEM in figures). For comparisons between multiple groups, a one-way analysis of variance 
(ANOVA) was used to analyse data obtained at a single point in time, a repeated-measures 
ANOVA was used to analyse data obtained at multiple points in time. Post-hoc correction 
according to Bonferroni was performed in case of multiple comparisons. To conform to 
normality, non-parametric data were transformed to natural logarithms before statistical 
testing (AGT, renin, angiotensin metabolites, albuminuria). Univariate linear associations 
were assessed by calculation of Pearson’s coefficient of correlation. Two-tailed P values 
<0.05 were considered statistically significant. 
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Supplemental Table S1. Identification of a dosing regimen in SHRs treated with a single dose of PBS, 3 mg/
kg, or 10 mg/kg siRNA on Day 0; 3 mg/kg or 10 mg/kg on Day 0 and 14; or 10 mg/kg on Day 0, 7, 14, and 
21. Circulating AGT levels were determined in serum collected at baseline (defined as Day 0), at two, and at 
four weeks post study start. Data are expressed as percentage of predose levels and presented as mean ± SD. 
Abbreviations: q2w, once every 2 weeks; qw, once per week.
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Supplemental Table S2. Sequences of primers for RT-PCR. Abbreviations: AT1a, angiotensin II type 1a receptor; 
AT1b, angiotensin II type 1b receptor; AT2, angiotensin II type 2 receptor; ACE, angiotensin converting enzyme; 
Ren, renin; (P)RR, (pro)renin receptor; ACTB, β-actin; B2M, β2-microglobulin.
Supplemental Table S3. Renin-angiotensin-aldosterone system (RAAS) parameters in blood and kidney after four 
weeks of vehicle, valsartan, captopril, AGT siRNA, captopril+valsartan or valsartan+siRNA treatment (all groups 
n=8). Data, represented as means ± SD, were analysed using ANOVA and post-hoc Bonferroni (*P≤0.05, †P≤0.01, 
‡P≤0.001, §P≤0.0001 vs. vehicle). 
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Supplemental Table S4. Growth, food and water intake after four weeks of vehicle, valsartan, captopril, AGT 
siRNA, captopril+valsartan or valsartan+siRNA treatment (all groups n=8). Data, represented as means ± SD, were 
analysed using repeated measures or one-way ANOVA and post-hoc Bonferroni (*P≤0.05, †P≤0.01, ‡P≤0.001, 
§P≤0.0001 vs. vehicle).
Supplemental Figure S1. Relationship between RAS parameters and antihypertensive effect. Correlation 
between A) angiotensinogen (AGT) and active plasma renin concentration (APRC), B) APRC and change in 
mean arterial pressure (ΔMAP; expressed as area under the curve), C) APRC and angiotensin (Ang) I, D) AGT 
and Ang I after four weeks of treatment with vehicle, valsartan, captopril, AGT siRNA, captopril+valsartan or 
valsartan+siRNA (all groups n=8). r denotes Pearson’s correlation coefficient.
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Supplemental Figure S2. Angiotensinogen, ACE, angiotensin receptor, renin and (pro)renin receptor 
expression. Gene expression of A) angiotensinogen (Agt) in liver and kidney (n=3 each for control, AGT siRNA, 
and valsartan+siRNA groups), B) angiotensin converting enzyme (ACE), C) ACE2, D) angiotensin II type Ia 
(AT1a), E) angiotensin II type Ib (AT1b), F) angiotensin II type 2 (AT2) receptors, G) renin and H) (pro)renin 
receptor ((P)RR) in renal cortex (closed bars) and medulla (striped bars) after four weeks of vehicle, valsartan, 
captopril, AGT siRNA, captopril+valsartan or valsartan+siRNA treatment (all groups n=8, except where noted). 
Data, expressed as fold induction relative to vehicle-treated control (means ± SEM), were analysed using one-way 
ANOVA and post-hoc Bonferroni (after logarithmic transformation for renin; * P≤0.05, ** P≤0.01, # P≤0.0001 vs. 
vehicle unless indicated otherwise in graph).
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Supplemental Figure S3. Vascular responses to acetylcholine and endothelin-1. A) Relaxations to 
acetylcholine (% reduction of preconstriction with U46619) in the absence (control; black circles) or presence of 
Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME; red triangles) or L-NAME+TRAM34+apamin (blue 
squares) and B) contractions to endothelin-1 (% of the response to 100 mM KCl) in the absence (control; black 
circles) or presence of BQ123 (blue squares) or BQ788 (red triangles) in iliac arteries obtained after after four 
weeks of vehicle, valsartan, captopril, AGT siRNA, captopril+valsartan or valsartan+siRNA treatment (all groups 
n=8). Emax (maximal effect) and pEC50 (the negative logarithm of the half-maximal effective concentration) were 
analysed using one-way ANOVA and post-hoc Bonferroni (* P≤0.05, ** P≤0.01 vs. control pEC50; # P≤0.01 vs. 
BQ123).
Supplemental Figure S4. Schematic summary of renin-angiotensin system (RAS) inhibitor drug targets 
and effects. Abbreviations: AGT, angiotensinogen; Ang, angiotensin; AT1R, angiotensin II type 1 receptor; 





Tubular (Pro)renin Release: the Curtain Falls
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Renin was first described in urine >50 years ago.1 Given the fact that its urinary levels 
usually do not correlate with plasma renin levels, a reasonable concept is that renin 
is released from renal tissue sites into urine under conditions where the renal renin-
angiotensin system (RAS) is activated. In other words: urinary renin reflects renal RAS 
activity. One such condition is diabetes, which is characterized by low circulating renin 
levels, and a paradoxical enhanced renal response to RAS blockers, suggestive for renal 
RAS upregulation. Indeed, urinary renin levels are elevated in diabetic patients.2 In this 
issue of Hypertension, Tang et al.3 shed new light on this important issue, making use of an 
extensive set of experiments in humans and mice.
Of course, a logical first question is why renin release into the circulation is diminished in 
diabetes, while simultaneously RAS activity in the kidney is enhanced. Here the intriguing 
in-vitro observation that the principal cells of the collecting duct synthesize renin may come 
to help.4 Remarkably, this synthesis, in contrast with renin synthesis in the juxtaglomerular 
apparatus, is stimulated by angiotensin II. Furthermore, these cells release prorenin rather 
than renin. It has even been suggested that the collecting duct is the source of the elevated 
circulating prorenin levels in diabetes.4 The latter has been known for decades, but remained 
a mystery due to the fact that prorenin is the inactive precursor of renin. Hence, its elevation 
would have no functional consequences. The final piece of the puzzle appeared to be 
the discovery of the (pro)renin receptor, which is also present in the collecting duct, and 
possibly even released into urine in a soluble form.5 Prorenin binding to this receptor allows 
prorenin to display activity, due to a conformational change in the prorenin molecule, not 
requiring actual prosegment cleavage. Subsequently, multiple effects of the prorenin-(pro)
renin receptor axis in the kidney have been postulated, ranging from local angiotensin 
production to direct prorenin-induced effects, e.g. on water reabsorption, epithelial Na+ 
channel expression, and fibrosis.6
However, these studies ignored the low (nanomolar) affinity of the (pro)renin receptor for 
prorenin, which implies that prorenin-(pro)renin receptor interaction in vivo, even in the 
kidney (with prorenin levels that might be somewhat higher than its picomolar levels in 
blood), would be negligible. Moreover, prorenin is normally barely detectable in urine, 
while urinary renin levels correspond with ≈5% of plasma renin levels.2 Importantly, early 
studies had revealed that urinary renin levels rise considerably when blocking proximal 
tubular reabsorption with lysine.7 Similarly, up to 40-fold higher renin levels were observed 
in patients with Dent’s disease and Lowe syndrome in whom megalin expression and 
tracking is impaired, thereby resulting in tubular dysfunction.8 In such patients prorenin also 








These data imply that normally, there is extensive reabsorption of renin (on average 95%), 
and suggest that such reabsorption might even be close to 100% in the case of prorenin 
(hence the inability to detect prorenin in urine under normal circumstances). Studies in 
rodents fully confirmed megalin-dependent reabsorption of renin,9 and accordingly massive 
rises in urinary renin occurred after megalin knockout, without affecting plasma renin 
levels.10
Here it is important to note that renin and prorenin, like albumin, can be filtered through 
the glomerulus. In fact, since both renin and prorenin are smaller than albumin, relatively 
larger amounts of renin and prorenin will pass the glomerulus in comparison with albumin. 
Not surprisingly, the glomerular sieving coefficients for renin and prorenin increase after 
damaging the glomerular filtration barrier.8 The disparity between plasma and urinary renin 
levels might then relate to 3 factors: variation at the level of the filtration barrier (dependent 
on the degree of glomerular damage), variation in reabsorption (dependent on the degree of 
megalin expression), and release of renin (or soluble (pro)renin receptor-bound prorenin?) 
from tubular sites into urine. Tang et al. are the first to address these factors in the diabetic 
setting.
They show that urinary renin levels are higher in diabetic patients with kidney disease 
(albumin/creatinine ratio >300 mg/g or estimated glomerular filtration rate (eGFR) <60 
mL/min per 1.73 m2 plus albumin/creatinine ratio >30 mg/g) than in those without kidney 
disease, and in mice made diabetic with streptozotocin versus healthy control mice. They 
next confirm that lysine increases urinary renin levels, not only in normal mice, but also in 
diabetic mice. Since the lysine-induced urinary renin rise in diabetic mice (≈10-fold) was 
smaller than in normal mice (>100-fold), they speculate that reabsorption is disturbed in 
diabetic mice. To investigate this further, they injected recombinant human renin (single 
i.v. injection of 0.5 µg/g, or in a mouse of 25 gram 12.5 µg renin), which if present in 
urine cannot have been released from renal tissue sites. Human renin was found to be 
≈25 times higher in urine of diabetic mice vs. normal mice. Unfortunately the authors 
did not measure human renin in plasma after injection, but 12.5 µg renin, if confined to 
the blood compartment, would translate to a >1000-fold higher plasma renin level than 
in humans. The urinary human renin levels increased after lysine in both normal (≈60-
fold) and diabetic mice (≈3-fold), although the rise in diabetic mice was not significant. 
These data unequivocally illustrate that tubular reabsorption is disturbed in diabetes. 
The authors were able to confirm that this was paralleled by lower megalin expression in 
diabetic kidneys. Like Kang et al.,4 they also observed diminished renin immunostaining 
in the juxtaglomerular apparatus and increased staining in the collecting tubules in diabetic 
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mice. Moreover, proximal tubules renin staining was diminished in diabetic mice, in 
agreement with the reduced megalin expression. Yet, renin mRNA levels were unaltered 
in microdissected cortical collecting ducts. This argues against increased renin synthesis at 
this site as an explanation of the increased staining, and rather favors renin uptake. Indeed, 
using a renin reporter mice model (Ren1d-Cre; mT/mG), allowing tracking of the migration 
of kidney renin lineage cells, no evidence was found for the migration of these cells to the 
collecting duct. Importantly, the authors also found very few tubular epithelial structures 
with a co-localization of renin and renin lineage cells. Taken together, these data confi rm 
previous results showing increased (pro)renin levels in the collecting duct of diabetic 
animals,4 but now reveal that this is a matter of uptake rather than local synthesis. Thus 
the collecting duct can no longer be considered a source of urinary (pro)renin, not even in 
diabetes. 
After this elegant clarification, several questions remain. What determines megalin 
expression/activity? One candidate is angiotensin II. Changes in urinary pH may also 
Figure. Determinants of urinary (pro)renin levels. After fi ltration of renin and prorenin from blood, megalin in 
proximal tubule cells sequesters both. This may either result in lysosomal destruction or basolateral release, thus 
potentially facilitating renal angiotensin generation. Megalin-mediated sequestration normally is near-complete, 
particularly in the case of prorenin, and thus prorenin is not detectable in urine, while urinary renin levels are 
≈5% of plasma renin levels. Yet, in diabetes, megalin expression is reduced. Combined with glomerular damage 
(allowing more fi ltration) this will result in much higher urinary renin levels, even when plasma renin levels in 
blood in diabetics are lower. Finally, (pro)renin levels have been reported to be elevated in the collecting duct of 
diabetics. Initially, this was attributed to diabetes-induced prorenin production in principal cells, which through 
binding to the (pro)renin receptor would result in secondary signaling and local angiotensin generation. Collecting 
duct-derived prorenin was even suggested to be the cause of the elevated prorenin levels in diabetics.4 The study 
by Tang et al.3 now reveals that there is no such (pro)renin production in diabetes, and that the higher levels are 
entirely due to uptake. This is unlikely to involve the (pro)renin receptor, given its very low affi nity for (pro)renin, 
and thus alternative possibilities need to be considered. One is that the collecting duct sequesters prorenin from 








play a role. Indeed, increased urinary acidification in response to acid-retention in patients 
with chronic kidney disease - either due to diabetes or other etiologies - is likely to inhibit 
megalin-(pro)renin interaction. Second, why does megalin distinguish between renin and 
prorenin? Is there a role for the prosegment, and might the (pro)renin receptor be involved in 
the endocytosis process? Third: what happens after megalin-mediated internalization? Does 
this result in intracellular degradation, or the release of renin/prorenin into renal interstitium 
or even the renal vein? Might this imply that megalin somehow determines renal RAS 
activity? If so, high urinary renin levels (due to low megalin levels) would be indicative for 
a reduction in renal RAS activity! Fourth: what determines the uptake of renin/prorenin by 
the collecting duct in diabetes? On the one hand, in this condition (characterized by reduced 
tubular reabsorption), the collecting duct is exposed to higher urinary renin/prorenin levels, 
allowing more binding. Yet, these urinary levels are still considerably lower than in blood, 
making a role for the (pro)renin receptor in the uptake very unlikely. Megalin is probably 
lacking at this location. A further possibility is sequestration of (pro)renin from peritubular 
capillaries. Since blood contains relatively high prorenin levels in diabetics, this would at 
least explain the predominance of prorenin in the collecting duct.  
Finally, as the authors acknowledge, one has to be very careful when applying different 
renin and prorenin assays. Assays that rely on the recognition of renin’s active site should 
detect renin only, while assays recognizing a common epitope on renin and prorenin will 
recognize both. However, a major hurdle is the fact that different assays apply different 
standards, and thus absolute numbers between various assays cannot be directly compared. 
Also, detecting prorenin release from cultured collecting duct cells does not automatically 
imply that these cells release prorenin in vivo, since the phenotype of renin-releasing cells 
may easily change in vitro.11  
In conclusion, based on the study by Tang et al. it appears that urinary renin is strictly 
blood-derived and does not represent release from tubular sites. Its determinants are 
glomerular filtration and megalin-mediated reabsorption. Since the latter normally is in 
the order of 95%, a reduction to 90% or 85% would already double or triple urinary renin 
levels. Hence, even small variations in megalin may cause great variation in urinary renin 
levels for a given plasma renin level, thus explaining why plasma and urinary renin are 
often unrelated. Increased (pro)renin uptake and not local synthesis underlies the elevated 
collecting duct (pro)renin levels in the diabetic kidney. How this occurs, and what its 
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Megalin: a Novel Determinant of Renin-an-
giotensin System Activity in the Kidney? 
Yuan Sun, Xifeng Lu and A.H. Jan Danser 




Megalin is well-known for its role in the reabsorption of proteins from the ultrafiltrate. Re-
cent studies suggest that megalin also reaborbs renin and angiotensinogen. Indeed, without 
megalin urinary renin and angiotensinogen levels massively increase, and even prorenin 
becomes detectable in urine. Intriguingly, megalin might also contribute to renal angioten-
sin production, as evidenced from studies in megalin knockout mice. This review discusses 
these topics critically, concluding that urinary renin-angiotensin system components reflect 
diminished reabsorption rather than release from renal tissue sites, and that alterations in 
renal renin levels or megalin-dependent signaling need to be ruled out before concluding 
that angiotensin production at renal tissue sites is truly megalin-dependent. Future studies 
should evaluate megalin-mediated renin/angiotensinogen transcytosis (allowing interstitial 
angiotensin generation), and determine whether megalin prefers prorenin over renin, thus 
explaining why urine normally contains no prorenin. 
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megalin, V-ATPase, chloride channel, renin, prorenin, angiotensinogen, proteinuria
Introduction
It is generally believed that renin-angiotensin system (RAS) activity in the kidney is inde-
pendent of RAS activity in the circulation. Indeed, angiotensin (Ang) II levels in the kidney 
are several orders of magnitude higher than the levels of Ang II in blood, and cannot be 
explained by uptake from the circulation [1, 2]. Virtually all renal Ang II is cell-associated, 
either bound to Ang II type 1 (AT1) receptors on the cell surface, or present intracellularly 
[3]. Studies in AT receptor knockout animals revealed that the intracellular presence of Ang 
II is dependent on AT1 receptor-mediated internalization, i.e., there is no evidence for intra-
cellular Ang II generation [4]. Renal angiotensin generation therefore most likely occurs in 
the interstitial space. Remarkably, despite evidence for local angiotensinogen synthesis in 
the kidney, such generation, like circulating angiotensin generation, depends on liver-de-
rived angiotensinogen [5,6,7• ,8]. With an identical substrate source, opposing changes in 
RAS activity in blood and kidney must be due to other RAS-regulatory mechanisms, like 
the (local) release of renin and its precursor prorenin, the uptake of angiotensinogen from 
blood (possibly involving more than simple diffusion), and/or local alterations in ACE ac-
tivity. For instance, in diabetes, the circulating RAS is suppressed, while renal RAS activity 
is increased [9]. This has been attributed to prorenin synthesis by the principal cells of the 
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collecting duct, evidenced by increased renin activity in the collecting duct and elevated 
urinary renin levels in this condition [10-12]. However, a recent study in diabetic mice 
challenged this view, and concluded that the increase in collecting duct renin under diabetic 
conditions reflects renin binding and not local synthesis [13• • ]. Moreover, the elevated uri-
nary renin levels were due to enhanced glomerular filtration of plasma renin in combination 
with incomplete reabsorption by megalin, i.e, they did not reflect renin release from renal 
tissue sites (like the collecting duct). Surprisingly, megalin knockout even affected renal 
angiotensin generation [14••  , 15• ]. This review describes the role of megalin as a novel 
determinant of renal and urinary RAS activity.        
What is megalin?
Megalin is a single transmembrane protein consisting of 4655 amino acids with a molecu-
lar weight of 600 kDa. It has a large extracellular domain, a transmembrane region, and a 
small intracellular tail of 209 amino acids. It was originally known as glycoprotein 330 [16]. 
Megalin belongs to the low-density lipoprotein receptor (LDLR) superfamily [17], and 
contains four regions that consist of cysteine-rich complement-type repeats, four regions 
that consist of growth factor repeats spaced by eight YWTD repeats, and a single epider-
mal growth factor (EGF)-like repeat in its extracellular juxtamembrane region. The regions 
containing complement-type repeats are believed to be important for ligand binding, while 
the regions containing growth factor repeats are likely required for pH-dependent ligand 
dissociation in the endosomal compartment [18, 19]. The overall structure of megalin re-
sembles LDLR-related protein 1 (LRP1), and therefore megalin is also known as LRP2 [17]. 
The very large extracellular domain allows megalin to bind multiple ligands [20], and until 
now, >50 ligands for megalin have been described, including albumin, insulin, insulin-like 
growth factor, lipoproteins, and drugs like aprotinin and polymyxin B [18, 21, 22]. 
Although megalin was initially identified as an antigen in glomerular podocytes, the expres-
sion of megalin in the glomerulus is negligible versus that in the proximal tubule [23, 24, 
18, 25, 16, 26]. Outside the kidney, megalin is also observed in absorptive epithelia in the 
lung, eye, gall bladder, placenta, and the (para)thyroid gland [18]. 
Megalin forms a 1:1 complex with the extracellular protein cubilin on the apical plasma 
membrane of proximal tubule cells, and together they mediate the endocytosis of ultrafil-
trate proteins for subsequent lysosomal degradation and retrieval of their ligands and con-
stituent amino acids into the blood. This prevents massive protein loss via urine. Megalin 
is a fast-recycling receptor with a long half-life, thereby making it ideal for reabsorption. 
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Its endocytosis depends on the enzymatic activity of an inositol 5-phosphatase encoded by 
the gene oculocerebrorenal syndrome protein 1 (OCRL1) [27] (Figure 1). The cytosolic 
tail of megalin is important for recycling and degradation [28]. Among others, it binds the 
small GTPase Rab11, and dominant negative mutations in Rab11 result in diminished api-
cal delivery of megalin due to disturbed recycling [29]. Autosomal recessive hypercholes-
terolemia (ARH), an adaptor protein that binds megalin in a similar manner as the LDLR 
and clathrin, retains megalin in the recycling endosomes, so that it cannot reappear on the 
cell surface [30]. Furthermore, phosphorylation of the cytosolic tail by glycogen synthase 
kinase 3β also inhibits its recycling from endosomes back to the plasma membrane [31]. 
Fast recycling requires rapid disruption of the megalin-ligand complex through acidification 
in endosomes, a process depending on voltage-gated chloride channel 5 (ClC-5) and vacu-
olar H+-ATPase. Their colocalization is believed to allow ClC-5 to move out chloride as a 
counter-ion to the proton that is pumped by the vacuolar H+-ATPase [32, 33], thus ensuring 
optimal acidification. 
Genetic mutations affecting megalin
LRP2 mutations, as occurring in the Donnai-Barrow/Facio-Oculo-Acoustico-Renal syn-
drome, result in impaired megalin function. Patients display proteinuria [34], hypercal-
ciuria, nephrocalcinosis, nephrolithiasis, and focal segmental glomerulosclerosis [35]. 
Genome-wide association studies confirmed the link between LRP2 and proteinuria [36]. 
Interestingly, patients with mutations in the genes encoding for OCRL1 (Lowe syndrome) 
and ClC-5 (Dent’s disease) also display megalin dysfunction and proteinuria [37-39]. This 
can be explained based on the importance of OCRL1 and ClC-5 for megalin endocytosis 
and endosomal acidification, respectively (Figure 1). 
Megalin and kidney disease
Megalin knockout mice display increased albumin excretion [40], and are protected against 
kidney damage resulting from a high-fat diet [24]. Similar protective effects are derived 
from megalin inhibition (e.g., with cilastatin) in relationship to acute kidney injury due to 
the uptake of nephrotoxic drugs like vancomycin and cisplatin [41]. Anti-brush border anti-
body disease or anti-LRP2 nephropathy involves the deposit of large amounts of circulating 
IgG through megalin in the renal tubule. This might explain why autoantibodies induce 
acute kidney injury [42]. Excess albumin, as occurring in patients with chronic kidney dis-
ease (CKD), directly contributes to the development and progression of CKD by inducing 
tubulointerstitial inflammation and fibrosis in a megalin-dependent manner [43]. Urinary 
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excretion of megalin associates with renal oxidative stress in CKD [44, 45], while megalin 
excretion in both urine and urinary extracellular vesicles correlates with the progression 
of albuminuria in type 2 diabetes mellitus [46, 47]. The latter implies that urinary megalin 
could be a biomarker for diabetic nephropathy. Yet, renal megalin expression is decreased in 
diabetes [13• • ], although increases have been observed in the early stage of type 2 diabetes 
[48, 49]. Among the factors that lower megalin, is Ang II [50].  
Megalin and urinary RAS components
Both renin and angiotensinogen can be detected in urine, albeit at very low levels (a few 
percent or less) when expressed as a percentage of their concomitant plasma concentra-
tions [12, 51]. Prorenin is undetectable in urine [12]. The latter is not due to prorenin-renin 
conversion in urine [12]. Remarkably, renin and angiotensinogen massively rise (up to 40-
fold) in urine of patients with Dent’s disease or Lowe syndrome [52], and the same occurs 
in urine of megalin knockdown mice [15• ], or after megalin inhibition with lysine [53]. 
Figure 1. Megalin and its associated molecules in the proximal tubule. EGF, epidermal growth factor; 
OCRL1, oculocerebrorenal syndrome protein 1; ClC-5, voltage-gated chloride channel 5; ARH, autosomal 
recessive hypercholesterolemia; (P)RR, (pro)renin receptor; V-ATPase, vacuolar H+-ATPase. CUB, complement 
subcomponents C1r and C1s,fibropellin and bone morphogenetic protein 1.
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In fact, prorenin can also be detected in the urine of patients with Dent’s disease or Lowe 
syndrome. From these data it can be concluded that RAS components are present in the 
ultrafiltrate, but normally are largely (>95%) reabsorbed in a megalin-dependent manner 
[53, 52, 54, 15• ], and possibly near-completely in the case of prorenin. Indeed, all 3 RAS 
components are filtered through the glomerulus, and co-localize with megalin in the kidney 
[49, 54]. In fact, since both renin and prorenin are smaller than albumin, relatively larger 
amounts of renin and prorenin will pass the glomerulus in comparison with albumin. Not 
surprisingly, the glomerular sieving coefficients of renin, prorenin and angiotensinogen 
increase after damaging the glomerular filtration barrier [52], e.g., in diabetes. Moreover, 
in mice, the rise in urinary renin after lysine was smaller under diabetic conditions than 
under normal conditions (≈10-fold vs. ≈100-fold) [13• • ]. This is suggestive for disturbed 
tubular reabsorption. Therefore, the elevated urinary RAS component levels in diabetes do 
not reflect release from renal (tubular) tissue sites, but are the consequence of enhanced 
filtration from blood plasma in combination with reduced reabsorption [13• • ]. One more 
condition where urinary renin, prorenin and angiotensinogen levels are unexpectedly high, 
is preeclampsia [55]. Like in diabetes, this may reflect enhanced filtration; to what degree 
megalin is downregulated in this condition is still unknown. It is also unknown whether 
megalin-dependent reabsorption is different for renin and prorenin.      
Megalin and renal angiotensin production
After establishing that renal angiotensin generation depends on liver-derived angiotensino-
gen, while renal angiotensinogen staining was limited to proximal tubule cells expressing 
megalin, Matsusaka and colleagues studied whether megalin is a determinant of angioten-
sin production at renal tissue sites [14• • ]. It was observed that proximal tubule-specific 
knockout of megalin in mice did not affect renal Ang II levels, although such knockout did 
massively increase urinary angiotensinogen levels. Yet, when inducing podocyte injury 
with the immunotoxin LMB2, the well-known rise in renal angiotensinogen and Ang II 
levels no longer occurred without tubular megalin. As a consequence, the Ang II-mediated 
Na+ reabsorption via sodium-hydrogen exchanger 3 and the epithelial sodium channel were 
diminished, and thus the megalin knockout mice excreted 5 times more sodium after podo-
cyte injury. In contrast with these findings, Ye et al. observed a profound (>70%) drop in 
renal Ang II levels in wildtype mice after megalin suppression based on the application of 
megalin antisense oligonucleotides (ASO) [15• ]. The ASO approach did not affect circulat-
ing Ang II and resulted in the expected huge increase in urinary renin and angiotensinogen. 
Yet, even more surprising, megalin ASO reduced the atherosclerotic lesions in LDLR KO 
mice fed a high-fat diet. This suggests that renal Ang II, generated in a megalin-dependent 
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manner, contributes to atherosclerosis. However, an alternative explanation might be that 
the ASO approach additionally interfered with megalin at extrarenal sites (as opposed to the 
proximal tubule-specific knockout applied by Matsusaka et al. [14• • ]), and that this under-
lies the beneficial effect on atherosclerosis. Indeed, megalin has been reported to contribute 
to Ang II internalization and signaling [56, 50] and binds lipoproteins. Ideally therefore, 
these data are confirmed in the proximal tubule-specific knockout model. With regard to 
renal angiotensin generation, both studies imply that this is reduced without megalin, either 
selectively under pathological conditions (following podocyte injury), or possibly already 
under healthy conditions. Here it is important to note that we do not know the renal renin 
levels in these studies, and thus a final possibility is that megalin knockout has altered these 
levels (although it did not affect renin gene expression). In fact, under most circumstances, 
it is variation in renin, and not variation in angiotensinogen, which underlies variations in 
renal angiotensin generation, and even an angiotensinogen suppression of >95% can be 
matched by a rise in renin [7• ]. Indeed, renin rises of >100-fold are easily achievable [57], 
and renal Ang II levels are unaltered when angiotensinogen is suppressed by 98% [7• ].
When proposing a role for megalin in renal angiotensin generation, the question is how ex-
actly this might occur. Obviously, endocytosis should then not result in angiotensinogen de-
struction. Wilson et al. [58] have reported that internalized angiotensinogen traffics intact to 
the mitochondria in isolated proximal tubules. However, given the absence of intracellular 
angiotensin generation [4], the implications of this finding are unclear. An attractive hypoth-
esis would be that angiotensinogen is transcytosed to the basolateral membrane and re-
leased into the renal interstitium (Figure 2). Such megalin-dependent transcytosis has been 
observed for albumin in rats [59, 60] and even for angiotensinogen in opossum kidney cells 
[54]. Diffusion of hepatic angiotensinogen from the circulation into the interstitial space has 
been reported decades ago as the most important, if not only, source of tissue angiotensin 
production [61]. It seems unlikely that the minute amounts of angiotensinogen in the ultra-
filtrate under healthy conditions would contribute significantly to the renal interstitial angio-
tensinogen levels. However, under conditions of excessive protein/angiotensinogen leakage, 
assuming that megalin-mediated transcytosis takes place, it may indeed increase interstitial 
angiotensinogen and contribute to renal angiotensin production. In the case of prorenin, the 
acidic pH in the endosomes might even lead to prorenin activation, since a low pH results in 
non-proteolytic removal of the prosegment from the enzymatic cleft [62]. Yet, in previous 
studies we were unable to show release of activated prorenin from prorenin-synthesizing 
cells, possibly because activated prorenin rapidly returns to the non-activated state in a neu-
tral pH environment [63].    
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Megalin and the (pro)renin receptor
Numerous studies have investigated the so-called (pro)renin receptor as a novel component 
of the RAS over the last 2 decades. Although this receptor was initially reported to bind and 
activate prorenin [64], later studies revealed that the prorenin levels required to allow such 
interaction are many orders above its in-vivo levels, even under pathological conditions 
[65, 66]. Hence, this concept is now being abandoned, also because it has become clear that 
the (pro)renin receptor is an accessory protein of vacuolar H+-ATPase (also known as AT-
P6AP2), and thus has important functions beyond the RAS, like facilitating vesicle traffick-
ing, intracellular signaling and lipid metabolism [67-70]. As such it may also contribute to 
megalin sorting and recycling, since it determines endosomal acidification in concert with 
ClC-5 (Figure 1). In agreement with this concept, ATP6AP2 inhibition impaired megalin 
protein regulation in Drosophila epithelial cells [71]. Thus, via megalin, the (pro)renin re-
ceptor may display a relationship with renin and prorenin.   
Conclusions and remaining questions
Megalin is a multi-ligand receptor mainly (but not exclusively!) expressed in the kidney, 
determining protein reabsorption in the proximal tubule. Both genetic mutations and kidney 
disease (e.g., diabetes, preeclampsia) affect its function and expression, thus contributing to 
kidney pathology. Since megalin also binds RAS components, an intriguing new concept is 
that it might even play a role in angiotensin generation at renal tissue sites. If so, its inter-
nalization should not result in destruction, but, for instance via transcytosis, result in an-
giotensinogen release into the renal interstitial space. Such release would obviously depend 
on the level of angiotensinogen in the ultrafiltrate (reflecting podocyte injury), and tubular 
megalin expression, thus explaining why renal angiotensin generation may not always oc-
cur in concert with angiotensin generation in the circulation. Furthermore, megalin deter-
mines the level of RAS components in urine, and in the absence of megalin (like in Dent’s 
disease or Lowe syndrome) urinary renin and angiotensinogen levels can easily rise by 2 
orders of magnitude [52]. As such, urinary renin and angiotensinogen components do not 
reflect release from renal tissue sites (like the collecting duct) but rather diminished uptake 
of filtered RAS components. Given the virtual absence of prorenin (despite its filtration) in 
urine, except under conditions where megalin function is disturbed, it seems that megalin 
prefers prorenin over renin. Future studies should now address this concept, e.g., making 
use of megalin-expressing cells like proximal tubule epithelial cells and Brown Norway Rat 
yolk sac epithelial cells. Such studies might also shed light on RAS component transcyto-
sis. Additionally, in vivo renal angiotensin generation should be verified in the presence or 
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 5absence of megalin, and during inhibition of hepatic angiotensinogen synthesis, ruling out 
that alterations in renal renin levels and/or megalin-dependent signaling underlie the ob-
served changes in kidney Ang II levels after megalin knockout [14•• , 15• • ]. Knowledge on 
megalin expression in preeclampsia might shed light on the occurrence of prorenin in urine 
of women with preeclampsia [55]. Finally, we need to know what determines renin uptake 
in the collecting duct, reported recently by Tang et al. [13• • ], given that megalin is unlikely 
to occur in significant amounts at this location. Here the link between megalin and the (pro)
renin receptor may be of particular interest. 
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Figure 2. Megalin-mediated endocytosis of prorenin, renin and angiotensinogen, resulting in lysosomal 
degradation and/or transcytosis and subsequent release into the renal interstitium, allowing angiotensin generation. 
The low pH in endosomes may result in non-proteolytic prorenin activation (i.e., removal of the prosegment from 
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Megalin is an endocytic receptor contributing to protein reabsorption. Impaired expression 
or trafficking of megalin increases urinary renin, and allowed the detection of prorenin, 
which normally is absent in urine. Here, we investigated (pro)renin uptake by megalin, us-
ing both conditionally immortalized proximal tubule epithelial cells (ciPTEC) and Brown 
Norway Rat yolk sac cells (BN16). To distinguish binding and internalization, cells were 
incubated with recombinant human (pro)renin at 4°C and 37°C, respectively. (Pro)renin 
levels were assessed by immunoradiometric assay. At 4°C, BN16 cells bound 3 times more 
prorenin than renin, suggestive for a higher affinity of prorenin. Similarly, at 37°C, prorenin 
accumulated at 3-4-fold higher levels than renin in BN16 cells. Consequently, depletion 
of medium prorenin (but not renin) content occurred after 24 hours. No such differences 
were observed in ciPTEC, and mannose-6-phosphate (M6P) greatly reduced ciPTEC (pro)
renin uptake, suggesting that these cells accumulate (pro)renin largely via M6P receptors. 
M6P did not affect (pro)renin uptake in BN16 cells. Yet, inhibiting megalin expression with 
siRNA greatly reduced (pro)renin binding and internalization by BN16 cells. Furthermore, 
treating BN16 cells with albumin, an endogenous ligand of megalin, also decreased bind-
ing and internalization of (pro)renin, while deleting the (pro)renin receptor affected the 
latter only. Exposing prorenin’s prosegment with the renin inhibitor aliskiren dramatically 
increased prorenin binding, while after prosegment cleavage with trypsin prorenin binding 
was identical to that of renin. In conclusion, megalin might function as an endocytic recep-
tor for (pro)renin, and displays a preference for prorenin. Megalin-mediated endocytosis 
requires the (pro)renin receptor.  
Keywords
megalin – renin – prorenin - (pro)renin receptor - tubular reabsorption
Introduction
Components of the renin-angiotensin system (RAS) in urine have been suggested to reflect 
renal RAS activity, i.e., to be released from renal tissue sites.1, 2 However, recent studies 
challenge this view and instead support the concept that urinary renin, prorenin and angio-
tensinogen are blood-derived (i.e., filtered through the glomerulus), and are reabsorbed in 
the proximal tubule.3-5 Hence, elevated urinary RAS component levels rather reflect the net 
result of enhanced filtration (due to an injured glomerular barrier) and/or diminished reab-
sorption (due to tubular dysfunction). Remarkably, prorenin reabsorption is close to 100%, 
151







and thus under physiological circumstances, prorenin cannot be detected in urine.6 Since the 
reabsorption is megalin-dependent, prorenin can be detected in urine of patients with Dent’s 
disease or Lowe syndrome, in whom tubular reabsorption is disturbed due to impaired renal 
expression and trafficking of megalin.7 It can also be detected in urine of women with pre-
eclampsia.8 
Megalin is a 600 kDa single transmembrane protein with a small intracellular tail and a 
large extracellular domain containing four ligand-binding regions, allowing it to bind >40 
different ligands, including albumin.9, 10 Megalin forms a 1:1 complex with the extracellular 
protein cubilin. The ligand binding regions and the gross structural composition of extracel-
lular motifs of megalin are identical in humans and rats.11 Megalin is the major endocytic 
receptor in proximal tubule cells.10 It co-localizes with renin in the proximal convoluted 
tubule,12 and disruption of megalin expression in rodents resulted in a significant rise in 
urinary renin levels.4 Megalin-mediated renin reabsorption amounts to ≈95%,5, 6 and thus a 
reduction to 90% or 85% would already double or triple urinary renin levels. Consequent-
ly, even small variations in megalin may cause great variation in urinary renin levels for a 
given plasma renin level, thus explaining why plasma and urinary renin are often unrelated. 
Angiotensin II negatively regulates megalin expression at both the mRNA and protein lev-
els through its type 1 receptor.13, 14
In the present study, we set out to compare megalin-mediated renin and prorenin uptake, 
making use of both human conditionally immortalized proximal tubule epithelial cells line 
(ciPTEC), which endogenously express multiple influx and efflux transporters, in addition 
to the entire endocytosis machinery,15-17 and Brown Norway rat yolk sac epithelial cells 
(BN16), which are known to highly express megalin.9 We hypothesized that megalin prefers 
prorenin over renin, thus explaining why urine normally contains renin only. A comparison 
was made versus other receptors capable of binding and/or internalizing renin and prorenin, 
i.e., the (pro)renin receptor [(P)RR] and the mannose-6-phosphate (M6P) receptor. We dis-
tinguished binding and internalization by performing studies at 4°C and 37°C, respectively, 
and made use of either receptor antagonists or siRNA to determine the contribution of each 
receptor separately. 
Methods
Human and rat renal cortex
Rest material of one healthy human kidney cortex was supplied by the Department of Pa-
thology. This occurred anonymously, in agreement with the Dutch regulations on medical 
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research. Similarly, the kidney cortex of one healthy, 12-week old Sprague Dawley rat was 
obtained. Both cortical tissue pieces were frozen immediately in liquid nitrogen and stored 
at -70°C.
Cell Culture 
ciPTEC cells were derived from a healthy donor and immortalized as described.15 Cells 
were cultured in phenol red-free DMEM/F12 (Invitrogen, Breda, The Netherlands) supple-
mented with 10% (v/v) FCS (MP Biomedicals, Uden, The Netherlands), containing insulin (5 
μg/mL), transferrin (5 μg/mL), selenium (5 ng/mL), hydrocortisone (36 ng/mL), epithelial 
growth factor (10 ng/mL), and tri-iodothyronine (40 pg/mL). P22-24 passages of ciPTEC 
were used. The cells were seeded at a density of 55.000 cells per cm2 in 96- or 24-well 
plates (Costar, Corning, New York, USA), cultured for 24 hours at 33°C, and matured for 7 
days at 37°C, in 5% CO2. BN16 cells
18 were cultured to confluence in a humidified incuba-
tor in 75 cm2 flasks with Minimum Essential Media (MEM) (Gibco, Thermo Fisher Scien-
tific, Paisley, UK) supplemented with 1×GlutaMAX (Gibco) and 10% FCS (GE Healthcare, 
Eindhoven, The Netherlands) at 37°C with 5% CO2 in air. Thereafter, cells were seeded into 
24-well plates and cultured for 48 hours to yield 2×105 cells per well (1.75 cm2). Passages 
10-14 of BN16 cells were used. 
Prorenin and Renin Binding and Uptake  
To study prorenin and renin binding and internalization, cells were incubated at 4°C or 37°C 
with 300 mL of 1000 U/L (≈2×106 pg/L) recombinant human prorenin or renin (a gift from 
Actelion Pharmaceuticals, Allschwil, Switzerland), aliskiren-pretreated recombinant human 
prorenin (10 mmol/L at 4°C for 48 hours) or trypsin-activated19 recombinant human pro-
renin in serum-free medium. Incubations lasted up to 24 hours and were performed in the 
absence or presence of 10 mmol/L M6P (Sigma, St. Louis, USA), 10 mmol/L of aliskiren 
(a gift of Novartis, Basel, Switzerland), and/or recombinant 100 μg/L of receptor-associat-
ed protein fused to glutathione-S-transferase (RAP-GST,plasmid kindly provided by dr. de 
Matteis, TIGEM, Naples, Italy, recombinant protein produced as described previously20). To 
further evaluate the role of megalin and the (P)RR, identical experiments were performed 
after transfection of BN16 cells with negative control siRNA (siNC), LRP2 siRNA (siLRP2) 
or (P)RR siRNA [si(P)RR] (Invitrogen, Paisley, UK) by using RNAi max transfection re-
agent (Invitrogen), for 48 hours. After incubation, the medium was removed, and the cells 
were washed twice with ice-cold 0.5% BSA in phosphate buffered saline (PBS) and twice 
with ice-cold PBS. Then, the cells were lysed with ice-cold 0.2% triton X-100 (SEEVA, 
Heidelberg, Germany) in PBS with protease inhibitor (Roche, Mannheim, Germany), and 
centrifuged for 10 minutes at 4°C at 14.000×g. Supernatants were collected and stored at 
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-80°C. Renin in the supernatants was measured with the Renin III (Cisbio, Gif-sur-Yvette, 
France) immunoradiometric assay. Prorenin was also measured with this assay, after its con-
version to the renin conformation (allowing its detection in the assay) by incubating it with 
10 mmol/L aliskiren at 4°C.21, 22 Prorenin measurements were performed both before and 
after aliskiren incubation, with levels being detected before aliskiren exposure representing 
prorenin that had been activated by the cells, and levels after aliskiren exposure represent-
ing the total amount of prorenin. 
Albumin Uptake 
To study whether M6P interferes with megalin-mediated uptake, cells were incubated in 
a 96-well plate setup at 37°C with 10 μg/mL fluorescently labelled BSA (BSA Alexa Flu-
or™ conjugate, Invitrogen, Carlsbad, USA), in the absence or presence of M6P (1 mmol-
10 mmol/L) or RAP-GST (1.5-200 μg/mL) for 4 hours.15 During the last 10 minutes, the 
Hoechst33342 stain (Life Technologies, Carlsbad, USA) was added to dye the nucleus. 
Then, the medium was removed, and the wells were washed with HBSS at room tempera-
ture. Florescence readings were performed using a CV7000S high-content imager (Yokoga-
wa, Tokyo, Japan). 
RNA isolation and qPCR analysis
Total RNA was extracted using the Direct-zol RNA kit (Zymo Research, Irvine, USA). 
One microgram total RNA was reverse transcribed by QuantiTect® Reverse Transcription 
Kit (Qiagen, Hilden, Germany). SYBR Green real-time quantitative PCR assays were 
performed on a One-step Plus (Thermo Fisher, Waltham, USA) using SYBR®Premix Ex 
TaqTM II kit (Qiagen, Venlo, The Netherlands). Primers are specified in Table S1.
Immunoblotting
For protein expression studies, cells were homogenized in lysis buffer (50 mmol/L Tris-
HCl, 150 mmol/L NaCl, 3 mmol/L KCl, 1 mmol/L EDTA, 1% Triton X-100, complete pro-
tease inhibitor cocktail (Roche), pH 7.4). Lysates were centrifuged at 14000×g at 4°C for 10 
minutes. Supernatants were collected and total protein concentrations were determined by 
BCA assay (Pierce, Waltham, USA). Twenty mg of total protein was loaded and separated 
on 6% Tris-glycine gels and transferred to PVDF membranes using Trans-Blot® Turbo™ 
Transfer System (Bio-Rad, Hercules, USA). The blots were probed with megalin (Santa 
Cruz, Dallas, USA, 1:200) and β-Actin (Merck Millipore, Darmstadt, Germany, 1:50.000) 
detected by Clarity Western ECL Substrate (Bio-Rad, Hercules, USA). The intensities of 




Results are shown as mean±SEM, unless n<3. For experiments with n>3, normal distribu-
tion was verified by Kolmogorov-Smirnov test, while for experiments with n=3, the Sha-
piro-Wilk test was used to evaluate distribution. Once normal distribution was confirmed, 
differences were either tested by one-way ANOVA, followed by Bonferroni multiple com-
parison test, or by Student’s t-test. P<0.05 were considered significant. Data below detection 
limit were assumed to equal the detection limit. 
Results
Proximal tubule epithelial cells 
Prorenin and renin binding and internalization largely depend on M6P receptors 
Incubating ciPTEC with either prorenin or renin at 37°C resulted in a time-dependent in-
crease in their cellular levels, a plateau being reached after 4-6 hours (Figures 1A and 
1C). The majority of cellular prorenin (up to 90%) was recognized as renin, suggestive 
for prorenin activation upon binding and/or internalization.  In contrast, following incuba-
tion at 4°C, the majority of prorenin was in its inactive form, and the steady-state levels of 
both prorenin and renin were »5-10-fold lower than those at 37°C (Figures 1B and 1D). 
At 37°C, M6P reduced the cellular accumulation of prorenin (P<0.05) and renin (P<0.01) 
by >80%, without altering the degree of prorenin activation. At 4°C, the blocking effect of 
M6P was much more modest, significance being reached only in the case of renin (P<0.05). 
In summary, these data demonstrate that ciPTEC bind and accumulate renin and prorenin 
largely via M6P receptors, and internalization is accompanied by prorenin activation. In 
agreement with this conclusion, M6P receptors were readily expressed in ciPTEC, while 
megalin was below detection limit (Figure S1). Human cortical tissue did express megalin 
and M6P receptors, while cubilin and the (P)RR were found in both cortical tissue and 
ciPTEC.  
RAP-GST blocks both (pro)renin and albumin internalization
At 37°C, the megalin ligand RAP-GST reduced cellular prorenin and renin accumulation 
after 8 hours by >80%, both in the absence and presence of M6P (Figure 2). At 4°C, its 
blocking effects were more modest, particularly in the presence of M6P. The combined 
effects of RAP-GST and M6P were not significantly different from those of each blocker 
alone. RAP-GST blocked the uptake of labeled BSA at 37°C (IC50=140 μg/mL, correspond-
ing with 21 mmol/L; Figure S2). Unexpectedly, M6P blocked the uptake of labeled BSA to 
the same degree as RAP-GST (IC50=10 mmol/L). These data suggest that either M6P is able 
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Figure 1. Cell-associated prorenin (A&B, distinguishing activated and total prorenin; n=5 and 4) and renin (C&D; 
n=5 and 3) levels in ciPTEC following their incubation at 37°C or 4°C with 2×106 pg/L  prorenin or renin in the 
presence or absence of 10 mmol/L M6P for maximally 24 hours. Data are mean±SEM. 
Figure 2. Cell-associated prorenin (A) and renin (B) levels in ciPTEC following their incubation at 37°C or 4°C 
with 2×106 pg/L prorenin or renin in the presence or absence of 10 mmol/L M6P and/or 100 μg/mL of RAP-GST 
for 4 hours. Data are mean±SEM of n=4. *P<0.05, **P<0.005, ***P<0.0005.
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to interfere with the megalin/cubilin-mediated uptake of BSA, or that RAP-GST, like M6P, 
prevents M6P receptor-mediated uptake of BSA.  
Brown Norway rat yolk sac epithelial cells 
Prorenin and renin binding and internalization: no role for M6P receptors
BN16 cells accumulated prorenin and renin in a concentration-dependent manner when 
incubated with increasing levels at 37°C, and all cellular prorenin was found to be in the 
activated form (Figure 3A). Importantly, for a given (pro)renin level in the incubation 
medium, cellular prorenin levels were 3-4-fold higher than those of renin (P<0.05), sug-
gesting that prorenin uptake occurred more efficiently. A similar pattern was observed at 
4°C, although now prorenin remained in the inactive form, and the cellular levels of both 
renin and prorenin were 3-10-fold lower than those at 37°C (Figure 3B). When incubating 
BN16 cells with 1000 U/L prorenin or renin at 37 or 4°C, peak levels were reached after 
2-4 hours under all conditions (Figures 3C-F). At 37°C, in the case of renin, peak levels 
remained constant up to 24 hours, while in the case of prorenin the levels started to fall after 
6 hours. This illustrates that after 6 hours the prorenin levels in the incubation medium had 
become too low to allow an equilibrium between internalization and degradation. Indeed, 
when measuring prorenin in the incubation medium after 24 hours, its levels had dropped 
to 30±8% of the levels measured at 4 hours, while in the case of renin the levels at 24 hours 
were still identical (86±4%) to those measured at 4°C (Figures 3C&E). M6P did not affect 
renin and prorenin accumulation at 37°C, nor renin binding at 4°C (Figure 3D). M6P did 
reduce prorenin binding at 4°C (P<0.005; Figure 3F). Taken together, these data indicate 
that BN16 cells bind and accumulate renin and prorenin largely via a non-M6P receptor-me-
diated mechanism (most likely megalin), and that this uptake mechanism prefers prorenin 
over renin. In agreement with this conclusion, BN16 cells readily expressed megalin, while 
M6P receptor expression was low (Figure S1). Rat cortical tissue did express megalin and 
M6P receptors, while cubilin and the (P)RR were found in both cortical tissue and BN16 
cells.
   
Megalin determines (pro)renin binding and internalization
To clarify whether megalin truly is the main receptor mediating (pro)renin binding and in-
ternalization in BN16 cells, we transfected BN16 cells with siRNA against megalin. This 
approach reduced megalin mRNA and protein by >50% and >80%, respectively (Figures 
4A&B). Parallel reductions were observed in the cellular renin and prorenin binding and 
internalization (Figures 4C&D). Obviously, given the fact that megalin was not fully sup-
pressed, this approach also did not fully suppress (pro)renin binding and internalization. 
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Importantly, adding 50 µg/mL of BSA (a well-known megalin ligand) similarly reduced 
(pro)renin binding and internalization (Figure S3). Although megalin reduction largely pre-
vented prorenin uptake at 37°C, it did not affect prorenin activation or its intracellular deg-
radation half-life (Figures 4E&F). Taken together, these data confirm that megalin is the 
predominant receptor for (pro)renin binding and internalization in BN16 cells. Yet, megalin 
does not affect intracellular prorenin activation and degradation. 
Prorenin prosegment facilitates binding to megalin, while aliskiren stabilizes renin and 
prorenin
Figure 3. Cell-associated prorenin (A-D) and renin (A&B, E&F) levels in BN16 cells following their incubation 
at 37°C or 4°C with 2×106 pg/L prorenin or renin in the presence or absence of 10 mmol/L M6P for maximally 
24 hours. Inserts display medium (pro)renin levels at 4 and 24 hours, expressed as a percentage of the levels at 4 
hours. Data are mean±SEM of n=5. 
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The much greater uptake of prorenin versus renin suggests a role for the prosegment. Since 
aliskiren is capable of removing the prosegment from the enzymatic cleft (while not cleav-
ing it), we studied whether co-incubating the cells with aliskiren-pretreated prorenin alters 
prorenin binding and internalization. For comparison, renin binding and internalization 
were also studied in the presence of aliskiren. As shown in Figures 5A and B, aliskiren fa-
cilitated renin and prorenin internalization at 37°C, but its effect on prorenin was much larg-
Figure 4. Megalin gene (A, n=5) and protein (B, n=5) expression levels in BN16 cells after transfection with 
control siRNA (siNC) or siRNA against megalin (siLRP2) for 48 hours; cell-associated prorenin (C, n=5) and 
renin (D, n=5) levels in BN16 cells following their incubation at 37°C or 4°C with 2×106 pg/L prorenin or renin 
for 4 hours after siNC (black bars) or siLRP2 (open bars) pretreatment; decrease in cell-associated prorenin levels 
after loading BN16 cells with prorenin (2×106 pg/L, 2 hours 37°C) following siNC (E, n=3) or siLRP2 (F, n=3) 
pretreatment. Data are mean±SEM, *P<0.05, **P<0.005, ***P<0.0005.
159






 er. At 4°C, aliskiren only facilitated prorenin binding. Incubation of prorenin with trypsin 
(cleaving off the prosegment) (Figures 5A&B) and megalin knockdown (Figure S4) anni-
hilated the difference between prorenin and renin. Importantly, as has been shown before,22 
aliskiren greatly increased the intracellular half-life of both renin and prorenin (from 35 and 
30 minutes, respectively, to >24 hours; Figures 5C&D), i.e., virtually preventing their deg-
radation. In summary, these data show that the prosegment facilitates binding to megalin, 
while aliskiren binding stabilizes both renin and prorenin, thus reducing their intracellular 
degradation. 
(P)RR contributes to prorenin internalization but does not affect prorenin binding in 
BN16 cells
The (P)RR binds renin and prorenin with low affinity.23 To study (P)RR-megalin interaction, 
megalin and/or (P)RR expression in BN16 cells were inhibited by transfecting with their 
respective siRNA for 48 hours (Figure 6A). Megalin knockdown again reduced prorenin 
Figure 5. Cell-associated prorenin and renin levels after incubating BN16 cells with 2×106 pg/L prorenin or renin 
at 37°C (A, n=6) or 4°C (B, n=6) for 4 hours with or without prior (pro)renin exposure to trypsin or 10 µmol/L 
aliskiren for 48 hours; decrease in cell-associated prorenin (C, n=3) and renin (D, n=3) levels after loading BN16 
cells with prorenin or renin (2×106 pg/L, 4 hours 37°C) with or without prior (pro)renin exposure to 10 µmol/L 
aliskiren for 48 hours. Data are mean±SEM, **P<0.005, ***P<0.0005.
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binding and internalization by about 50% (Figure 6B&C), while (P)RR inhibition reduced 
internalization only. Dual (P)RR/megalin inhibition induced the same effect of megalin 
inhibition alone. These data suggest that the (P)RR contributes to prorenin endocytosis, but 
not binding, and that endocytosis involves megalin and the (P)RR simultaneously.  
Discussion
This study shows that megalin is an endocytic receptor binding both renin and prorenin, dis-
playing a preference for the latter. This preference involves the prosegment, and moving out 
the prosegment from the enzymatic cleft further enhanced binding. Endocytosis, occurring 
at 37°C, depended on the (P)RR and was followed by intracellular degradation of both renin 
and prorenin. Aliskiren reduced degradation, most likely because renin inhibitor-binding 
stabilizes renin and prorenin.22, 24
Megalin-dependent renin binding has been demonstrated before,12 and recent studies have 
shown that this process rather than tubular (pro)renin release determines urinary renin 
Figure 5. Cell-associated prorenin and renin levels after incubating BN16 cells with 2×106 pg/L prorenin or renin 
at 37°C (A, n=6) or 4°C (B, n=6) for 4 hours with or without prior (pro)renin exposure to trypsin or 10 µmol/L 
aliskiren for 48 hours; decrease in cell-associated prorenin (C, n=3) and renin (D, n=3) levels after loading BN16 
cells with prorenin or renin (2×106 pg/L, 4 hours 37°C) with or without prior (pro)renin exposure to 10 µmol/L 
aliskiren for 48 hours. Data are mean±SEM, **P<0.005, ***P<0.0005.
161







levels. Indeed, blocking megalin with lysine,25 impaired megalin trafficking3 and megalin 
deletion4 all greatly increased urinary renin levels, implying that normally >95% of filtered 
renin is reabsorbed in a megalin-dependent manner. Human urine did not contain detectable 
levels of prorenin, except in patients with Dent’s disease and Lowe syndrome in whom 
megalin expression and trafficking is impaired, and in women with preeclampsia.8 The 
current data now explain the absence of prorenin under normal conditions: its reabsorption 
is 4-5 times more efficient than that of renin, and thus might be closer to 100%. Tang et al. 
have claimed suppressed megalin expression in experimental diabetes, which, particularly 
in combination with the increased glomerular protein filtration in this condition, results in 
elevated urinary renin levels, despite the well-known circulating RAS downregulation in 
diabetes.25, 26 Future studies should now evaluate whether the same is true in preeclampsia, a 
condition characterized by hypertension, proteinuria and RAS downregulation.27
Tojo et al., after infusing human prorenin in diabetic rats, reported increased renal prorenin 
accumulation versus non-diabetic rats, which they attributed to (P)RR and/or megalin bind-
ing.28 Similar observations were made for human angiotensinogen, and no comparison was 
Figure 6.  A, siRNA-induced reduction of megalin and (P)RR expression levels in BN16 cells. B and C, cell-
associated prorenin levels after incubating BN16 cells with 2×106 pg/L prorenin at 37°C (B) or 4°C (C) for 4 
hours in the presence or absence of megalin (LRP2) and/or the (pro)renin receptor ((P)RR). Data are mean±SEMs 
of n=5. *P<0.05, **P<0.005, ***P<0.0005.
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made versus human renin. Given the reduced expression of megalin under diabetic condi-
tions observed by Tang et al., these data are most likely explained on the basis of enhanced 
glomerular filtration of prorenin and angiotensinogen. Combined with our current findings, 
they suggest that the earlier reported upregulation of prorenin immunoreactivity in the col-
lecting duct of diabetic rodents29 is the consequence of enhanced filtration and subsequent 
tubular reuptake. Furthermore, we now reveal that the (P)RR contributes to the internaliza-
tion of megalin-bound prorenin. Given the fact that the (P)RR is identical to ATPA6P2, i.e., 
accessory protein 2 of vacuolar ATPase (V-ATPase), this may not be too surprising, since 
V-ATPases are expressed on the membrane of intracellular compartments in virtually every 
cell type, and play important roles in vesicle trafficking, protein degradation and intracel-
lular signaling.30 Indeed, also in the case of megalin, V-ATPase ensures optimal endosomal 
acidification, resulting in rapid dissociation of the megalin-ligand complex and fast recy-
cling of megalin to the cell membrane. Hence, inhibiting ATP6AP2 impairs megalin regula-
tion.31
Our data subsequently illustrate that, at least under the applied cell culture conditions, 
megalin/(P)RR-mediated (pro)renin uptake results in intracellular degradation of both renin 
and prorenin, with a half-life of »30 minutes. In the case of prorenin, this metabolic process 
involves prosegment removal, i.e., prorenin-renin conversion.32 As has been shown before,22, 
24 aliskiren binding stabilizes (pro)renin, thereby greatly suppressing its metabolism. Com-
bined with aliskiren’s high affinity (virtually excluding dissociation), this explains why the 
renin inhibitor enhances intracellular renin and prorenin accumulation at 37°C. Importantly, 
aliskiren also increased prorenin binding to megalin, evidenced by the elevated cell-asso-
ciated prorenin levels at 4°C in the presence of the renin inhibitor. The latter did not apply 
to renin, suggesting that the aliskiren-induced conformational change of prorenin, resulting 
in the removal of the prosegment from the enzymatic cleft,21, 33 underlies this phenomenon, 
rather than aliskiren-induced stabilization of the (pro)renin molecule. This indicates that the 
prosegment, particularly when fully exposed, facilitates prorenin-megalin interaction. In 
summary, aliskiren facilitates binding only in the case of prorenin, and slowed down degra-
dation for both renin and prorenin. Hence, at 37°C, when both binding and internalization 
occur, aliskiren’s effects were largest for prorenin. 
ciPTEC express most of the transporters and efflux pumps physiologically present in the 
proximal tubule, and possess the complete endocytosis machinery, making these cells an 
appropriate model to study proximal tubule physiology.17 In many studies with different 
cell types such as rat vascular smooth muscle cells, cardiomyocytes, fibroblasts, and human 
endothelial cells, it has been demonstrated that besides megalin, M6P receptors bind and 
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internalize renin and prorenin.32, 34, 35 In the current study, the >80% decrease in prorenin and 
renin uptake induced by M6P in ciPTEC suggests an important role for M6P receptor-me-
diated uptake of renin and prorenin in these cells. Not surprisingly, the effect of M6P was 
best seen at 37°C, since at this temperature (but not at 4°C), M6P receptors cycle continu-
ously between the cell surface and the intracellular compartment, thus allowing substantial 
(pro)renin accumulation in the cells. In contrast, at 4°C, renin and prorenin can only bind 
to cell surface M6P receptors, without being internalized,23 and prorenin activation will not 
occur. In agreement with a predominant role for M6P receptors in ciPTEC, we observed 
high M6P receptor expression and low to undetectable megalin expression in these cells. 
The cells additionally expressed cubilin, and the (P)RR. Interestingly, the M6P receptor has 
been described as a ligand for megalin.36, 37 To what degree M6P itself acts as a ligand for 
the megalin receptor is unknown. Our results revealed that the megalin inhibitor RAP-GST 
exerted identical effects as M6P: up to 90% inhibition of renin/prorenin uptake at 37°C in 
ciPTEC, and a comparable, but much smaller effect at 4°C. Given the low expression of 
megalin in ciPTEC, the simplest explanation of these findings is that RAP-GST addition-
ally blocks M6P receptors. Alternatively, megalin may interact with M6P receptors,38 or 
M6P might block megalin-mediated pathways. To evaluate the latter, we studied the effect 
of M6P on the uptake of BSA by ciPTEC, a widely accepted megalin ligand.39 It was ob-
served that M6P not only blocked BSA uptake to the same degree as RAP-GST, but that it 
also decreased RAP-GST endocytosis (data not shown). Although this suggests that M6P is 
a megalin receptor blocker, an important caveat remains the low expression of megalin in 
ciPTEC. Given these observations, we focused on BN16 cells rather than ciPTEC to verify 
megalin-(pro)renin interaction, and we used megalin siRNA knockdown instead of RAP-
GST to inhibit megalin in these cells. Conveniently, M6P receptor expression in BN16 cells 
was low, and M6P did not interfere with (pro)renin binding. 
 
Perspective
Megalin is major determinant of urinary renin and prorenin levels. Given its preference for 
prorenin, urinary prorenin is normally undetectable. Since even filtered renin is reabsorbed 
by >95% via megalin, decreases in megalin expression (as occurring in diabetes) may easily 
result in rises in urinary renin that are entirely unrelated to plasma renin levels. These rises 
therefore reflect tubular (dys)function rather than upregulation of the intrarenal RAS, as is 
often advocated.3, 12 Future studies should now unravel 1) megalin-prosegment interaction, 
which appears to underlie the preference for prorenin, 2) renal megalin alterations in dis-
eases other than diabetes (like preeclampsia), 3) the potential role of megalin outside the 
kidney, if any, 4) megalin-(P)RR and megalin-M6P receptor interaction, and 5) the destiny 
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of megalin-internalized (pro)renin: destruction or abluminal release into the renal intersti-
tium and a contribution to renal angiotensin production? An exciting recent study supports 
the latter following podocyte injury.40 The link with the (P)RR might explain why previous 
studies reported (P)RR-(pro)renin interaction in the kidney – this is unlikely to represent 
actual (pro)renin binding to the (P)RR, given its low affinity,41-44 but might simply represent 
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Megalin is a novel endocytic receptor for renin and prorenin which displays a preference 
for the latter. 
Megalin-dependent (pro)renin internalization, but not binding, involves the (pro)renin re-
ceptor. 
What is relevant?
These data explains why urine normally does not contain prorenin, except under conditions 
where megalin trafficking is disturbed, like in patients with Dent’s disease or Lowe syn-
drome. 
Summary
To investigate (pro)renin binding and internalization by megalin, Brown Norway Rat yolk 
sac cells were incubated with renin and prorenin. The cells bound and internalized much 
more prorenin than renin, and inhibiting megalin expression with siRNA greatly reduced 
both binding and internalization, while inhibiting the (pro)renin receptor inhibited the lat-
ter only. Exposing prorenin’s prosegment with the renin inhibitor aliskiren dramatically 
increased prorenin binding, while after prosegment cleavage with trypsin prorenin binding 
was identical to that of renin. In conclusion, megalin is a novel endocytic receptor for (pro)





Table S1. Primers lists
Figure S1. Gene expression of megalin (panel A), mannose 6-phosphate receptor (M6PR, panel B), cubilin 
(panel C), and (pro)renin receptor ((P)RR, panel D) in ciPTEC (n=5) and BN16 cells (n=5) compared with human 
kidney cortex (Human KC, n=1; RNA samples were collected from two different locations) and rat kidney cortex 
(Rat KC, n=1; RNA samples were collected from two different locations). Arbitrary units (A.U.) were obtained 
by correcting target gene expression for β-actin expression in the same sample. The bar represents the mean of 
the individual data points. Regarding megalin, no signal was obtained after 40 cycles in 4 samples, while in one 
sample a signal was obtained with a Ct value of 39.9.
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Figure S2. Inhibition of BSA uptake in ciPTEC by M6P and RAP-GST (top panels), and fluorescence staining 
representing BSA accumulation (bottom panels). Data (2 measurements in duplicate) have been expressed as a 
percentage of control (cells incubated with BSA in the absence of inhibitor). 
Figure S3. Cell-associated prorenin and renin levels after incubating BN16 cells with 2×106 pg/L prorenin or renin 
with or without 50 µg/mL of bovine serum albumin (BSA). Data represents mean (bar) of n=3. In all cases values 
with BSA were lower than without BSA.
Figure S4. Cell-associated prorenin levels after incubating BN16 cells with 2×106 pg/L native prorenin or 
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(Pro)renin receptor in lipid metabolism (Chapters 1-2)
The plasma concentrations of prorenin, the precursor of renin, are normally 10-fold higher 
than those of renin, and this can go up to ~100-fold under pathophysiological conditions. 
However, its function, except being an inactive precursor of renin, remains unknown. Pre-
vious studies found that elevated plasma prorenin concentrations correlate with the inci-
dence of macro- and micro-vascular complications, such as nephropathy and retinopathy, 
in diabetes mellitus, despite the normal or even reduced plasma renin concentrations in this 
condition.1-3 Moreover, evidence suggests that a local renin-angiotensin system (RAS) ex-
ists in multiple organs, which might display increased or decreased activity in the absence 
of changes in the circulating RAS. Examples are the kidney in diabetes and the placenta 
in pre-eclampsia.4, 5 Since renin synthesis is limited to the juxtaglomerular cells in the kid-
ney, these local RAS must rely on a mechanism that either allows uptake of renin and/or 
prorenin activation. The discovery of the (pro)renin receptor [(P)RR] about two decades 
ago seemed to provide the solution to this problem, as discussed in Chapter 1. The (P)RR 
binds both renin and prorenin, and displays higher affinity for prorenin.6 Upon binding, it 
activates prorenin in a non-proteolytic manner, allowing the generation of angiotensins. Ad-
ditionally, (P)RR binding of renin and prorenin, denoted herein as (pro)renin, triggers intra-
cellular signaling cascades in an angiotensin-independent manner, resulting in activation of 
p38 mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase 1/2 
(Erk1/2), for instance in vascular smooth muscle cells (VSMCs), collecting duct cells, and 
adipocytes.7, 8 Activation of p38 MAPK and Erk1/2 leads to upregulation of profibrotic and 
proliferative gene expression, resulting in accelerated cell proliferation and end-organ dam-
age. However, to observe angiotensin II-dependent and -independent effects, (pro)renin had 
to be applied at concentrations that are several orders of magnitude above its normal plas-
ma levels and the ultrahigh levels achieved in transgenic rodent models.9 Moreover, unlike 
other RAS components, deletion of the (P)RR is lethal, even when it is limited to certain 
cell types, such as cardiomyocyte and podocytes.10-12 This questions whether the interaction 
between (pro)renin and the (P)RR truly is of relevance in vivo. 
Interestingly, the cytosolic domain (CD) of the (P)RR was previously identified as an ac-
cessory protein of vacuolar H+-ATPase (V-ATPase).13Identification and characterization of 
a novel 9.2-kDa membrane sector-associated protein of vacuolar proton-ATPase from chro-








domain and an ATP-hydrolyzing V1 domain.
14  V-ATPases are expressed in virtually all cell 
types and mainly found in the membrane of intracellular compartments, such as signaling 
endosomes, lysosomes, and the Golgi apparatus.15 By acidifying the intracellular compart-
ments, they play an important role in the induction of intracellular signaling cascades, re-
ceptor-mediated endocytosis, and protein degradation. Intriguingly, global genetic ablation 
of most, if not all, V-ATPase subunits in mice or zebrafish are embryonically lethal.16 This 
indicates a close functional relationship of the (P)RR with V-ATPase. Indeed, inhibiting the 
(P)RR or blocking V-ATPase using bafilomycin both abolished Wnt-mediated activation 
of β-catenin.17 Moreover, deletion of the (P)RR in cardiomyocytes and podocytes resulted 
in decreased protein abundance of several V-ATPase subunits and a disturbed lysosomal 
pH, suggesting that the (P)RR is required to maintain V-ATPase integrity. Additionally, our 
group has previously shown that inhibiting the (P)RR abolishes arginine vasopressin-stimu-
lated V-ATPase activity but not basal V-ATPase in collecting duct cells.18 These studies thus 
highlighted that the (P)RR has (pro)renin-independent functions. 
In the approach to unravel (pro)renin-independent function(s) of the (P)RR, our group dis-
covered that the (P)RR controls the protein abundance of low-density lipoprotein receptor 
(LDLR) and sortilin-1 (SORT1), the two key regulators for LDL metabolism, highlighting 
its potential role in LDL metabolism.19,20 Thus, in Chapter 2, we studied the consequence 
of inhibiting the hepatic (P)RR on lipid metabolism in vivo. As expected, hepatic (P)RR 
inhibition indeed raised plasma LDL levels in normal diet (ND) fed C57BL/6J mice, as a 
consequence of reduced hepatic LDLR and SORT1 abundance. Unexpectedly, we found 
that hepatic (P)RR deficiency also prevented diet-induced obesity and  non-alcoholic fatty 
liver disease. Using a state-of-the-art comparative proteomics approach, we found that ace-
tyl-CoA carboxylase (ACC) and pyruvate dehydrogenase (PDH) abundance were reduced 
in (P)RR-inhibited livers. PDH converts pyruvate to acetyl-CoA to flux the carbon sources 
into complete oxidation in tricarboxylic acid cycle or biosynthetic pathways, such as fatty 
acid (FA) and cholesterol synthesis. ACC plays a crucial role in regulating FA biosynthesis 
and oxidation.21 Genetic ablation of ACC led to reduced lipid synthesis and increased fatty 
acid oxidation, resulting in a similar phenotype as hepatic (P)RR inhibited mice. Using both 
human hepatic cells and mouse primary hepatocytes, we confirmed that inhibiting the (P)
RR reduced cellular acetyl-CoA levels and promotes FA oxidation. Our study thus revealed 
a previous unrecognized role of the (P)RR in regulating lipid metabolism. 
Angiotensinogen siRNA as a novel blood pressure-lowering tool (Chapter 3)
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Increased RAS activity is a major contributor for elevated blood pressure (BP), hence RAS 
blockers have been widely used in treating hypertension and associated diseases. However, 
conventional RAS blockers, including angiotensin-converting enzyme inhibitors (ACEi), 
angiotensin (Ang) II receptor blockers (ARBs), and direct renin inhibitors (DRi), all lead 
to increased plasma renin levels and may complicate the treatment as such a rise in renin 
may restore Ang II to pretreatment levels. Moreover, poor adherence with the regular RAS 
blockers presents another challenge in optimally controlling BP. Since the effector of the 
RAS derives from angiotensinogen (AGT) originating from the liver, inhibiting hepatic 
AGT may provide a more effective way in controlling RAS activity. In Chapter 3, we thus 
explored the effects of siRNA targeting AGT in spontaneously hypertensive rats. We found 
that a single injection of N-acetylgalactosamine (GalNAc)-siRNAs at a dose of 10 mg/kg 
body weight effectively reduced BP to a similar extent as captopril (ACEi) and valsartan 
(ARBs) for at least 4 weeks. Although inhibiting hepatic AGT also increased active plasma 
renin concentrations due to the negative feedback loop, it did not cause the rise in plasma 
Ang I levels as captopril and valsartan did. However, silencing hepatic AGT did not reduce 
plasma Ang II levels. This is likely a result of residual AGT presence and the presence of 
Ang I. However, when combined with valsartan, AGT siRNA treatment greatly reduced 
plasma Ang I and Ang II levels, paralleled by a further reduction in BP. Thus, our study 
highlights AGT inhibition alone or in combination with valsartan as an effective mean to 
control BP.   
Megalin and (pro)renin uptake (Chapters 4-6)
Remarkably, although plasma prorenin levels are ≈10-fold higher than those of renin, only 
renin can be detected in the urine. Furthermore, even when plasma prorenin levels are 
elevated ≈200-fold, as seen in the Cyp1a1-Ren2 transgenic rats, urinary prorenin is still 
undetectable. The small differences in their molecular weight are unlikely to result in large 
discrepancies in glomerular filtration of prorenin and renin,22 and thus cannot explain why 
prorenin is undetectable in urine. Interestingly, in patients with Dent’s disease or Lowe 
syndrome, urinary renin and prorenin levels are markedly increased. These patients carry 
genetic mutations in OCRL1 or CLC-5, resulting in megalin dysfunction. In line with this, 
genetic ablation or pharmacological inhibition of megalin increases renin levels in urine.23 
These observations thus points towards megalin as an endocytic receptor for (pro)renin 
(Chapter 4&5). In Chapter 6, we set out to compare megalin-mediated renin and prorenin 
uptake in BN16 cells which highly express megalin, to study (pro)renin binding and uptake. 
We found that BN16 cells actively accumulate both renin and prorenin, the latter with much 








for (pro)renin, did not affect this uptake, while knocking down megalin did. These data con-
firm that megalin is a novel endocytotic receptor for (pro)renin, and given the much greater 
efficiency of prorenin uptake, they also explain why prorenin is normally lacking in urine.
RAS in preeclampsia (Chapter 7)
As a consequence of drastic increased plasma AGT levels and a modest increase in plasma 
renin levels,  plasma RAS activity is increased during pregnancy, to ensure adequate blood 
supply for the growing fetus. However, in preeclampsia, a disorder characterized by hyper-
tension and proteinuria after 20 weeks of gestation in women, the rise in circulating AGT 
and renin are suppressed, which may contribute to the onset of the disease. However, con-
sidering the local production of the RAS components in the placenta, it is still possible that 
placental RAS activity is upregulated in preeclampsia. In Chapter 7, we set out to explore 
if the placental expression of RAS components and their release are altered in early onset 
preeclampsia. Major RAS components, including renin, ACE, ACE2, AT1R, and AT2R 
were expressed in the placenta, and their expression levels were comparable in healthy and 
preeclamptic placentas. Placental (pro)renin levels were also comparable between healthy 
and preeclamptic pregnancies, in line with unaltered placental renin expression in this con-
dition. Although AGT mRNA levels were at or below detection limit, AGT protein could 
be detected in healthy placental tissue, implying that placental AGT is taken up from blood. 
In agreement with this observation, placental AGT levels were markedly reduced in pre-
eclamptic placentas. Moreover, using the placental perfusion technique, we observed that 
placental AGT release decreased over time, suggestive for washout of blood-derived AGT. 
In contrast, placental (pro)renin release remained stable over a 3-hour perfusion period, and 
amounted to quantities that were >5-fold higher than the levels measured in tissue, indicat-
ing ongoing synthesis. The majority of this was prorenin. In conclusion, our data suggest 
that placental RAS activity depends on maternal AGT taken up from blood. They do not 
support elevated placental RAS activity in preeclampsia.    
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Perspectives 
Whether the (P)RR plays a direct role in local RAS activation has been a subject of debate 
over the past decade. A number of studies have revealed that the (P)RR plays important 
roles in regulating Wnt signaling, autophagy, lipid metabolism, and glucose metabolism, in-
dependent of the RAS. These findings extended our understanding on the functions of the (P)
RR, and also questions whether the (P)RR is a true member of the RAS. Yet, inhibiting the 
(P)RR in BN16 cells did reduce prorenin uptake to a similar extent as achieved by megalin 
inhibition. However, dual inhibition of the (P)RR and megalin did not further decrease pro-
renin uptake in BN16, thus suggesting that the (P)RR and megalin lie in the same pathway 
in regulating cellular prorenin uptake. One plausible explanation is that (P)RR inhibition 
impairs megalin endocytosis, and the other possibility is that inhibiting the (P)RR reduces 
prorenin binding. The later seems unlikely since the cellular binding of prorenin was unal-
tered by (P)RR inhibition in BN16 cells. Therefore, these data further argue that the (P)RR 
is not a major receptor for prorenin, at least not in BN16 cells. However, how (P)RR defi-
ciency leads to impaired megalin-mediated prorenin endocytosis is still unknown. 
In general, ligand endocytosis rate is determined by receptor density at the plasma mem-
brane and receptor recycling rate. For a receptor to recycle back to plasma membrane after 
delivery of the bound ligand into cells, it is critical to dissociate from its ligand. This re-
quires an acidic pH. If ligand dissociation does not occur, the receptor will be targeted to 
lysosomes for degradation, thereby eventually reducing receptor-mediated ligand endocyto-
sis. Acidification of the endosomes is achieved by vacuolar H+-ATPase (V-ATPase). Intrigu-
ingly, the (P)RR is an accessory protein of V-ATPase. Hence, it is convenient to hypothesize 
that inhibiting the (P)RR impairs V-ATPase function and endosomal pH, leading to reduced 
prorenin endocytosis in BN16 cells. Indeed, we found that inhibiting the V-ATPase using 
bafilomycin A1 almost completely abolished renin uptake in BN16 cells without affecting 
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its binding, highlighting that megalin-mediated (pro)renin uptake requires V-ATPase activi-
ty. 
However, the notion that (P)RR deficiency impairs V-ATPase integrity and activity is chal-
lenged by recent findings. The first evidence comes from a study by our group that (P)RR 
inhibition reduces LDLR endocytosis by accelerating its lysosomal degradation. Since ly-
sosomal protein degradation depends on proteases whose acivities requires acidic pH, one 
would expect to see reduced lysosomal protein degradation if (P)RR deficiency abolishes 
V-ATPase activity and lysosomal pH. However, the opposite was observed in case of the 
LDLR. Moreover, the degradation rate of membrane LDLR (receptor recycling rate) is not 
affected by (P)RR deficiency, ruling out a defective endosomal pH as the cause for reduced 
endocytosis. Inhibiting the (P)RR in hepatocytes in vivo reduced the protein abundance 
of acetyl-CoA carboxylase and pyruvate dehydrogenase without affecting their transcript 
levels. Additionally, our group recently found that leupeptin, a lysosomal protease inhibitor, 
could block (P)RR deficiency-induced reduction in protein abundance of lysosomal-asso-
ciated protein 1 (LAMP1) and LAMP2 (unpublished data). Furthermore, we found that de-
leting the (P)RR increased, rather than decreased, the protein abundance of most V-ATPase 
subunits. Taken together, these data support normal or even increased lysosomal activity in 
the absence of the (P)RR, arguing that V-ATPase activity can stay intact without the (P)RR. 
Indeed, a recent study by Kissing et al. also concluded that (P)RR deficiency did not affect 
V-ATPase activity and lysosomal pH, at least in pancreatic b-cells.24 Hence, the (P)RR may 
regulate megalin function by controlling its lysosomal degradation rather than its recycling. 
It is worthy to notice that megalin is also expressed in syncytiotrophoblasts and cytotropho-
blasts in the placenta. Whether it is playing a role in preeclampsia is not yet clear. Megalin 
recently has been suggested contribute to renal angitotensin II generation.25 Intriguingly, 
we and others have recently reported that proton pump inhibitors (PPIs) lower the placen-
tal release of soluble Fms-like tyrosine kinase-1 (sFlt-1), a well-known biomarker for the 
prediction of preeclampsia or adverse pregnancy outcomes. Ang II is known to stimulate 
sFlt-1 production, and thus we wondered if PPIs could reduce sFlt-1 levels in preeclamp-
sia by inhibiting placental RAS activation. We found that esomeprazole, a type of PPI, 
dose-dependently reduced renin uptake in BN16 cells, suggesting that PPIs may inhibit 
cellular RAS activation. However, further studies are required to explore if suppression of 
megalin-dependent (pro)renin uptake is the underlying cause for reduced sFlt-1 production. 
Unexpectedly, we found that esomeprazole also increased renin binding in BN16 cells. The 
exact cause for increased renin binding is not yet clear. Considering the short incubation 








megalin. One possibility is that this PPI may increase plasma membrane density of megalin 
via an as yet unknown mechanism. However, placental megalin expression did not seem 
to be altered in preeclamptic pregnancies and its protein abundance only tended to be in-
creased in preeclampsia. Therefore, more studies are needed to clarify the role of placental 
megalin and its connection with RAS in the onset of preeclampsia.   
Blocking RAS activity remains a major therapeutic mean to treat hypertension and its as-
sociated diseases. A problem with currently available RAS blockers is that they often raise 
plasma Ang II levels to their pretreatment stage, thereby overcoming RAS blockade. Since 
all angiotensin is derived from angiotensinogen (AGT), which is primarily synthesized in 
the liver, hepatic AGT represents an attractive therapeutic target for blocking RAS activity. 
We found that inhibiting hepatic AGT indeed effectively reduced BP to a similar extent as 
ACEi and ARBs. However, hepatic AGT inhibition alone did not reduce plasma Ang II lev-
els. Since AGT siRNA nearly completely abolished hepatic AGT expression and reduced 
plasma AGT levels by more than 95%, while increasing plasma renin levels, the most likely 
explanation of this finding is that trace amounts of AGT combined with elevated renin lev-
els are still sufficient to maintain normal plasma Ang II generation. Yet, renal Ang I levels 
and to a lesser degree renal Ang II levels did decrease during hepatic AGT suppression, 
implying that this approach particularly affects tissue angiotensin generation. In agreement 
with this observation, renal NCC and NHE3 activities were lowered by hepatic AGT inhi-
bition. Since NCC and NHE3 are the main regulators of sodium balance, which affects BP, 
it is likely that the BP lowering effect of hepatic AGT inhibition, at least in part, relies on 
regulation of sodium balance. Importantly, blocking the AT1R with valsartan on top of AGT 
inhibition virtually annihilated plasma and renal Ang II levels, due to a further rise in renin, 
which rapidly metabolized any remaining AGT. As a consequence BP fell synergistically, 
to a much greater degree than the sum of the effects of valsartan and siRNA alone. Future 
studies should now evaluate the tissue-protective effects of AGT siRNA, e.g., in the diabet-
ic kidney or the hypertrophied heart in hypertension models, focusing on the possibility that 
these effects occur in a BP-independent manner. Finally, several studies have reported that 
AGT and/or des(AngI)AGT  (i.e., the product remaining after Ang I has been cleaved off) 
are biologically active by themselves, regulating body weight gain and liver steatosis inde-
pendent of Ang II,26 and inhibiting angiogenesis.27 The AGT siRNA approach allows further 
investigation of this possibility, evaluating simultaneously whether such effects contribute 
to BP lowering and/or organ protection.
 
In summary, in this thesis, we have clarified the role of the (P)RR in regulating lipid me-
tabolism in vivo, expanding our understanding of the (pro)renin-independent role of the (P)
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RR. Moreover, we have identified megalin as a novel endocytic receptor for (pro)renin, and 
that the (P)RR determines its activity. This discovery allows a unifying concept, i.e., that 
the (P)RR is not a direct receptor for (pro)renin, but that interference with the (P)RR could 
indirectly exert effects that normally depend on (pro)renin and megalin. One of these effects 
might be megalin-mediated transcellular transport of (pro)renin and angiotensinogen into 
the renal interstitium, thereby allowing local angiotensin generation in this compartment. 
Future studies should investigate this possibiliy. Finally, hepatic AGT suppression is a new 
tool to lower BP, displaying effects that are minimally identical to those of classical RAS 
blockers, but require at most a few injections per year, as opposed to daily intake of tablets. 









De (pro)renine receptor in relatie tot lipidenmetabolisme (Hoofdstukken 1-2)
De plasma concentraties van prorenine, de voorloper van renine, zijn normaliter 10 maal 
zo hoog als die van renine, hetgeen kan oplopen tot ≈100-maal onder pathofysiologische 
omstandigheden. Behalve het feit dat het de inactieve voorloper van renine is, is de functie 
van prorenine nog steeds onbekend. Eerdere studies hebben aangetoond dat verhoogde 
prorenine concentraties in plasma in verband staan met het optreden van macro- en micro-
vasculaire complicaties zoals nefropathie en retinopathie bij patiënten met diabetes mellitus, 
terwijl de renine concentraties bij deze patiënten juist normaal of zelfs verlaagd zijn.1-
3 Bovendien zijn er aanwijzingen voor een lokaal renine-angiotensine systeem (RAS) in 
meerdere organen, hetgeen mogelijk zorgt voor verhoogde of verlaagde activiteit bij de 
afwezigheid van veranderingen in het circulerende RAS. Voorbeelden hiervan zijn de nieren 
bij diabetes en de placenta bij pre-eclampsie.4, 5 Aangezien renine synthese zich beperkt 
tot de juxtaglomerulaire cellen in de nieren, moet dit lokale RAS afhankelijk zijn van een 
mechanisme dat de opname van renine en/of prorenine activatie toestaat. De ontdekking 
van de (pro)renine receptor [(P)RR], ongeveer twintig jaar geleden, leek de oplossing 
voor dit probleem te zijn, zoals besproken wordt in Hoofdstuk 1. De (P)RR bindt zich 
aan zowel renine als prorenine, en vertoont een hogere affiniteit voor prorenine.6 Bij het 
binden wordt prorenine op een niet-proteolytische wijze geactiveerd, hetgeen de vorming 
van angiotensines mogelijk maakt. Daarnaast zorgt (P)RR binding van renine en prorenine, 
hierna aangeduid als (pro)renine, voor angiotensine-onafhankelijke intracellulaire 
signaalcascades, wat resulteert in de activatie van p38 mitogeen-geactiveerd proteïne 
kinase (MAPK) en extracellulair signaal-gereguleerd kinase 1/2 (Erk1/2), bijvoorbeeld in 
vasculaire gladde spiercellen (VSMCs), verzamelbuiscellen, en vetcellen.7, 8 Activatie van 
p38 MAPK and Erk1/2 heeft verhoging van profibrotische en proliferatieve genexpresssie 
tot gevolg, wat resulteert in versnelde celproliferatie en orgaanschade. Om de angiotensine-
afhankelijke en -onafhankelijke effecten te kunnen detecteren, moet (pro)renine wel worden 
toegediend in concentraties die vele malen hoger zijn dan het reguliere plasma-niveau en 
die zelfs boven de ultrahoge spiegels in transgene knaagdiermodellen liggen.9 Bovendien 
is, in tegenstelling tot andere RAS componenten, volledige afwezigheid van de (P)RR 
dodelijk, zelfs wanneer dit beperkt wordt  tot bepaalde celtypen zoals cardiomyocyten en 
podocyten.10-12 Dit gegeven roept de vraag op of de interactie tussen (pro)renine en de (P)
RR in vivo werkelijk relevant is. 
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Interessant is dat het cytosolische domein van de (P)RR reeds eerder is geïdentificeerd als 
een eiwit behorend bij vacuolair H+-ATPase (V-ATPase).13 V-ATPase is een multisubunit 
complex dat bestaat uit een H+- translocerend Vo domein en een ATP-hydrolyserend V1 
domein.14  V-ATPases worden in vrijwel alle celtypen tot expressie gebracht en worden 
voornamelijk gevonden in de membraan van intracellulaire compartimenten zoals 
signaalendosomen, lysosomen en het Golgi-apparaat.15 Door verzuring van de intracellulaire 
compartementen, spelen deze een belangrijke rol in de inductie van intracellulaire 
signaalcascades, receptor-gemedieerde endocytose en de afbraak van eiwitten. Genetische 
ablatie van de meeste, zo niet alle, V-ATPase subeenheden in muizen of zebravissen is 
embryonaal dodelijk.16 Dit wijst op een nauw functioneel verband tussen de (P)RR en 
V-ATPase. Inderdaad leidde remming van de (P)RR of V-ATPase (met bafilomycine) tot 
verminderde Wnt-gemedieerde activatie van b-catenine.17 Daarnaast resulteerde (P)RR 
deletie in cardiomyocyten en podocyten tot afgenomen expressie van diverse V-ATPase 
subeenheden en een verstoorde lysosomale pH, wat de suggestie wekt dat de (P)RR 
noodzakelijk is om de V-ATPase-integriteit te bewaren. Bovendien heeft onze groep eerder 
al aangetoond dat remming van de (P)RR wel de arginine vasopressine-gestimuleerde 
V-ATPase activiteit onderdrukt, maar niet de basale V-ATPase in verzamelbuiscellen 
beinvloedt.18 Deze studies onderstrepen dat de (P)RR inderdaad (pro)renine-onafhankelijke 
effecten bewerkstelligt. 
Tijdens het bestuderen van (pro)renine-onafhankelijk functie(s) van de (P)RR, heeft 
onze groep ontdekt dat de (P)RR de dichtheid van de low-density lipoproteïn receptor 
(LDLR) en sortiline-1 (SORT1) reguleert, i.e., de twee belangrijkste regulatoren van 
het LDL metabolisme, daarmee een potentiële rol van de (P)RR in LDL metabolisme 
implicerend.19,20 Daarom bestudeerden we in Hoofdstuk 2 de consequentie van remming 
van de hepatische (P)RR op het lipidenmetabolisme in vivo. Zoals verwacht, verhoogde 
hepatische (P)RR remming inderdaad de plasma LDL concentratie bij een normaal dieet 
in C57BL/6J muizen, als gevolg van verminderde hepatische LDLR en SORT1 dichtheid. 
Een onverwachte vondst was dat hepatische (P)RR deficiëntie ook de door een hoog 
vetdieet veroorzaakte obesitas en  non-alcoholic fatty liver disease voorkwam. Dankzij de 
toepassing van proteomics werd duidelijk dat de concentraties van acetyl-CoA carboxylase 
(ACC) en pyruvaat dehydrogenase (PDH) verminderd waren in de levers met volledige (P)
RR remming. PDH zet pyruvaat om in acetyl-CoA, terwijl ACC een cruciale rol speelt bij 
de regulatie van vetzuur biosynthese en oxidatie.21 Genetische ablatie van ACC resulteerde 
in een afname van synthese van de lipiden en een toename in vetzuur oxidatie, wat leidde 
tot eenzelfde fenotype als muizen met (P)RR-remming in de lever. Gebruik makend van 








dat remming van de (P)RR de cellulaire acetyl-CoA spiegels afremt en vetzuur oxidatie 
bevordert. Onze studie heeft hiermee een niet eerder beschreven rol van de (P)RR in de 
regulatie van het lipidenmetabolisme aangetoond. 
Angiotensinogeen siRNA als nieuw bloeddrukverlagend middel (Hoofdstuk 3)
Verhoogde RAS activiteit is een belangrijke factor bij verhoogde bloeddruk (BD), zodat 
RAS blokkers veel gebruikt worden voor de behandeling van hypertensie en gerelateerde 
ziekten. Conventionele RAS blokkers, zoals angiotensine-converterend enzym inhibitoren 
(ACEi), angiotensine (Ang) II receptor blokkers (ARBs), en directe renine inhibitoren 
(DRi), kunnen echter allemaal tot een verhoogde renine spiegel in plasma leiden en 
mogelijk de behandeling bemoeilijken, bijvoorbeeld omdat de toename in renine de 
Ang II spiegel terugbrengt naar hetzelfde niveau als voor de behandeling. Bovendien 
vormt slechte therapietrouw van de reguliere RAS blokkers een andere uitdaging voor de 
optimale controle van de BD. Aangezien al het Ang II voortkomt uit angiotensinogeen 
(AGT) uit de lever, kan remming van hepatisch AGT mogelijk leiden tot een effectievere 
RAS onderdrukking. In Hoofdstuk 3 hebben we daarom de effecten onderzocht van 
siRNA gericht op AGT in spontaan hypertensieve ratten. We vonden dat een enkele 
injectie van N-acetylgalactosamine (GalNAc)-siRNA met een dosering van 10 mg/kg 
lichaamsgewicht effectief de BD verlaagde, in dezelfde mate als captopril (ACEi) en 
valsartan (ARB) gedurende minimaal 4 weken. Hoewel remming van hepatisch AGT ook 
de renine concentraties verhoogde als gevolg van het wegvallen van de negatieve feedback 
loop, veroorzaakte het geen verhoogde Ang I spiegel in het plasma zoals captopril en 
valsartan. Dat hepatische AGT onderdrukking de Ang II spiegels in plasma niet verlaagde, 
is waarschijnlijk het gevolg van het nog aanwezig zijn van restanten AGT en Ang I. 
Behandeling met AGT siRNA in combinatie met valsartan zorgde echter wel voor een 
sterke afname van Ang I en Ang II in plasma, alsmede een verdere verlaging van de BD. 
Onze studie onderstreept derhalve dat AGT remming alleen of in combination met valsartan 
een effectieve methode is om de BD onder controle te krijgen.   
Megaline en (pro)renine opname (Hoofdstukken 4-6)
Hoewel de proreninespiegels in plasma  ≈10-maal zo hoog zijn als die van renine, kan 
opmerkelijk genoeg alleen renine gedetecteerd worden in urine. Zelfs wanneer de prorenine 
spiegels in plasma ≈200-maal verhoogd zijn, zoals het geval is in Cyp1a1-Ren2 transgene 
ratten, is prorenine in de urine nog steeds niet detecteerbaar. Door de kleine verschillen 
in hun moleculaire gewicht is het onwaarschijnlijk dat er grote discrepancies ontstaan in 
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de glomerulaire filtratie van prorenine en renine,22 en dit kan dus niet de verklaring zijn 
voor het feit dat prorenine niet detecteerbaar is in urine en renine wel. Opmerkelijk is dat 
de renine- en proreninespiegels in urine van patiënten met de ziekte van Dent of het Lowe 
syndroom sterk verhoogd zijn. Deze patiënten zijn drager van genetische mutaties in het 
OCRL1 of CLC-5 gen, hetgeen tot megalinedisfunctie leidt. In het verlengde hiervan 
verhoogt genetische ablatie of farmacologische remming van megaline de reninespiegels 
in urine.23 Deze observaties wijzen dus op de mogelijke functie van megaline als een 
endocytische receptor voor (pro)renine (Hoofdstukken 4&5). In Hoofdstuk 6 hebben we 
de megaline-gemedieerde renine en prorenine binding en opname in BN16 cellen (i.e.., 
cellen met hoge megaline-expressie) bestudeerd. We vonden dat BN16 cellen zowel renine 
als prorenine opnemen, waarbij prorenine met grotere efficiëntie werd gebonden. Remming 
van de mannose-6-fosfaat receptor, een bekende klaringsreceptor voor (pro)renine, had geen 
effect op deze opname, terwijl blokkade van megaline wel effect had. Deze bevindingen 
bevestigen dat megaline een nieuwe receptor voor (pro)renine is, en gezien de veel grotere 
efficiëntie van de opname van prorenine, verklaart dit ook waarom prorenine normaal 
gesproken niet in urine te vinden is.
Het RAS bij pre-eclampsie (Hoofdstuk 7)
Als gevolg van drastisch verhoogde AGT spiegels in plasma en een bescheiden verhoging 
van de renine spiegels in plasma, is de activiteit van het RAS in plasma verhoogd tijdens 
zwangerschap. Dit is o.a. nodig om voldoende toevoer van bloed naar de de groeiende 
foetus te verzekeren. Bij pre-eclampsie, een aandoening die gekenmerkt wordt door 
hypertensie en proteïnurie bij vrouwen na 20 weken zwangerschap, wordt de verhoging van 
circulerend AGT en renine echter onderdrukt, hetgeen mogelijk bijdraagt aan het ontstaan 
van de ziekte. Gezien de lokale productie van RAS componenten in de placenta is het nog 
steeds mogelijk dat de RAS activiteit in de placenta juist verhoogd is bij pre-eclampse. 
In Hoofdstuk 7 hebben we onderzocht of de expressie van RAS componenten in de 
placenta en hun afgite veranderen bij pre-eclampsie in een vroeg stadium. Belangrijke RAS 
componenten, waaronder renine, ACE, ACE2, AT1R, en AT2R, kwamen tot expressie in 
de placenta, en hun expressie niveaus waren vergelijkbaar in gezonde en pre-eclamptische 
placentas. De (pro)renine-spiegels in de placenta waren ook hetzelfde bij gezonde en pre-
eclamptische zwangerschappen, hetgeen in lijn is met ongewijzigde renine-expressie in 
de placenta bij deze aandoening. Alhoewel de AGT mRNA spiegels net op of onder de 
detectiegrens lagen, kon het AGT eiwit wel gemeten worden in gezond placentaweefsel, wat 
erop wijst dat AGT in de placenta opgenomen wordt vanuit het bloed. In overeenstemming 








eclamptische placentas. Placenta perfusie bevestigde dat de afgifte van AGT in de placenta 
in de tijd afneemt, hetgeen wijst op een ‘washout’ van uit het bloed opgenomen AGT. In 
tegenstelling hiermee, bleef de afgifte van (pro)renine uit de placenta juist stabiel tijdens 
een 3 uur durende perfusie, en steeg tot hoeveelheden die >5-maal hoger lagen dan de 
spiegels die in placentaweefsel gemeten worden, wat op voortdurende synthese wijst. 
Dit was overwegend prorenine. Concluderend suggereren onze bevindingen dat de RAS 
activiteit in de placenta afhankelijk is van maternaal AGT dat opgenomen wordt vanuit het 
bloed. Er is geen bewijs voor verhoogde RAS-activiteit in de placenta bij pre-eclampsie.    
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